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Abstract
Clostridium difficile was identified as an infective agent in the late 1970s and early
1980s and causes a spectrum of disease ranging from asymptomatic carriage, mild
colitis, pseudomembranous colitis (PMC) to fulminant colitis and even death. Since
its recognition as an infective pathogen, C. difficile has become the principal cause of
nosocomial diarrhoea in adults. The main aims of this four-part thesis were to
determine the extent of Clostridium difficile infection (CDI) within the local in¬
patient population and to establish the epidemiology of CDI within the specialty of
colorectal surgery.
The first study focused on the burden of CDI to the diagnostic laboratory and the
relative incidence of disease in different clinical specialties over an 8-year period
(2000 to 2007) in a region that had not been affected by the hypervirulent 027 strain.
A 27-fold increase in the number of faecal samples analysed by the enteric laboratory
occurred from 2000 to 2006 and the total number of potential CDI cases increased
over the same period, with a decline finally seen in 2007. One-fifth of all toxin-
positive samples were from age groups under 60 years of age providing further
evidence that CDI was not just a disease of the elderly. Although Medicine of the
Elderly provided the greatest faecal analysis workload; Renal Medicine / Transplant
Surgery, Intensive Care, Infectious Disease and Gastrointestinal Medicine all had
higher incidences of CDI than Medicine of the Elderly. Similarly the low risk group
of Paediatrics was also starting to show a small but notable increase in potential
incidence. Potential excess costs for CDI in this region rose from £3.5 million to £29
million over the study period.
The second study aimed to assess the potential impact of CDI within all surgical
services. In the absence of 027, a further aim of this study was to assess if the more
severe and extreme forms of C. difficile disease were occurring from 2000 to 2006.
Colorectal surgery had the greatest number of CDI episodes followed by Upper
Gastrointestinal Surgery and Urology. Despite the total number of C. difficile toxin-
positive in-patients increasing each year, a similar increase was not demonstrated in
the number of patients diagnosed with more severe forms of CDI or in the number of
CDI patients treated with surgical intervention. In the cases requiring surgical
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intervention up to 40% of patients did not present with diarrhoea and up to 50% of
patients did not have a C. difficile toxin-positive faecal sample prior to surgery.
Demonstrating the importance of clinical recognition of the entire spectrum of C.
difficile related disease. The post-operative mortality rate for fulminant CDI was
26%. High mortality figures for fulminant CDI treated surgically have not changed
significantly over the last two decades and may relate to surgical referral for CDI
often occurring late when the patient is in extremis.
The third and fourth studies examined the specific burden of C. difficile in the
colorectal surgical patient population and the environmental surface contamination
within colorectal wards. An asymptomatic carrier rate of 6.1% was identified in the
out-patient colorectal surgical population. Asymptomatic carriers admitted from the
community play an important role in sustaining the transmission of disease within the
hospital environment with 42.8% of C. difficile strains only identified in the in¬
patients faecal samples but not on the surface environment of the wards. Standard
enteric hospital laboratory CDI diagnosis using enzyme immuno-assay for toxin A+B
detection was 52% less sensitive then toxigenic culture with a false positive rate of
2.5%. Toxigenic culture identified a further 58 colorectal surgical in-patients with
CDI. Of all the C. difficile isolates identified from in-patients and the surface
environment ribotype 001 was the commonest strain, consistent with other local
studies where ribotype 001 has emerged as the dominant strain. A large proportion of
the in-patient ribotype 001 isolates showed resistance to ceftriaxone and
ciprofloxacin. The ribotype 001 isolates from the surface environment showed
decreased resistance to ceftriaxone compared with the in-patient strains. Similarly
4.6% of all in-patient isolates showed intermediate resistance to vancomycin but no
vancomycin resistance was demonstrated in the environmental surface isolates and
may represent increased development of C. difficile resistance mechanisms in the
host. The patient bed frames were the commonest contaminated environmental
surface with C. difficile, followed by the patient's bedside lockers and tables.
Therefore the risk of a patient ingesting a C. difficile spore from the surface
environment is high. Following the introduction of a new cleaning protocol during the
environmental sampling study a statistically significant reduction in environmental C.
difficile surface contamination and in the number of CDI colorectal in-patients was
demonstrated. Acquisition of CDI from the surface environment in hospitals is not to
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be under-estimated and judicious application of infection control measures remains an
important factor in preventing CDI transmission.
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Clostridium difficile (C.difficile) is a Gram-positive, anaerobic, motile, spore-forming
bacillus. Hall and O'Toole first identified the organism in 1935 from the stool
samples of healthy neonates and named it Bacillus difficilis due to the difficulties they
encountered in isolating the organism. Due to its presence in the faecal samples of
healthy neonates it was deemed a commensal, although they demonstrated the
organism was highly pathogenic in rabbits and guinea pigs. Finney, a surgeon, first
described an entity later recognised as pseudomembranous colitis (PMC), a rarer
severe form of disease in 1895, in one of his post-operative patients. Antibiotic-
associated colitis and pseudomembranous colitis were later identified in the 1950s;
however Staphylococcus aureus was thought to be the causative organism (Pearce &
Dineen 1960). C. difficile was first recognised as an infective agent in 1962 by Smith
and King, but they were unable to identify it as the primary causative pathogen of
disease.
In 1974 Tedesco et al. reviewed 200 patients who had received clindamycin, and
found a significant proportion to have antibiotic associated diarrhoea, but that 10%
had life-threatening pseudomembranous colitis. However, they were unable to isolate
pathogens from the plaque-like lesions (pseudomembranes) seen in the colon. Then in
1977 to 1978 key groups made great strides in the recognition of C. difficile as a
pathogen. In 1977, Larson et al. identified a cytopathic toxin in the faeces of patients
with PMC, in the same year Bartlett et al. observed typhlitis in hamsters was caused
by a clindamycin resistant, toxin producing Clostridium species, and Rifkin et al.
demonstrated Clostridium sorde/lii antitoxin neutralised a clostridial toxin found in
the faecal samples of patients with PMC and antibiotic-associated diarrhoea. In 1978,
George et al. determined that only pure cultures of C. difficile caused the same
cytotoxic effects as that found in patient faeces neutralised by C. sordellii antitoxin.
This was also confirmed by Bartlett et al, Larson et al. and Chang et al. in the same
year. C. difficile is now the most common cause of nosocomial infectious diarrhoea
in adults and is considered the primary aetiological agent of pseudomembranous




C. difficile cells are Gram positive although the stain can be lost in older cultures.
They are 2 to 8 pm long with elongated sub-terminal or nearly terminal spores and are
motile due to the presence of a few flagella distributed around their surface providing
them with characteristic "dancing" motility on wet films.
1.2.2 Macroscopic morphology
C. difficile colonies are flat, white, opaque and non-haemolytic with irregular
filamentous edges. On selective media used for C. difficile isolation such as
cycloserine cefoxitin fructose egg yolk agar (CCFA) and cycloserine cefoxitin egg
yolk agar (CCEY) the colonies have a yellowish appearance with greater
pronouncement of their filamentous edges. Under UV-light the colonies produce a
characteristic chartreuse (yellow-green) fluorescence. C. difficile produces a
characteristic odour which any health-care worker dealing with patients with C.
difficile diarrhoea would recognise, it is said to resemble that of a horse stable or
dung.
1.3 Virulence factors
1.3.1 The pathogenicity locus (PaLoc)
The PaLoc is a 19.6kb region of the chromosome and is present at the same site, in
only one copy in all C. difficile strains (Braun et al., 1996). The PaLoc encodes five
genes; toxin A (tcdA), toxin B (tcdB), tcdC, tcdR and tcdE. Pathogenic C. difficile
strains produce at least one of the two toxins and in non-toxigenic strains the PaLoc is
replaced by a unique conserved 115 bp fragment (Cohen et ci/., 2000). The PaLoc has
feature of a distinct genetic element, with a single integration site, unidirectional
orientation and conserved bordering sequences (Braun et a I., 1996).
tcdR is the first gene of the PaLoc and is the positive regulator of toxin production.
TcdR regulates the transcription of the PaLoc by mediating binding of the RNA
polymerase holoenzyme to promoters of the toxin genes (Mani & Dupuy, 2001).
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tcdC is the last gene of the PaLoc and is the negative regulator of toxin production. It
was found that TcdC destabilises the RNA polymerase-TcdR complex and this
prevents it from recognising and binding the tcdA and tcdB promoters, thereby
inhibiting gene expression (Dupuy et al., 2008).
tcdE is located between tcdA and tcdB and is thought to have a role in the secretion of
toxins from within C. difficile cells. TcdA and TcdB lack a signal sequence mediating
trafficking to the cell membrane (Aktoires, 1997). Secretion of toxins is therefore
associated with cell death, however toxin release correlates with sporulation and
therefore continued survival of the organism.
1.3.2 Toxin A and toxin B
Toxin A and Toxin B are exotoxins which are taken up from the gut lumen by
enterocytes and are the most important virulence factors of C. difficile. C. difficile
exotoxins TcdA and TcdB are large clostridial cytotoxins and have molecular weights
of 308kDa and 269kDa respectively (Dove et al., 1990). Conventionally TcdA was
defined as an enterotoxin and TcdB as a cytotoxin (Schirmer & Aktoires, 2004).
TcdA does have some cytotoxic activity but it is up to a 1000 times less potent than
that of TcdB. TcdB was initially believed to have no enterotoxic activity (Sullivan et
al., 1982) however TcdB has now been observed to be as enterotoxic as TcdA
(Savidge et al., 2003) and a study by Lyras et al., (2009) provides evidence that of the
two toxin B is more important.
Toxins A and B have three regions; the N-terminal catalytic domain, the C-terminal
toxin-receptor binding domain and a putative translocation domain (von Eichel-
Streiber et al., 1992). This three-part toxin structural model has now been replaced
with a four domain structural model which involves the glucosyltransferase domain,
the cysteine protease domain, the translocation domain and the receptor-binding
domain (Albessa-Jove et al., 2010).
The N-terminal is responsible for the catalytic activity of the toxins, the C-terminal
mediates cell-binding (Sauerborn et al., 1997), the cysteine region plays a role in
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endocytosis (Barroso et al., 1994) and the translocation domain as the name suggests
is essential for translocation (von Eichel-Streiber & Sauerborn, 1990).
Until recently it was thought that both toxins A and B were required to elicit disease
however Clostridium difficile infection (CDI) outbreaks have been caused by A-B+
strains, which refutes this view (Kuijper et al., 2001).
Cell-binding
The interaction of toxin receptors is the primary process of entry of toxins into cells.
The C-terminal binding domain is composed of repetitive oligopeptide elements
known as CROPs and are considered the host cell surface polysaccharide binding sites
(Just & Gerhard, 2004). Carbohydrate receptors for TcdA were identified in the brush
border membranes of hamsters and TcdA has been shown to bind on human cells to a
disaccharide present on the I, X and Y antigens (Tucker & Wilkins, 1991). TcdB has
been found to bind to a variety of cell types however its receptor has not been
identified (Voth & Ballard, 2005). The toxin and receptor interaction results in
receptor-mediated endocytosis (Just & Gerhard, 2004). TcdA and TcdB are then
processed to reach the cytosol where they are able to induce cytotoxic effects.
Membrane translocation
Translocation of the toxins into the cytosol requires acidification of an endosome. In
response to an acidic pH in the endosome the toxins undergo structural changes that
expose hydrophobic domains and result in the insertion of the toxin into the
endosomal membrane (Qa'Dan et al., 2000). Barth et al., (2001) found that cytotoxic
activity of toxin B could be inhibited by treating the cells with a proton pump
inhibitor. Pfeifer et al., (2003) demonstrated that the C-terminal of toxin B remained
in the endosome whilst the N-terminal was found in the cytosol. TcdB undergoes
proteolytic cleavage by a cysteine which is activated by inositol hexakiphosphate
(Egerer et al., 2009).
Activity of Enzymes and the effects of glucosylation on GTPases
Cytosolic targets of TcdA and TcdB are proteins belonging to the Rho and Ras
families. These proteins are GTPases and belong to a superfamily of low molecular
weight proteins, which act as molecular switches in a variety of key-signalling
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pathways. These include adhesion, epithelial barrier function, immune cell-migration,
progression of the cell-cycle, secretion of cytokines, phagocytosis and endocytosis
(Aktoires et al., 2000).
The GTPases alternate between active and inactive forms; an inactive GTP-bound
form in the cytosol and an active GTP-bound form at the cell membrane. In the
cytosol nucleotide exchange is prevented by Rho proteins binding to the nucleotide
dissociation inhibitor. Following receptor-mediated interaction the GTPases
translocate to the cell membrane and here in a process catalysed by guanine exchange
factors GDP is exchanged for GTP. GTP is then hydrolysed to GDP by GTPase
activating proteins which return GTP to its original form. Both TcdA and TcdB
glucosylate the target protein resulting in the inactivation of the GTPases (Schirmer &
Aktoires, 2004).
The glycyosylation of Rho proteins and subsequent lethal depolymerisation of the
actin cytoskeleton in epithelial cells leads to cell rounding and detachment form the
basal membrane (Mahida el al., 1996). Inactivation of the the GTPases results in the
breakdown of the tight junctions of the colonic epithelial barriers. This increases the
permeability of the epithelial barrier resulting in diarrhoea. The resultant acute
inflammatory response stimulates the release of pro-inflammatory cytokines and
allows neutrophils, mast cells and macrophages to pass through the tight junctions
(Kelly & Kyne., 2011). TcdA also induces enteric neurones to secrete substance P
which causes mast cell activation further increasing mucosal secretion and
inflammation (Castagliuolo el al., 1997). The presence of neutrophils, mucus, fibrin
and sloughed epithelium within the gut lumen results in the formation of
pseudomembranes (Linevsky el al., 1997), as the inflammatory response continues
toxic megacolon and perforation can ensue.
1.3.3 Binary toxin
Some C. difficile strains produce a third toxin known as binary toxin (CDT). The
binary toxin consists of two molecules (subunits) which are both required for activity
(Rupnick et al., 2003). The subunit CDTa is the enzymatic subunit which causes
cytoskeletal disruption and subunit CTDb is the binding subunit which allows
translocation of the enzymatic subunit CDTa into the cytoplasm (Barth et al., 2004).
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This toxin has similar characteristics to the binary toxins in other Clostridia and does
not produce the cytopathic effect usually seen with TcdA or TcdB.
The role of the binary toxin in CDI pathogenesis is not wholly understood and it is
thought to contribute to severity rather than act as a key component in CDI
development as A-B+ CDT+ strains in a hamster model produced colonisation but no
disease (Geric et al., 2006). The prevalence of binary toxin genes was reported in only
17.2% of toxigenic strains in a European study (Barbut et al., 2007), but those strains
with binary toxin caused more severe disease and increased mortality.
1.3.4 Surface-associated proteins
To establish infection the bacteria must be able to bind to host cells, colonise tissues,
invade them and continually interact and modulate the host immune system to allow
disease to persist (Pizarro-Cerda & Cossart, 2006). Therefore adherence of C. difficile
to the gut mucosa is vital to sustain CDI and this is achieved with a number of cell-
surface proteins known as adhesions.
The S-layer protein is a protective surface comprised of two sub-units. These S-layer
proteins are involved in adherence to mucus and epithelial cells (Calabi et al., 2002)
and were found to be the most commonly recognised antigens in CDI patients (Wright
et al., 2008). The flagella of C. difficile may also be involved in adherence
mechanisms. The flagellar fdament (FliC) and flagellar cap (FliD) can both mediate
mucus binding an important first step in colonisation (Tasteyre et al., 2001) and
antibody responses to both these antigens in patients have been observed (Pechine el
al., 2005).
Another surface protein Fbp68 is a fibro-nectin binding protein present mainly in the
cytoplasmic membrane of C. difficile cells and has been found to induce a high
antibody response in patients (Hennequin et al., 2003, Pechine et al., 2005 ). Cwp84
and CwpV are further surface-associated proteins and important virulence factors.
1.3.5 Clostridium difficile spores
C. difficile produces spores that are metabolically dormant. These spores are
important in the pathogenesis, persistence and transmission ofCDI. C. difficile spores
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can persist in the environment for long periods of time and are resistant to
environmental changes including disinfection as discussed further in Chapter 6.
These spores once ingested attach to the gastrointestinal tract via proteinaceous
exosporial filaments (Panessa-Warren et al., 1997). Only vegetative cells are able to
produce spores and therefore germination and outgrowth of the spores is vital to CDI.
Spore germination is mediated by receptors once the spore is in a nutrient-rich
environment. The spores have been found to germinate in response to bile salts with
germination in humans stimulated by taurocholate in the small intestine (Howerton et
al., 2011).
C. difficile are unable to undergo germination and outgrowth in the presence of
normal gut flora. Normal gut flora is able to modify primary bile salts to secondary
bile salts. The primary bile salt chenodeoxycholate can inhibit spore germination due
to the decreased affinity of spores to taurocholate in its presence. When the gut is
stripped of its normal intestinal flora, following exposure to certain risk factors such
as antibiotics, the ratio of primary to secondary bile salts changes, this allows spores
to germinate into vegetative cells which can produce toxins (Giel et al., 2010). The
precise germination factor however has not been identified.
1.4 Typing methods
Typing of C. difficile isolates is vital to the comprehension of its epidemiology and its
ability to cause disease. Initially techniques employed methods to identify phenotypic
characteristics of C. difficile whereas current methods assess the genotype.
1.4.1 Phenotypic methods
The initial methods used resistance patterns to antibiotics to type strains (Burdon,
1982), crossed Immunoelectrophoresis, analysis of plasmid profiles, analysis of
soluble proteins and protein patterns by SDS-PAGE, and bacteriocin and
bacteriophage typing methods rapidly followed (Wust et al., 1982; Poxton et al.,
1984) and proved to be useful. The immunochemical finger-printing of EDTA-
extracted cell surface proteins was also used in studying out-breaks of CDI (Poxton et
al., 1984).
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Serogrouping was developed by Delmee el al., (1985 and 1986) who were able to
identify 19 different sero-groups and a comparison of serogrouping with SDS-PAGE
protein profiles showed that either method could be used to type C. difficile isolates.
Serogrouping is often used as a comparative standard with other schemes (Brazier,
2001).
Surface-layer typing (S-layer typing) was a further phenotypic method of typing C.
difficile. This method interrogated the inter-strain variability in the molecular mass of
the high and low weight surface layer proteins (McCoubrey & Poxton, 2001;
McCoubrey et al., 2003).
1.4.2 Restriction enzyme analysis
This method of C. difficile typing uses restriction endonuclease analysis (REA).
Kuijper et al., (1987) used HindlU, a frequent cutter, to restrict whole cell-DNA
which produced distinguishing restriction patterns for different C. difficile strains on
agarose gels, these were compared by eye to existing exemplars and the method
correlated well with the strains' protein profiles. The method was reproducible and
highly discriminatory but technically demanding.
1.4.3 Pulse field gel electrophoresis
Pulse field gel electrophoresis (PFGE) is a typing method that analyses the whole
genome of an organism following restriction using rare cutting enzymes such as Smal
and SacU (Brazier 2001). This method was also highly discriminatory and correlated
well with serogrouping. PFGE is commonly used in North America and the strains are
assigned NAP (North American pulsed-field) types.
1.4.4 Ribotyping
This method of ribotyping is based on the variability in length of the 16s - 23 S spacer
regions present in different alleles. It was first suggested as a typing method in 1993
(Gurtler, 1993). It had been reported that C. difficile carried 14 copies of the rRNA
gene each with intergenic spacer regions of varying lengths. By amplifying these
regions of DNA and running them on long denaturing polyacrylamide gels Gurtler
identified different banding patterns for different strains. Cartwright et al. (1995)
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found the method to be simple and reproducible allowing them to differentiate a large
number of isolates. The method was modified by O'Neill et al. (1996) and became the
typing method of choice by UK reference laboratories with 116 ribotypes defined in
1996 (Stubbs et al., 1999). They had modified the method by extracting DNA by
boiling with resin and re-designed the primers to give bands between 260 and 585 bp
and used high resolution agarose. Recently capillary gel electrophoresis-based PCR
ribotyping has been developed, which seems to overcome the problems of inter-
laboratory variation (Indra et al., 2008).
1.4.5 Toxinotyping
Toxinotyping uses the inter-strain variability in the toxin genes tedA and tcdB
(Rupnik et al., 1997) which encode for toxins A and B. The variations are
concentrated in the A3 fragment and B1 fragment. The restriction of these DNA
regions with the enzymes EcoKl, Accl and Hindi and the resultant length of the
products is then analysed with electrophoresis. This method has correlated well with
PFGE, serogrouping and ribotyping however ribotyping remains more discriminatory.
Strains which carry a PaLoc identical to that of the reference strain VPI10463 are
known as toxinotype 0; currently there are 24 variant toxinotypes.
1.4.6 MLVA and MLST
Multilocus sequence typing (MLST) and multilocus variable-number tandem-repeat
analysis (MLVA) are useful in determining epidemiological links between isolates
and therefore can help differentiate between isolates of the same serogroups,
toxinotypes and ribotypes and their subtypes and is therefore very useful in CDI
outbreak situations. With MLST by sequencing the toxin genes and their positive
regulator, the binary toxin gene and other virulence involved genes, several C.
difficile clones can be identified (Lemee et al., 2005). MLVA is a technique that
amplifies seven regions featuring short tandem repeats distributed over the genome,
different isolates are distinguished by analysis of repeat numbers (van den Berg et al.,
2007).
1.4.7 sIpAST
The sipA gene encodes the precursor of the S-layer proteins. The inter-strain
differences in the variable region of the sipA gene of C. difficile were sufficiently
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discriminatory to be used as a typing scheme (Karjalainen et al., 2001). Variable
regions of the gene are amplified by PCR and analysed by restriction digest and DNA
sequencing and can be used to discriminate between types and subtypes.
1.5 Clostridium difficile out with the human host
C. difficile is widely distributed in the environment. An extensive survey performed in
Wales found C. difficile in many water sources including the sea, rivers, lakes, tap
water and swimming pools and also in soil samples and on root vegetables (al-Saif &
Brazier, 1996). Bakri et al., (2009) isolated C. difficile from 7.5% of packaged
supermarket salads. Metcalf ei al., (2010) found C. difficile in 4.5% of vegetables
purchased from a greengrocer.
Animals are a further potential source of C. difficile to humans. CDI colitis has been
diagnosed in several neonatal pigs (Songer, 2004) and carriage has been reported in
horses, calves and domestic pets (Arroyo et al., 2007; Rodriguez-Palacios et al.,
2006). The predominant toxinotype in pigs and calves is toxinotype V which is now
being seen more in human CDI cases across the globe. Ribotype 078 toxinotype V
isolates from diarrhoeal pigs and human patients in the Netherlands were found to be
both phenotypically and genotypically identical (Debast et al., (2009). This suggests
commonality between animal and human strains or the possibility of zoonotic
transmission.
C. difficile has also been isolated from a variety of meat products. Songer et al.,
(2009) found heavy contamination of up to 40% of the raw meat products they tested
sold in North America and Weese et al., (2009) found 71% of ground meat products
to be contaminated with C. difficile and in 2010 they found C. difficile in 12.8% of
retail sold chicken. Much lower C. difficile rates were identified in meats sold in
Europe, Bouttier et al., (2010) found C. difficile in only 1.9% of tested products and
this 1.9% was found only in vacuum-packed meats. A study performed in our
laboratory did not identify any C. difficile from the 100 packaged meats tested
(Jobling & Poxton unpublished). The higher incidence found in meats that are
packaged suggest contamination during the processing (Songer et al., 2009).
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The significance of the presence of C. difficile and its ability to transmit disease to
human hosts from food and other environmental sources mentioned is uncertain.
1.6 Clostridium difficile disease acquisition and risk factors
1.6.1 Acquisition of C. difficile
Clostridium difficile is spread by the faecal-oral route and ingestion of C. difficile
spores into the gastrointestinal tract is the first step towards development of CDI.
Contaminated hands are the most common method for ingestion by the host. C.
difficile is able to colonise the host and under the correct environmental conditions
within the gut the spores are able to germinate into vegetative cells which produce
toxins and other virulence factors. These trigger the host's inflammatory response
within the gastrointestinal tract resulting in symptomatic disease. The host also goes
on to produce and disseminate more spores.
Symptomatic CDI patients are the main source of disease transmission. These infected
patients shed large numbers of vegetative cells and spores into the surrounding
environment (Wilcox et al., 2003). This is particularly significant in nosocomial
settings where the close proximity of individuals allows spores to spread and cross-
contaminate other patients via commonly touched surfaces.
1.6.2 Risk factors
Antibiotics
The disruption of the indigenous gut flora means that it is no longer able to provide
protection against enteric pathogens. Antibiotics are the most common causal agent
that disrupts the normal gut flora resulting in symptomatic CDI. Many early
experiments used clindamycin as this was the antibiotic CDI was initially
synonymous with and its effects were demonstrated in animal models (Tedesco et al.,
1974; Chang et al., 1978). The replacement of clindamycin with broad-spectrum
penicillins and third-generation cephalosporins led to their use becoming the most
implicated cause of CDI (Bartlett, 2008). Starr et al., (2003) found that the use of
third-generation cephalosporins increased the risk of an individual becoming culture
positive and also demonstrated that an individual's risk of becoming toxin-positive
increased with antibiotic use. More recently fluoroquinolones have become implicated
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in CDI development as their wide-spread use has increased so has C. difficile
resistance to fluoroquinolones (McDonald et al., 2005; Mutlu el al., 2007). Newer
fluoroquinolones have greater activity against anaerobes and are therefore more likely
to disrupt the host's normal gut flora; they may then exert selective pressure allowing
fluoroquinolone resistant strains to emerge during fluoroquinolone treatment
(Guerding 2004). Deshpande et al., (2008) suggested an association between
fluoroquinolone use and CDI caused by the hypervirulent 027 ribotype and this was
later supported by Sundram et al., (2009). The duration of antibiotic exposure and the
number of antibiotics a patient is treated with are further risk factors for CDI
development (Pepin et al., 2005).
Age
Nosocomial CDI is primarily seen in those over 65 years (Sunenshine & McDonald,
2006; McFarland et al., 1995). This population's susceptibility to CDI is thought to
relate to increased co-morbidity such as underlying disease including chronic renal
impairment and malignancy; increased exposure to common risk factors such as
antibiotics and increased hospitalisation. These patients are also more likely to be on
immunosuppressive agents decreasing their immune response to enteric pathogens
and have greater alterations in the normal gut flora (Hopkins et al., 2002).
CDI is now also being diagnosed in previously low risk groups mainly children
peripartum women and young healthy adults (Benson et al., 2007; Kim et al., 2008;
Rouphael et al., 2008). Most of these infections are thought to be community acquired
and are less likely to be associated with morbidity or mortality (Naggie et al., 2010).
However mortality has been associated with the peripartum group in particular
(Rouphael et al., 2008).
Co-morbidity
Co-morbidity and immunosuppression increases with age along with the associated
risk of CDI (Pepin et al., 2004). Co-morbidities include diabetes mellitus, HIV
infection, malignancy, cellulitis, anaemia, burns patients, and gastro-intestinal,
pulmonary and urinary tract infections to name but a few (Kyne et al., 2002, Changela
et al., 2004; Polgreen et al., 2010).
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Inflammatory bowel diseases including Crohn's disease and ulcerative colitis have
both been associated with higher rates of CDI (Riccardi et al., 2009; Nguyen el al.,
2008). These patients are often from a younger patient cohort. Increased mortality has
been reported in patients with inflammatory bowel disease and CDI then
inflammatory bowel disease alone (Pituch, 2009).
Patients who have undergone recent surgery are also at increased risk of CDI
development with CDI rates in patients who have undergone abdominal surgery
quoted at 6% to 9% (Bradbury, 1997). (Surgery and CDI is discussed further in
chapter 4).
These co-morbidities are thought to impair the immune response of the host making
them more susceptible to CDI (Kyne et al., 2002). In addition they propagate other
risk factors by increasing the likelihood patients are on antibiotics, immune
modulating agents and had recent or prolonged hospitalisation (McFarland et al.,
1990).
Duration of hospitalisation
The risk of acquiring CDI was found to be directly proportional to the length of stay
in hospital (Johnson & Gerding, 1998). Colonisation rates in hospitalised patients
were noted to be high between 14% and 20% (Kyne et al., 2002 and Johnson &
Gerding, 1998). More recent colonisation rates are discussed further in chapter 5.
Patients who were transferred between several wards were also found to be at
increased risk of CDI (Starr et al., 2003) as they were more likely to have prolonged
hospitalisation and exposure to antibiotics.
Gastric acid suppression
Proton pump inhibitors PPIs are often suggested as risk factors for CDI (Dial et al.,
2006). By making the pH of gastric acid less acidic it was thought that C. difficile
vegetative cells are able to survive and therefore increase the risk of infection. Their
effects were demonstrated in animal models and the subsequent inflammatory
response following infection in these animals was comparable to that of antibiotics
(Kaur et al., 2007). However several other studies have found either no link or a
limited link between CDI and PPIs (Wilcox et al., 2008, Muto et al., 2005).
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Other interventions and treatments
Chemotherapeutic agents, diuretics, opiates, laxatives and bowel preparatory agents
have all been suggested to be associated with increased risk of CDI (Halim et al.,
1997; Raveh et al., 2006; McFarland et al., 1990, Faris et al., 2010). Procedures such
as nasogastric tube placement, enema administration and endoscopy have also been
associated with an increased risk of CDI (Kyne et al., 1999; McFarland et al., 1990).
This may reflect contamination of equipment with spores rather than decreased host
defences mechanisms.
Strain type
The large variety of C. difficile strains can stimulate a varied inflammatory response
in the patient and the extent of CDI is also dependant on the host's immunity. Certain
hypervirulent strains notably ribotype 027 (Pepin et al., 2005) and more recently 078
(Jhung et al., 2008) have been reported on. Ribotype 027 was seen to cause increased
disease severity and increased disease transmission. Other ribotypes 001 and 016 have
also been associated with severe disease (Arvand et al., 2009).
1.7 The disease spectrum of Clostridium difficile infection
The spectrum of C. difficile disease is varied with simple colitis being the most
common form of symptomatic disease. The following disease spectrum categories are
adapted from Bradbury, 1997; Dallal et al., 2002 and Starr et al., 2005. The more
severe forms ofCDI are discussed further in chapter 4.
1.7.1 Asymptomatic carriage
Asymptomatic carriage has commonly been reported in neonates and children and
carrier rates in these populations varied from 4% to 60% (Hoist et al., 1981,
McFarland et al., 2000). Asymptomatic C. difficile carriage in healthy adults also
occurs but not as commonly as in neonates and infants, with adult carriage rates
varying from 3% to 7% (Kato et al., 2001; Kelly & Lamont, 1998). Asymptomatic
carriage and its potential importance in the adult population are discussed further in
chapter 5.
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1.7.2 Simple colitis and severe colitis
Patients with simple C. difficile induced colitis develop mild to moderate watery
diarrhoea which occurs greater than two to three times a day, and can be associated
with colicky lower abdominal pain. The faeces produced is foul-smelling, due to the
characteristic smell of C. difficile. Occasionally the diarrhoea may contain mucus and
rarely blood.
Patients with severe colitis often have diarrhoea greater than five times per day and
have more severe abdominal pain and abdominal distension can be present. They
often have a leucocytosis and occasionally leucopaenia.
1.7.3 Pseudomembranous colitis (PMC)
Pseudomembranous colitis is one of the severest forms of CDI and is rare compared
to the milder CDI forms. PMC is often a florid pancolitis but can occur segmentally
and also eccentrically to involve the bowel wall. PMC gains its terminology from the
classic yellow adherent plaques seen at sigmoidoscopy that can be scraped off the
luminal surface of the bowel hence the term pseudomembrane. The
pseudomembranous plaques can range in size from 2 to 10 mm or may be confluent.
As previously mentioned the pseudomembranes are made up of neutrophils, mucus,
fibrin and sloughed epithelium. Patients with PMC often have severe abdominal pain
and abdominal distension with a marked leucocytosis and hypoalbuminaemia.
Diarrhoea is not always present.
Patients with typhlitis have a similar presentation and are severely immunosuppressed
due to a pre-existing condition. The term typhlitis originally related to inflammation
of the caecum only but has now become a generic term and includes the whole colon.
These patients do not have pseudomembranous formation as they are neutropaenic.
1.7.4 Fulminant colitis
Fulminant colitis the most severe form of pseudomembranous colitis and is a very
rare presentation of the disease. These patients are usually those that require surgical
intervention for treatment. This presentation of CDI is discussed in more detail in
chapter 4.
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1.7.5 Small bowel enteritis
Spore germination is not affected by aerobic conditions (Wheldon et al., 2008), and
therefore spores germinate within the small bowel. Patients who have ileostomies or
ileo-anal pouches have been found to have CDI and in some cases
pseudomembranous enteritis (Hayetian et al., 2006). This is thought to occur due to
histological changes in the ileal mucosa which results in a neo colonic environment
(Mann et al., 2003).
1.7.6 Community-acquired CDI
Although CDI is classically regarded as a nosocomial infection, community-related
CDI cases are increasing and have been reported in up to 34% of cases (Kutty et al.,
(2008). The European Centre for Disease Prevention and Control defined community
acquired CDI as the onset of CDI symptoms outside a healthcare facility with the
patient not having been discharged from a healthcare facility within 12 weeks of the
onset of symptoms or the onset of symptoms within 48 hours of admission to a
healthcare facility without a healthcare stay within 12 weeks preceding the symptom
onset (Kuijper & van Dissel, 2008). Community acquired CDI can affect a younger
age group (CDC, 2008) and often patients have no underlying risk factors or previous
antibiotic exposure (Wilcox et al., 2008).
1.8 Clostridium difficile diagnosis
This section is described in more detail in chapters 4 and 5.
1.8.1 Clinical diagnosis
Clinical diagnosis is dependant upon the clinical symptoms of the patient and
recognition of the disease and a patient's risk factors by health-care professionals.
Following certain risk factors in particular exposure to antibiotics clinical suspicion
for CDI should be high.
1.8.2 Laboratory diagnosis
This is most commonly done by detection of C. difficile toxins A and / or B in faecal
specimens. Many laboratories use commercially produced enzyme immunoassay kits
to detect any available toxins within the faecal samples. Those that test for both A and
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B toxins should be ideally used due to toxin A-B+ C. difficile strains which can also
cause symptomatic disease.
Further laboratory tests such as cytotoxic assay, toxigenic culture, glutamate
dehydrogenase antigen detection, PCR assays and nucleic acid amplification tests are
discussed further in chapter 5.
1.9 Treatment
1.9.1 Conventional therapy
In those patients with mild CDI stopping the inciting antibiotic may be all that is
required. In 20% to 30% of CDI patients symptoms can resolve without further
treatment (Starr, 2005; Johal et al., 2004).
For those patients requiring antibiotic therapy metronidazole, vancomycin, bacitracin,
fusidic acid and teicoplanin have all been shown to be effective for CDI treatment
(Nelson, 2007). Oral metronidazole and oral vancomycin are the most commonly
prescribed antibiotics for CDI treatment. Metronidazole is usually commenced in the
first instance for milder disease; this is partly related to cost and also due to the
presence of vancomycin resistant enterococcus. Vancomycin has been found to be
more effective in severe and recurrent disease (Sailhamer et al., 2009), whereas
increased failure rates and recurrence rates have been reported with metronidazole
therapy (Pepin et al., 2005). A combination of intravenous metronidazole and
nasogastric/oral vancomycin is given to patients with the most severe forms of CDI
(Lothian prescribing guidelines 2010).
1.9.2 New antimicrobials
Fidaxomicin is a new macrocyclic antibiotic for the treatment of CDI and it has been
found to be superior to vancomycin for clinical cure and time to resolution of
symptoms. The greatest use for this antibiotic is for those patients with recurrent
disease as fidaxomicin has been shown to produce fewer recurrences (Poxton, 2010).
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1.9.3 Probiotics and faecal microbiota transplants
Since disruption of the normal intestinal flora leads to CDI, restoration of the
intestinal flora through replacement by other means has been considered as an
alternative therapeutic option.
Generally only inconclusive evidence on the benefits of probiotics is available (Pillai
& Nelson 2008) and on occasion probiotics have been the cause of fungaemia and
bacteraemia in critically ill and immunocompromised patients (Tung et ah, 2009).
Faecal microbiota transplants although less appealing have been performed with
success to treat primarily recurrent CDI (Nood et al., 2009). This process uses healthy
donor stool usually from a patient's relative which is administered via a nasojejenal
tube or as an enema.
1.9.4 Non toxigenic Clostridium difficile strains
The aim of this therapy is to colonise the colon of patients who have been treated for
initial episodes of CDI with non-toxigenic C. difficile strains to prevent re-infection
with toxigenic strains. Trials are currently continuing to determine if this will help
prevent recurrent CDI.
1.9.5 Vaccines
A vaccine containing toxoids A and B have been shown to resolve recurrent CDI
symptoms in a study of three patients (Sougioultzis et al., 2005). Six months
following vaccination the patients remained symptom free. Transcutaeneous injection
with toxoid A in conjunction with cholera toxin in an animal model using mice
induced both systemic and mucosal responses and may be a further immunisation
technique (Ghose et al., 2007).
1.9.6 Surgery
Surgery is usually only performed in cases of fulminant colitis, however mortality
rates are high (Longo el al., 2004). Prompt surgical referral for patients with severe
CDI not responding to aggressive medical management is advised (Sailhamer et al.,
2009). Surgery for CDI is discussed in depth in chapter 4.
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1.10 Prevention and control of Clostridium difficile infection
Prevention and control of CDI in healthcare facilities involves effective
decontamination of the environment, good hand hygiene and barrier precautions and
restriction of the use of antibiotics (Gerding et al., 2008; Vonberg et al., 2008) and all
these strategies have been shown to reduce CDI rates. The prevention and control of
CDI is discussed in greater depth in chapter 6.
1.11 Aims
The main intentions of this thesis were to determine the local extent of CDI within
hospitals and to establish the epidemiology of CDI within the specialty of colorectal
surgery. This thesis consists of four studies, with their aims as follows:
1. Very limited information had been published on the burden of CDI to the
diagnostic laboratory and the relative incidence of disease in different clinical
specialties due to a paucity of suitable data. The study used locally collected
data from 2000 to 2007 to assess the laboratory workload associated with C.
difficile testing, and the potential clinical workload by calculating the maximal
potential rates of CDI across all specialties and age groups. Severe outbreaks
of C. difficile nosocomial diarrhoea caused by Type 027/BI/NAP 1 had been
seen worldwide since 2003 and dominated prevalence studies pertaining to C.
difficile. This study provided data on an area that had not been affected by this
strain during the period of the study.
2. This study used locally collected data to assess the potential impact of CDI
within all surgical services as very few studies had compared the individual
surgical specialties within the same urban population. In the absence of
hypervirulent C. difficile, a further aim of this study was to assess if the more
severe and extreme forms of C. difficile disease were occurring and to
determine the proportion of patients affected and treated for the critical forms
of CDI. The final aim of this study was to review the cohort of patients who
had undergone surgical treatment for severe CDI.
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3. The aim of this study was to prospectively determine the specific burden of C.
difficile in the colorectal surgical patient population. This involved assessing
the efficacy of hospital laboratory diagnostic testing methods for CDI and
determining asymptomatic carrier rates and in-patient CDI rates within the
colorectal surgical population. In addition the study aimed to provide
epidemiological data on the strains of C. difficile and their antibiotic resistance
patterns within this particular patient cohort.
4. This final study aimed to review the effect of C. difficile environmental
surface contamination within the colorectal surgical wards. The study aimed to
determine the extent of environmental C. difficile surface contamination and
identify potential surface reservoirs for C. difficile. In addition the study was
designed to assess changes in C. difficile surface contamination and the
incidence of CDI within colorectal surgical in-patients following
implementation of a new cleaning strategy. The final study objective was to
provide epidemiological data of C. difficile strains found in the colorectal
surgical wards surface environment and to compare them with those found in
the colorectal surgical in-patient population.
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2. Materials and Methods
2.1 Lothian database analysis for Clostridium difficile
2.1.1 Setting
Lothian University Hospitals Division (LUHD) provides services for around 620 000
people in the Edinburgh area of South-East Scotland (the second largest residential
population in Scotland). Six of the major LUHD hospitals based within Edinburgh,
comprising three tertiary and three secondary care hospitals and totalling
approximately 2300 beds, were included in our analysis.
2.1.2 Laboratory diagnosis of Clostridium difficile
All faecal samples were processed by Lothian microbiology staff, in a single
combined enteric microbiology laboratory for all the hospitals, following local
guidelines prior to September 2006 and national guidelines after September 2006
(Health Protection Scotland, Protocol for the Scottish Surveillance Programme for
Clostridium difficile Associated Disease, User Manual, Version 2.0, Revised October
2007). From 2003 to 2008 inclusive, all diarrhoeal (semi, unformed or liquid) faecal
samples were tested if they were from hospital in-patients aged over 1 year old, if a
diagnosis of antibiotic-associated diarrhoea or pseudomembranous colitis was present,
on clinical request, or if the patient had been on recent antibiotic therapy. Appropriate
faecal samples were tested for the presence of C. difficile toxins A and B via
commercial enzyme immunoassay kits in accordance with the manufacturer's
guidelines.
2.1.3 Inclusion Criteria
All in-patients from whom a faecal sample was submitted for C. difficile toxin testing
were included in the data analysis. Patients were identified using the hospital
laboratory computer filing system (Apex, iLab, Isoft, Banbury, UK) which stores
details of each sample tested from 2000 to date. The data available included patient
demographics, ward and speciality, where the patient was admitted at the time of
sample collection, date of sample collection, test performed and results. The database
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thus obtained, was filtered to exclude samples with indeterminate results, quality
control samples, and those from hospitals which were not included in the study.
In line with national Scottish guidelines a new potential CDI episode was defined as
"Only persons that have not been diagnosed with CDAD (Clostridium difficile-
associated disease) within the previous 28 days are counted as new cases" (HPS 2007.
Annual report on the surveillance of Clostridium difficile-associated disease in
Scotland, October 2006-September 2007. The HPS C. difficile Working Group,
December 2007). Therefore any repeat samples taken within a 28 day period
following a positive toxin result for any individual patient were also excluded.
Retrospective analysis of this prospectively collected data was then performed.
2.1.4 Potential Clostridium difficile infection rates
With recognition that every faecal sample that tests positive for C. difficile toxin does
not always equate to symptomatic CDI, we have referred to the information gathered
as potential CDI rates.
Potential CDI rates were calculated as potential episodes per 1000 in-patient occupied
bed days (OBD) using statistics data obtained from the Information Analysis
Department of the Health Intelligence Unit at NHS Lothian, courtesy of Ms Caroline
Brown, on annual hospital occupied bed days from 2000 - 2007 per speciality. Data
for renal medicine and transplant surgery had to be combined due to the combined
ward set-up within Edinburgh from 2003. Therefore potential incidence rates for the
renal medicine / transplant surgery specialty are only provided from 2003 - 2007.
The paediatric population i.e. under 18 years old, were excluded from the calculation
of total potential CDI rates for the Edinburgh Lothian Hospitals, as paediatric age
groups have been previously reported to have disproportionately elevated carriage
rates (Tullus et al., 1989 and Bryant et al., 2009). This enables comparison of our




The most recent published data at the time of analysis was used to calculate potential
associated costs (Vonberg el al., 2008).
2.2 Colorectal surgical in-patient database analysis
2.2.1 Patient identification
The cohort of colorectal surgical in-patients identified from the total Lothian in¬
patient database analysis was assessed further.
In addition, patients who had required surgical treatment for severe CDI resulting in
pseudomembranous colitis, over a ten year period from 1997 to 2006 inclusive, were
identified using the Lothian Surgical Audit database and pathological data obtained
from the Lothian hospital pathology filing system (APEX). 2007 data was not used as
it was not available during the period of initial analysis.
2.2.2 Clostridium difficile diagnosis
Only those patients with a histo-pathological diagnosis of pseudomembranous colitis
in their colectomy specimens between 1997 and 2006 inclusive were included in the
database analysis surgical outcome sub-group.
For the surgically treated patient sub-group, clinical notes and the microbiology
database were further scrutinised in order to obtain further clinical information.
2.3 Clostridium difficile carriers
2.3.1 Clinical setting and study participants
The Lothian colorectal service is primarily situated at the Western General Hospital in
Edinburgh. The carrier cohort were recruited from those colorectal patients either
attending the Western General Hospital colorectal service via the surgical out-patient
clinic or those patients admitted for elective surgery including day-case and in-patient
admission. Consent from the study participants was obtained by me.
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2.3.2 Study group
Study participants were allocated a sequential identification number by Dr Allison
Wroe as part of her Doctor of Philosophy thesis and this number was used to identify
the faecal isolates.
Carriers were defined as those individuals who were asymptomatic and faecal sample
culture positive for C. difficile.
2.3.3 Carrier faecal sample collection
Faecal samples were collected by me from asymptomatic participants during clinic
appointments or on the day of admission for elective procedures prior to any surgical
intervention. These samples were obtained in accordance with the terms granted and
governed by the Local Research Ethics Committee.
2.3.4 Carrier faecal sample analysis
Analysis of these samples was performed by Dr Allison Wroe. Fresh faecal samples
i.e. within 24 hours of collection were assessed for the presence of toxins A and B
using a commercial ELISA kit (TechLab) in accordance with the manufacturer's
protocol.
Culture of faecal samples and identification and characterisation of C. difficile was
performed as per sections 2.4.3 to 2.4.5 and section 2.5.
2.4 Identification of Clostridium difficile in colorectal surgical
in-patients
2.4.1 Clinical setting
In-patient colorectal services are situated at the Western General Hospital in
Edinburgh. The in-patient colorectal surgical wards at the time of the study were
wards 22, 23, 24 and 27. Ward 58 is the surgical High Dependency Unit. In-patient
colorectal surgical boarders were situated in other speciality wards namely wards 56,
57 and 25.
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2.4.1 Colorectal in-patient faecal sample collection
All faecal samples submitted to Lothian Hospitals microbiology enteric laboratory for
C. difficile testing were processed following national guidelines. During the period of
the study hospital diarrhoeal in-patient samples were tested by the enteric laboratory
for C. difficile toxins A and B by enzyme immunoassay. All faecal samples submitted
to the enteric laboratory from the colorectal surgical in-patient wards were reclaimed
by me on a weekly basis. Any submitted faecal samples from colorectal in-patient
surgical boarders on other wards were also reclaimed.
Faecal samples were reclaimed from the enteric laboratory from the period November
2007 to January 2009 inclusive.
The non identifiable patient faecal sample specimen number issued by the lab for each
sample was maintained during the study to allow for continuity.
Samples were collected and analysed in accordance with the terms granted by the
Local Research Ethics Committee. Due to the fact that samples were collected latterly
from the enteric laboratory, any findings relating to a sample and hence a particular
patient would therefore be retrospective and hence any findings of the study was not
to impact on individual patient treatment.
2.4.2 Diarrhoeal Samples
All faecal samples collected were assessed for consistency using the Bristol Stool
Chart. Dual observation for agreement between myself and Mr M. Baldock was used





Separate hard lumps, like nuts
(hard to pass)
Type 2 mSausage-shaped but lumpy
Type 3
Like a sausage but with
cracks on the surface
Type 4
Like a sausage or snake,
smooth and soft
Type 5
Soft blobs with clear-cut
edges
Type 6 Fluffy pieces with ragged




Watery, no solid pieces.
Entirely Liquid
Figure 2.1 Bristol Stool Chart used for determining the consistency of faecal samples
to identify diarrhoeal faecal samples.
2.4.3 Culture of faecal samples
All faecal samples reclaimed from the enteric laboratory were cultured on Brazier's
CCEY (cefoxitin, cycloserine and egg yolk) agar (Oxoid) and incubated at 37°C
under anaerobic conditions (10% hydrogen, 10% carbon dioxide and 80% nitrogen) in
an anaerobic chamber (Don Whitley Scientific, Mark III station). These cultures were
then reviewed at 24 hours, 48 hours and 5 days for the presence of C. difficile
colonies.
All faecal samples that were C. difficile culture negative but identified as toxin
positive by the enteric laboratory were re-cultured.
2.4.4 Identification of Clostridium difficile
C. difficile identification was made on characteristic colony morphology, smell and
Gram stain. Colonies were assessed for characteristic chartreuse, golden-yellow,
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fluorescence under a Wood's lamp (long wave UV light) and motility in a wet film by
light microscopy.
2.4.5 Storage of Clostridium difficile isolates
A single colony only was isolated per culture positive sample and stored as spores in
Robertson's cooked meat broth medium (Watt, 1973 and Brown et al., 1996) at room
temperature.
2.5 Characterisation of isolates
2.5.1 In-vitro detection of toxin production
C. difficile isolates obtained from the culture positive faecal samples and stored in
Robertson's cooked meat broth were plated on blood agar (39g/L Columbia agar base,
5% defibrinated horse blood) and incubated anaerobically. The isolates were then sub-
cultured into 3mls of pre-reduced proteose peptone, yeast extract medium (PPY;
20g/L proteose peptone, 5g/L yeast extract, 5g/L trypticase, 5g/L NaCl, 0.75g/L L-
cysteine-HCl, 0.4g/L Na2C03; pH7.1) and incubated anaerobically for 48 hours.
The growth medium for each isolate was then tested for C. difficile toxins A and B
using Tox A/B II™ (Techlab) kit. 1ml of the PPY culture supernatant was centrifuged
at 16000 g for 1 minute, the supernatant was then diluted 5-fold in buffered diluent.
The supernatant samples were then used to test for the presence of toxin in accordance
with the manufacturer's protocol. Positive and negative controls were always tested
with any samples. All isolates were tested in triplicate.
2.5.2 DNA extraction
Genomic DNA was extracted using two methods:
1. Using 1ml of C. difficile overnight cultures, these were centrifuged at 16000 g
for 2 minutes. The NucleoSpin kit (Macherey-Nagel GmbH) was used to
extract DNA by lysis of cells in a Proteinase K/SDS solution at 56°C for 3
hours. DNA was then bound to a silica filter using ethanol, following washing
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with two buffers to remove contaminants; DNA was eluted using 100 jd of
alkaline elution buffer.
2. Colonies grown on blood agar plates were suspended in a 5% Chelex-100
suspension (Bio-Rad Laboratories) and boiled for 10 minutes. The suspensions
were centrifuged at 16000g for 2 minutes to separate out the DNA containing
supernatant. The supernatant was aliquoted and stored at -20 °C.
2.5.3 Ribotyping
Using the method described by O'Neill et al., (1996) ribotyping was performed by
amplification of the 16S-23S rRNA intergenic spacer region. The primers used were:
5' -CTGGGGTGAAGTCGTAACAAGG-3'
5 '-GCGCCCTTTGTAGCTTGACC-3'
Amplification was performed in a 50j.il reaction mixture containing 1.5 mM MgCL
lOMm Tris-HCl, 50mM KC1, 2U of Taq polymerase (Promega), 200pM of each
dNTP (Amersham Pharmacia BioTech), 50 pmol of each primer and lOgl of genomic
DNA or sterile water for negative controls.
The thermal PCR profile used involved initial denaturation at 94°C for 4 minutes
followed by 35 amplification cycles of denaturation at 96°C for 1 minute; annealing at
56°C for 1 minute and extension at 72°C for 1 minute, with a final elongation step at
72°C for 5 minutes. The PCR products were concentrated by heating at 45°C for 100
minutes. A 3% Metaphor gel (ABgene) containing 30j.il of Safe View Nucleic Acid
Stain (NBS Biologicals) was used for the product electrophoresis at 80V for 3 hours,
in conjunction with a 100 base pair ladder (Promega). The final gels were
photographed under UV light and the band patterns analysed by Bionumerics Gel
Compar software which compared them with those held on the local laboratory
database to determine the ribotypes.
Limited ribotyping was performed by myself on 20 isolates. The main body of
ribotyping data was produced by Dr M Desai under the direction of Prof H Shah at the
Health Protection Agency, Colindale, London; by use of a multi-analyser system used
for multilocus variable number tandem-repeat analysis (MLVA) typing of a number
of bacterial and viral organisms. AH C. difficile isolates obtained during the study
were transported to Colindale on charcoal swabs.
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2.5.4 Toxinotyping
Using the method described by Rupnik et a/., (1997; 1998) toxinotyping was
performed. The fragments of tedA (A3) and tcdB (Bl) genes were amplified by PCR.
The primers used to amplify the B1 fragment are:
5AGAAAATTTTATGAGTTTAGTTAATAGAAA-3'
5' -CAGATAATGTAGGAAGTAAGTCTATAG-3'
The primers used to amplify the A3 fragment are:
5'-TATTGATAGCACCTGATTTATATACAAG-3'
5 '-TTATCAAACATATATTTTAGCCATATATC-3'
The amplified PCR products were then digested by restriction enzymes.
Amplification was performed in a 50gl reaction mixture containing 1.5mM MgCfy
lOmM Tris-HCL, 50mM KC1, 0.5U of Taq polymerase (Promega), 200 pi of each
dNTP (Amersham Pharmacia Biotech), 50pmol of each primer and 5pl of genomic
DNA or sterile water for negative controls. Amplification of the A3 fragment reaction
mixture also contained 5mg bovine serum albumin (BSA, Sigma-Aldrich), 0.05% W1
and TMA (tetramethylammonium chloride, Sigma-Aldrich) with a final concentration
of ImM.
The thermal PCR profile used involved initial denaturation at 93°C for 3 minutes,
followed by 35 amplification cycles involving annealing and extension at 47°C for 8
minutes; denaturation at 93°C for 4 seconds and a final extension at 47°C for 10
minutes. PCR products were concentrated by heating at 75°C for 45 minutes.
Restriction was performed for A3 using 1 Opl of product and 2pl of the enzyme EcoRI
and for Bl 20pl of product was digested using the enzymes HincII, lpl, and AccI,
1 (4.1. (Enzymes were obtained from New Engand BioLabs). Incubation at 37°C for 2
hours allowed completion of the restriction fragment length polymorphism step. The
final fragments were visualised on a 1% agarose gel which had been placed in Tris-
borate-EDTA buffer (TBE) containing lOpl of SafeVeiw nucleic acid stain (NBS
Biologicals). The toxinotypes were determined by reference to the Rupnik et a!.,
papers.
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2.6 Antibiotic Susceptibility testing
2.6.1 Antibiotics
Antimicrobial susceptibility testing of the C. difficile isolates was performed using
four antibiotics; ceftriaxone, ciprofloxacin, metronidazole and vancomycin. These
antibiotics were chosen as metronidazole and vancomycin were used to treat CDI,
ceftriaxone was the commonest used antibiotic along with metronidazole in colorectal
surgery at the time of this study and fluoroquinolone use was being increasingly used
in other specialties. The concentrations tested and the guidelines for minimum
inhibitory concentration interpretation were adapted from the Clinical Laboratories
Standards Institute Guidelines criteria for anaerobes (Mutlu et al., 2007), and are as
follows:
Range of Susceptible Intermediate Resistant
Antibiotic concentrations (pg/ml) (pg/ml) (pg/ml)
tested (pg/ml)
Ceftriaxone 16.0-256.0 <16 32 >64
Ciprofloxacin 4.0-128.0 >16
Metronidazole ©Gi 1 00 o <8 16 >32
Vancomycin ©001o <2 4- 16 >32
2.6.2 Minimum inhibitory concentration (MIC)
The Wadsworth agar-dilution method was used to assess the minimum inhibitory
concentrations for each antibiotic. For two isolates where the MIC could not be
clearly determined for Metronidazole E-test strips were used.
The C. difficile isolates were sub-cultured from the Robertson's cooked meat broth
stores and grown on blood agar. Following anaerobic incubation at 37°C for 24 to 48
hours, a minimum of five colonies were inoculated into 3mls of pre-reduced
thioglycollate medium (Oxoid) enriched with 5pg/ml haemin, lpg/ml vitamin Ki and
lmg NaHCCb ml"1, which were incubated anaerobically overnight at 37°C. The
turbidity of the cultures were adjusted to an optical density of 0.5 McFarland standard
by the further addition of pre-reduced enriched thioglycollate broth. Aliquots of the
cultures were spotted under aseptic technique using a multipoint inoculator onto pre-
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reduced Brucella agar (Oxoid) supplemented with haemin 5pg/ml, 5% lysed horse
blood, vitamin Ki and 2ml of a given concentration of an antibiotic. The antibiotic
stocks (lOOOOpg/ml) were diluted ten-fold to the maximal initial concentration to be
tested, then two-fold stock dilutions were prepared using distilled water until the ten¬
fold minimal concentration per antibiotic to be tested was attained. The lowest
concentration plate for each set of antibiotics was inoculated first. Two quality control
plates prepared with 2mls of distilled water to replace the antibiotic agent were also
inoculated prior to and a further two control plates after each antibiotic set. The
control plates were then separated for aerobic and anaerobic incubation to assess for
contamination. The C. difficile reference strain 630 was used as a control strain, this
strain belongs to ribotype 012 and represents an historic isolate in Scotland, with its
MICs available from a previous study with the exception of ciprofloxacin
(Drummond et al., 2003). Growth on the plates was assessed at 24 and 48 hours of
incubation and the MIC of each antibiotic for each isolate were determined by the
lowest concentration of antibiotic to inhibit visible bacterial growth. All isolate MIC
testing was repeated in triplicate.
The E-test method was performed on two isolates where despite triplicate assessment
the MIC for metronidazole could not be accurately determined. Isolate cultures were
swabbed onto the pre-reduced enriched Brucella agar plates to obtain a lawn of
growth. Metronidazole test strips were kindly donated by the enteric laboratory of
NHS Lothian, these were impregnated with an exponential gradient of antibiotic and
were smoothly placed on each isolates' plate. The plates were incubated anaerobically
at 37°C and assessed at 24 and 48hours. The MIC was determined by the antibiotic
concentration on the strip where the isolate growth zone of inhibition began.
2.7 Environmental Contamination of Clostridium difficile
2.7A Setting
The acute surgical wards with colorectal surgical patients at the Western General
Hospital Edinburgh with the exception of the surgical High Dependency Unit were
sampled for the presence of C. difficile. The wards sampled were 22, 23, 24 and 27,
comprising 80 beds. Ward 22 at the start of the study became primarily a day-case
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with overnight stay ward for both Colorectal and Urology surgical patients. Please
note these were the same wards from which patient faecal samples were reclaimed
from the enteric laboratory.
2.7.2 Environmental Sampling
During the period January 2008 to March 2009 inclusive, 180 Brazier's CCEY
contact plates were used to sample the aforementioned colorectal surgical wards
environment approximately every six weeks, with the first sampling session in
January 2008 commenced at the end of the month. The same areas were sampled on
each occasion using the same method, in the same manner to provide consistency.
The surfaces were sampled by touching the domed inverse meniscus agar of the
contact plate to the required surface. The plates were labelled in conjunction with the
sampling process. Following completion of sampling within the hospital environment,
the plates were transported by car to our laboratory. The contact plates were incubated
within the anaerobic chamber at 37°C and assessed at 48 hours and 5 days for C.
difficile growth. Any C. difficile isolates were identified and assessed as per previous
sections 2.4.4 and 2.5.
A new cleaning regime was introduced by NHS Lothian on 3rd June 2008, six months
into the study. The new cleaning protocol was integrated into an existing infection
control pathway. Once a patient with diarrhoea was identified in a shared main bay,
the patient was isolated in a side room and a faecal sample was to be obtained for
microbiology testing. The new cleaning protocol involved requesting a terminal clean
of vacated bed spaces and the surrounding environment with Actichlor plus (sodium
dichloroisocyanurate (NaDCC)) at a concentration of lOOOppm and a bed space
curtain change. Once the patient was isolated, the room door was to be kept closed
and standard infection control precautions implemented. Soap and water only was to
be used for hand hygiene and gloves and apron for contact with the patient and their
room environment. A daily clean with Actichlor plus, again at lOOOppm, of the
isolated symptomatic patient's room environment and equipment was to occur.
Isolated patient's also had disposable equipment for the duration of their isolation
such as blood pressure monitor (sphygmomanometer) cuffs.
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Actichlor plus replaced the standard detergents of a quaternary ammonium based
compound and or bleach (sodium hypochlorite (NaOCl) the dilution of which was
variable between 1000 to 3000ppm) for deep cleaning.
2.8 Ethics approval
Permission for samples obtained to determine the asymptomatic carrier rate was
provided by the Lothian Local Research Ethics Committee. An addendum to the
provided ethical approval was also submitted and granted in regards to reclamation
and assessment of faecal samples from the enteric laboratory with no results obtained
to interfere with individual patient management as the faecal samples would be
retrospectively collected weekly. Review of any patient clinical data was performed
by me as stipulated in the given ethical approval. Local Caldicott approval was given
for review and analysis of the microbiology databases. Review and analysis of the
surgical and pathological databases, in addition to review of patient data was covered
by ethical approval, local ethics and local audit procedures and guidelines.
Environmental sampling was performed following permission of the Colorectal
Surgical Team including consultants and charge nurses in addition to the Infection
Control Team at the Western General Hospital at the time of the study. Environmental
sampling was only performed when it would not interfere with any patient care or
privacy and therefore verbal consent was also taken for each patient prior to sampling
of their bed area.
2.9 Statistical Analysis
All statistical analysis was performed using the GraphPad Software Prism 4.0. Data
were analysed using the Student's unpaired t-test and the Kruskal-Wallis one-way
analysis of variance (ANOVA) testing. P values of < 0.05 were considered
statistically significant.
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3. Changes in local trends, laboratory and clinical
workload for Clostridium difficile infection from 2000 -
2007.
3.1 Introduction
The incidence of Clostridium difficile infection has increased particularly in the
industrialised world over the past three decades. CDI is the principal cause of
nosocomial diarrhoea in adults in these countries and is an important cause of
antibiotic-associated diarrhoea.
Very limited information had been published on the burden of CDI to the diagnostic
laboratory, and the relative incidence of disease in different clinical specialties was
not well known at the time of this study. This was largely due to the paucity of
suitable data. In Scotland voluntary data submission of CDI was present from 1984,
with reporting of CDI becoming mandatory for those aged 65 years and over in
September 2006.
The study aimed to use locally collected data from 2000 to 2007 to assess the
laboratory workload associated with C. difficile testing and to analyse the maximal
potential rates of CDI across specialties and age groups, thus providing information
on potential clinical workload. Severe outbreaks of C. difficile nosocomial diarrhoea
caused by Type 027/BI/NAP 1 have been seen worldwide since 2003. However, this
chapter provides data on an area that has not been affected by this strain during the
time period of the analysis. To our knowledge this was one of the first studies to
provide information on laboratory workload associated with C. difficile testing.
The paediatric population i.e. under 18 years old, were excluded from the calculation
of total potential CDI rates for the region to enable comparison of our results with
other studies, which have only included populations aged 18 and over. Therefore most




Over the analysis period a total of 50589 faecal samples were tested for C. difficile
toxin, of these 7294 were positive (14.4%). After excluding repeat positive samples
from the same patient in a 28-day period, 5909 new potential episodes of CDI were
identified in the period 2000-2007, increasing from 112 potential cases in 2000 to
1231 in 2006 (Figure 3.1a). The overall rate of potential CDI for in-patients admitted
over this period was 1.52 cases per 1000 in-patient occupied bed days (OBD),
increasing from 0.36 potential cases/1000 OBD in 2000 to a peak of 1.98 potential
cases/1000 OBD in 2006 (Figure 3.1b). Although both graphs follow different
patterns; both the potential number and rate of CDI episodes fell in 2007 to 928 and
1.48 cases/1000 OBD, respectively.
Laboratory Workload
The number of faecal samples tested for C. difficile increased from 526 in 2000 to
14207 in 2006 falling to 10359 in 2007. Although the proportion of these samples
identified as positive has decreased from 28% in 2000 to 11% in 2007, with the
proportion of positive samples from 2003 to 2007 varying annually from 11% to 16%
(Figure 3.2a). There was an almost equal division of samples sent from Medicine of
the Elderly, all Medical Specialties and all Surgical Specialties. Medicine of the
Elderly was the specialty which sent the greatest number of samples for analysis
overall and was almost double the proportion of samples sent by the next three
specialties individually; these were General Surgery, Gastrointestinal Medicine and
Infectious Diseases. Medicine of the Elderly had the greatest proportion of positive
samples (24%) followed by Urology (17.7%), Renal Medicine and Transplant Surgery
(16.8%), Respiratory Medicine (15.7%) and General Surgery (15.5%) (Figure 3.2b).
Stratifying the data according to age, the greatest proportion of samples was sent from
the 61-80 year old age group and the highest positivity rate was seen in those aged
over 80 years. One third of all samples were sent from those aged 60 years or younger
and 18.5% of all positive samples came from this age group (Table 3.1).
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Clinical workload
Renal Medicine/Transplant Surgery with 7.36 cases/1000 OBD and Intensive Care
and High Dependency (ITU+HDU) with 5.73 cases/1000 OBD had the highest
potential incidences of CDI followed by Infectious Diseases and Gastrointestinal
Medicine whose rates were 4.75 and 4.26 cases/1000 OBD, respectively. Medicine of
the Elderly in comparison had an incidence of 1.95 cases/1000 OBD (Figure 3.3a).
On review of the trends in potential CDI incidence of the seven specialties with the
highest rates over the 8-year time frame (Figure 3.3b), all latterly had a reduction in
potential CDI rates despite following varying trends. Medicine of the Elderly,
Infectious Diseases and Gastrointestinal Medicine appeared to have the greatest rate
reduction. For each specialty the potential CDI rates peaked at different time points.
Renal Medicine and Transplant Surgery had a maximal rate in 2006, ITU+HDU in
2004, Infectious Diseases and Gastrointestinal Medicine in 2005, Medicine of the
Elderly in 2006, General Surgery in 2003 and General Medicine in 2002.
The incidence of potential CDI rates also increased with age, over the total study
period, from 0.33 cases/1000 OBD in the 0-20 years old age group to 1.81 cases/1000
OBD in the 61-80 years old age group. Similar to the specialty trends, all age groups
latterly saw a reduction in rates. The potential peak incidence occurred in 2002, 2003
and 2006 for those aged 41 years and over, with the peak incidence in the younger
two age groups, occurring later; in 2005 in the 21-40 years old age group and 2006 in
the 0-20 years old age group (Figure 3.4).
Of all toxin-positive patients 10.3% were transferred through a minimum of two
specialties and 17% of all these inter-specialty transferred patients were transferred
through a minimum of three to a maximum of six specialties. These transfers also
included movement through acute service areas which comprise Accident and
Emergency, Combined Assessment Units and Acute Receiving Units.
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Figure 3.1 Difference between the changing incidence and number if CDI episodes
from 2000-2007.
a) Total number of episodes of CDI per year (as defined by a stool sample
positive for C. difficile toxin). In the case of multiple positive samples from
the same patient within a 28-day period only one was included in the total.
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Figure 3.2 Trends in number of laboratory requests for Clostridium difficile toxin
detection 2000-2007. a) Total number of lab requests C. difficile detection per year
and b) Total number of lab requests for C. difficile distributed by specialty.
Shaded areas: positive results for C. difficile toxin; non-shaded areas negative results
for C. difficile toxin. HAEM-ONC: Haematology and Oncology; INF-DIS: Infectious
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Diseases, ITU/HDU: Intensive Care and High Dependency Units; MED: General
Medicine; MED-CARDIO: Cardiology; MOE: Medicine of the Elderly; MED-GI:
Gastrointestinal Medicine; MED-OTHER: includes all other medical specialties
including dermatology and rheumatology; MED-RESP: Respiratory Medicine;
RENAL MED: Renal Medicine and Transplant Surgery; SURG-CT: Cardiothoracic
Surgery; SURG-GEN: General Surgery; SURG-ORTH: Trauma and Orthopaedic
Surgery; SURG-OTHER: includes all other surgical specialties including vascular,
ENT, plastics and maxillo-facial ; SURG-URO: Urology; UNKNOWN: Samples that
could not be allocated to a particular specialty.
Age
range
Number of samples (%)
Tested Positive
0-20 2,060 (4.1) 104(1.4)
21-40 5,092 (10.1) 344 (4.7)
41-60 9,570 (18.9) 905 (12.4)
61-80 20,272 (40.1) 3,196 (43.8)
>80 13,595 (26.9) 2,745 (37.9)
Total 50589(100) 7294(14.2)
Table 3.1 Number of samples tested (total and proportion positive) by the laboratory




Figure 3.3 Distribution of CDI incidence among the various specialties from 2000-
2007. a) The overall incidence of CDI episodes per 1000 occupied patient bed days
per specialty and b). Annual incidence ofCDI in the seven specialties with the highest
overall incidence of CDI (episodes per 1000 occupied patient bed days). (Data for
Renal Medicine and Transplant Surgery available from 2003 onwards only), Key as
for figure 3.2.
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Figure 3.4 Distribution of annual age-related CDI incidence (episodes per 1000
OBD) from 2000-2007.
2000 2001 2002 2003 2004 2005 2006 2007
Figure 3.5 Excess potential costs ofCDI in-patient cases per year.
41
3.3 Discussion
The C. difficile-related burden handled by the diagnostic microbiology enteric
laboratory and the potential clinical workload over an 8-year period within this region
of Southeast Scotland (2000-2007 inclusive) were assessed. The results represent the
first study from Scotland, and possibly the first ever, demonstrating CDI laboratory
workload, with recent CDI trends and maximal potential specialty-dependent clinical
CDI rates also reported. Although the study reviews presumptive rates of specialty
based CDI based on toxin positive faecal samples rather than symptomatic defined
disease, the study still provides valuable information on the burden of disease prior to
mandatory data reporting, introduced in September 2006, and for age groups below 65
years.
Despite the total number of potential CDI cases increasing from 2000-2006 followed
by a decline in 2007, a fall in the potential rate ofCDI occurred between 2003 - 2004
and 2006 - 2007, following an initial marked increase from 2000-2002. This
difference could reflect an increase in the number of patients being treated as an in¬
patient. The initial reduction in CDI rates may be the result of increased awareness
and improved infection control practices with the subsequent rise occurring if
infection control measures relaxed with an associated increase in antibiotic usage (e.g.
fluoroquinolones). The decline in CDI rate seen latterly is likely to represent a true
decline as this reduction occurred throughout all specialties and may represent
enhanced infection control measures including improvements in CDI-related
education and antibiotic stewardship. This reduction is converse to some other
European and international reported CDI incidence figures. In Canada, an increase in
incidence from 2.5 cases/1000 admissions to 4.6 cases/1000 admissions occurred
from 2002 to 2007 (Gravel et al 2009). In Spain where ribotype 027 is not prevalent
(as in our study), the prevalence rates have increased from 0.39 to 1.22 cases per 1000
hospitalised patients from 1999 to 2007 (Asensio et al 2008). The incidence of 1.27
CDI cases/1000 OBD in the whole of Scotland from October 2006 to September 2007
for those aged 65 years and over (HPS December 2007) was lower than the 1.99 CDI
cases/1000 OBD incidence found in this study for the same period and patient cohort.
This may be a result of our study representing potential CDI in a concentrated urban
population.
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There has been a 27-fold increase in the number of faecal samples analysed by the
diagnostic microbiology laboratory from 2000-2006, with a 54% increase in the
number analysed from 2003 to 2006. Although the number decreased from 2006 to
2007, there was a 37% increase from 2003 to 2007. The overall increase will have
impacted upon staff requirements including appropriate analysis of samples, timely
data reporting, storage of samples and further testing of repeat samples sent from
previously positive patients. In addition this increase will also have had implications
for ward-based staff with regards to rapid and appropriate isolation of patients,
cleaning procedures and continued patient management. Local guidelines prior to
2008 required all in-patient diarrhoeal samples to be tested for C. difficile toxin. Since
then in an attempt to reduce laboratory workload, diarrhoeal samples sent from those
aged 16 years and under are only tested for C. difficile if specifically requested.
One third of samples tested were submitted from those aged 60 years and under, and
this population also accounted for approximately one-fifth of total positives (Table
3.1). This was similar to the results from the 2009 European Study (Bauer el al.,
2011) where 37% of samples were submitted from those aged 65 years or under. In
the Netherlands in 2005, 42% of samples were submitted from the same age group
(Paltansing et al., 2007). With the exception of those aged under 20 years, all the
remaining age groups followed similar trends over the study period with an
exponential increase from 2000-2002 followed by a smaller variable incidence change
of 10 potential CDI episodes/10000 OBD between 2002-2006. In this study, CDI
toxin positivity was identified in all age groups including those aged 0-20 years, and
the potential incidence in those aged 21-40 and 41-60 years was not largely dissimilar
from those aged over 60 years. It should be noted that the potential false positive rates
will be higher among the younger age groups because the potential prevalence in
these age groups i.e. aged 60 years and under is <10%. With mandatory data reporting
in Scotland initially introduced for those aged 65 years and above only, a large
proportion and important subset of patients were being excluded from national
figures. Subsequent to May 2009, mandatory data reporting in Scotland now includes
those aged 16 years and above.
Traditionally the elderly population has been deemed high risk for CDI; however, it is
no longer the only at risk group (McFarland et al., 2007). An analysis of our data by
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specialties revealed that Obstetrics and Gynaecology patients, a group with minimal
CDI association, have a low but noteworthy incidence of disease. The GDI rate in
Obstetrics and Gynaecology was found to be greater than Orthopaedics an erstwhile
higher risk population for CDI development due to an older patient base. Because
there is only a few reports of CDI in peripartum women (MMWR 2005; Venogopal.,
et al., 2011), in general a young patient cohort, they, along with paediatric patients
comprise a sub-group where there should be vigilance and a high index of clinical
suspicion in symptomatic patients.
Medicine of the Elderly accounted for the largest number of samples tested by the
diagnostic laboratory for a single specialty which was almost double the proportion of
samples sent by the next three specialties individually (General Surgery,
Gastrointestinal Medicine and Infectious Diseases). Therefore it is of interest to note
that Medicine for the Elderly did not have the highest potential rate ofCDI. Advanced
age has been found to be an independent predictor of mortality in CDI patients (Ang
et al 2008). However, in our study, Medicine of the Elderly, had a much lower
incidence than several other specialties, although it provided the maximal specialty
laboratory workload and had the greatest proportion of positive samples. Renal
Medicine/Transplant Surgery, ITU, Infectious Diseases and Gastrointestinal Medicine
all had higher incidences of CDI. This is similar to a study from Amsterdam where
CDI occurred more frequently in ICU patients and those admitted to surgery (Kuijper
et al. 2001). Conversely however, in Spain, admission to a general medical ward has
been associated with an increased CDI prevalence as opposed to an ITU admission
(Asensio et al 2008). All the aforementioned specialties had a peak incidence at
different time points followed by a sustained decline. This may represent heightened
awareness within that particular specialty during peak periods resulting in improved
infection control measures which were maintained.
Renal Medicine/Transplant Surgery had the highest incidence of CDI over the study
period. This may reflect the overall antibiotic usage, immunosuppression and required
repeated admissions in this population. Chronic haemodialysis patients have a greater
risk of developing nosocomial infections including CDI (D'Agata et al 2000) and
renal insufficiency is associated with increased risk of CDI following live donor liver
transplantation (Hashimoto et al. 2007). Liver disease is also independently associated
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with severe CDI outcome (Gravel et al 2009) adding to the risk of CDI development
in this cohort of patients which includes both renal and hepatic transplant patients.
OBD figures were only available from 2003 onwards in this group and it is probable
that the overall rate may have been slightly lower if calculated from 2000.
Recognition of patients with severe CDI, as a result of increased awareness following
the Canadian CDI outbreaks in 2002 (Pepin et al, 2004) and the Stoke Mandeville
(Bucks, UK) outbreaks from 2003 to 2005 (Healthcare Commission. Investigation
into outbreaks of Clostridium difficile at Stoke Mandeville Hospital. London:
Buckinghamshire Hospitals NHS Trust, 2006) could have resulted in an increased
number of patients being referred to ITU and hence the observed peak in 2004. The
marked decline in potential CDI incidence observed afterwards within ITU and HDU
areas may be a result of increased awareness, stringent infection control and the
overall decrease seen across all specialties. The potential incidence of CDI, in
intensive care and high dependency patients in this study was 5.73 cases /1000 OBD.
Lawrence et al. (2007) found the incidence of CDI acquisition in ITU to be 3.2 cases/
1000 patient days in the absence of an outbreak. This difference may be a result of
differing patient populations and our figure represents a maximal potential incidence,
which includes those patients transferred to ITU with CDI. A specific subgroup of
young critically ill trauma patients admitted to ITU had been found to develop CDI
even though administration of antibiotics was for surgical prophylaxis only
(Lumpkins et al., 2008). This may have also contributed to the overall rate of
incidence in the ITU & HDU group.
The high incidence associated with patients in Infectious Diseases could be the result
of direct referral of symptomatic patients to the service from the community or
transfer of patients to Infectious Diseases from other specialties.
Gastrointestinal Medicine may handle a substantial burden of CDI as a result of
increased prevalence of CDI among patients with inflammatory bowel disease. CDI
has been reported to be eight times more prevalent in patients with ulcerative colitis
and five times more prevalent in patients with Crohn's disease affecting the colon
compared to the general population (Ricciardi et al., 2009 and Nguyen et al., 2008).
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General Surgery had a greater overall incidence than General Medicine and was the
only specialty where a plateau in incidence occurred from 2002-2006 despite a rise in
the total CDI incidence in 2006. This is in contrast to other studies which have noted a
rise in CDI among patients admitted in surgery, particularly for patients requiring
surgical intervention for CDI (Longo el al., 2004, Koss et al., 2006). This is examined
further in Chapter 4.
The potential incidence of CDI in the 0-20 year age group exponentially rose from
0.059/1000 OBD to a peak rate of 1.04/1000 OBD in 2006. Kim et al,. (2008)
similarly demonstrated a rise in incidence in a similar population (0-18 years) of
treated CDI patients over a similar time period with an incidence rise from 4.4 cases /
10000 patient days (0.44 cases/1000 patient days) in 2001 to 6.5 cases / 10000 patient
days (0.65 cases/1000 patient days) in 2006. The difference in the 2006 incidences
may be due to an over-estimation in our cohort as our study intimates potential rates
and the paediatric age groups have been previously reported to have
disproportionately elevated carriage rates (Tullus et al., 1989 and Bryant et al., 2009).
Also the 18 -20 year old group was included in our cohort. Due to the small but
notable rise in figures in this low-risk group, the paediatric data i.e. those aged less
than 18 years, was assessed further.
Of the total faecal samples 4.1% of all samples were submitted from the 0 to 20 year
old age group (table 1) to the enteric laboratory for testing (table 3.1) of these 3.1%
were from those aged less than 18 years old, with 4.6% of samples sent from the
paediatric population testing toxin positive. Taking into account multiple samples
testing for individual patients, 51 paediatric patients were identified as toxin-positive,
with the majority of toxin positive patients identified between 2006 -2007; with 23
toxin positive patients in 2006 and 20 in 2007. Of these 51 patients there was no
gender bias, male:female = 25:26, however the median age was 4 years (range
2months to 17 years). This young median age in the paediatric CDI population is not
uncommon; Rexach et al., (2006) noted average ages of 3.5 and 5.3 years, and Kim et
al., (2008) also noted a median age of 4 years in their study of 4895 paediatric
patients with CDI. A range of 1 to 31 faecal samples were tested per patient, for the
toxin-positive paediatric cohort, over a range of 1 - 133 days. Only 54% of these
patients were found to be toxin positive on their first sample. A median period of 17
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days (range 2 to 102 days) was conceded, for the remaining 46% prior to the detection
of C. difficile toxins, from the time of their first negative sample being assessed to the
positive sample, with a median of 3 samples sent per patient prior to toxin detection.
This prolonged period and need for repeated sample testing during a single admission
implies the patient had more complex medical problems and therefore may be an
indicator that diarrhoeal symptoms may not have initially been a result of C. difficile
disease. Underlying medical disease and complex chronic medical conditions doubles
the likelihood of colonisation with toxigenic C. difficile strains (Rexach et al., 2006).
High C. difficile prevalence has also been documented in hospitalised paediatric
patients with inflammatory bowel disease (Pituch, 2009). Previous exposure with 3 or
more antibiotics particularly within a 30day period increases the risk of severe CDI in
the paediatric population (Kim et al., 2012). Of these positive patients, 23% went on
to be identified as toxin-positive following a negative sample, using 28 days as a cut¬
off between positive samples (range 28 to 104 days) on separate admissions. This
suggests that just under one-quarter of toxin positive patients develop re-infection or
re-colonisation with toxigenic C. difficile strains. Interestingly Rexach et al., 2006
noted that paediatric in-patients were less likely to be colonised with toxigenic C.
difficile strains than out-patients and Benson et al., (2007) noted a significant increase
in incidence ofCDI in the out-patient setting. This sub-group of positive patients have
risk factors for C. difficile acquisition including their recent hospital admission and
therefore re-colonisation with C. difficile in the community leading to disease
recurrence rather than re-infection from their original strain may be more common in
the paediatric population.
Within General Medicine the apparent dramatic decrease in potential CDI rates seen
from 2003 onwards may reflect a change in initial admission and treatment protocols
as patients are now rapidly transferred to an appropriate sub-specialty following
administration of initial treatment in acute services (Accident and Emergency, Acute
Receiving Units and Combined Assessment Units). There was also a change in
hospital administration policies for general medicine subsequent to relocation into
new hospital premises in 2003 and introduction of the hospital at night scheme.
Approximately one-tenth of all toxin-positive patients were transferred through a
minimum of two specialties when remaining positive for C. difficile toxins. The
maximum number of inter-specialty transfers (and therefore wards) for an individual
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CDI patient was six. This does not take into account the number of individual bed
moves within the same ward itself. C. difficile spores contaminate the hospital
environment and are more likely to be recovered from a room housing a CDI patient
(Dubberke el al., 2007) and can be recovered from the room for up to 28 to 40 days
following discharge of a CDI patient (Verity et al 2001, Poxton et al., 2001).
Acquisition of CDI is more rapid occurring after 3.2 days for patients who share a
room with a CDI patient, compared with 18.9 days compared to those patients who do
not have direct or close contact (Keshava et al., 2002). Therefore CDI spread
secondary to transfer of patients through various specialties and thus wards is an
important risk factor that infection control measures should also address.
Estimated costs over the study period for toxin testing kits alone were in the region of
£126 500 (€143 000). On the basis of the most recent published European costs of
nosocomial CDI published at the time of the initial analysis by Vonberg et al. (2008),
the excess costs per CDI in-patient case was €7147. This was in accordance with the
only published cost figures available for Great Britain from Wilcox et al. where extra
costs were estimated at £4000 per CDI case. Without adjusting for inflation the
potential excess costs for CDI patients over the study period, demonstrated in Figure
3.5, increased from approximately £3.5 million to £29 million.
Local C. difficile strains associated with CDI during this study period belong to
ribotypes 001 and 106 (Mutlu et al., 2007). Ribotypes 027 and now 078 (Goorhuis et
al., 2008) have been associated with increasing CDI rates and more severe disease,
however, ribotype 027 has not been identified in this region during the period of the
study. The incidence of potential CDI demonstrated locally by this study is similar to
regions where ribotype 027 were prevalent. Control of CDI should not be solely
focused on ribotype 027 and strategies to reduce CDI should consider the pathogenic
potential of local strains.
This study is limited by review of potential rates of specialty-associated CDI based on
appropriately tested toxin positive faecal samples rather than defined symptomatic
disease. Additionally we have not been able to provide mortality rates and associated
co-morbidity for the entire cohort. However, it was the first study from Scotland
demonstrating CDI laboratory workload, recent CDI trends, maximal potential
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specialty-dependent clinical CDI rates and provided valuable information on the
burden of disease prior to mandatory data reporting, introduced in October 2006, and
for age groups aged below 65 years, prior to 2009.
The incidence of patients identified with CDI despite rising markedly appears now to
be decreasing. Not surprisingly the incidence has also been noted to increase with age,
however, approximately one fifth of potential CDI cases occurred in those aged under
65 years. Medicine of the Elderly had a much lower incidence than several other
specialties and therefore risk assessment ofCDI development and containment should
now also be targeted within other specialties including paediatrics.
With a reasonable proportion of identified CDI patients transferred through different
specialties and the significant financial burden CDI imposes on healthcare institutions
judicious application of infection control measures remains an important factor in
preventing CDI transmission.
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4. Clostridium difficile and colorectal surgery
4.1 Introduction
Clostridium difficile causes a spectrum of disease ranging from asymptomatic
carriage, simple colitis, pseudomembranous colitis, fulminant colitis and death. The
fulminant form of Clostridium difficile infection (CDI) includes the presence of
hypotension, unremitting ileus, toxic megacolon and perforation. This extreme
fulminant form of CDI has been found to develop in 3% to 10% of patients (Dallal et
a/., 2002; Olivas et al., 2010).
Surgical intervention is generally only required to treat severe CDI cases i.e. patients
with fulminant CDI, with the indications for surgical intervention including toxic
megacolon, perforation, peritonitis, progressive multi-organ dysfunction, vasopressor
requirements and refractory sepsis due to a failure to respond to medical management.
Surgical intervention is generally associated with high mortality rates ranging from
30% to 80% and therefore determining the optimal timing for surgical treatment is
one of the greatest challenges associated with the management of fulminant CDI.
The most commonly performed surgical procedure for fulminant CDI is a subtotal
colectomy (rectal sparring) with end ileostomy formation. Hemi-colectomies have
also been reported with some success as a colonic sparing alternative. More recently
Neal et al. (2011) describe a complete colonic sparring procedure for fulminant CDI
treatment, where possible a loop ileostomy is formed laparoscopically, the colon is
then lavaged with polyethylene glycol via the ileostomy, a catheter is left in the
efferent limb of the loop ileostomy and vancomycin delivered through this to the
colon for lOdays.
This study used locally collected data to assess the potential impact on surgical
services in particular colorectal surgery, within the adult in-patient population from
2000 to 2006 inclusive. Incidence rates from chapter 3 have been referred to for
individual surgical specialties and therefore additionally include 2007 data. Transplant
surgery (hepatic and renal) had to be excluded due to the combination local ward set¬
up with renal medicine. However, studies have found CDI to be an independent risk
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factor for mortality in hospitalised liver transplant patients and found that patients in
the early post-transplant period had the highest risk of developing CDI (Ali et al.,
2012; Albright et al., 2007)
4.2 Results
4.2.1 Clostridium difficile in Surgery
The surgical specialties were assessed to determine the number and trends of CDI
episodes occurring over the study period. As per previous, a new potential CDI
episode was defined as "Only persons that have not been diagnosed with Clostridium
difficile-associated disease within the previous 28 days are counted as new cases"
(Materials and Methods section 2.1.3).
Colorectal surgery had the greatest number of CDI episodes over the study period,
399 episodes, with an exponential increase to 2003 and a further peak in 2006. Upper
- gastrointestinal (UGI) surgery had the second highest number of episodes, 225
episodes, however an exponential increase was demonstrated from 2002 to 2004,
again with a further peak in 2006. Following these in descending order the number of
episodes per surgical specialty were Urology - 162 episodes, Orthopaedic and
Trauma Surgery - 152 episodes, Cardiothoracic Surgery - 71 episodes, Vascular
surgery - 64 episodes and other surgical specialties - 36 episodes (includes ENT -
ear, nose and throat; Plastic surgery and Maxillo-facial surgery).
Colorectal, UGI and Urology surgical specialties demonstrated a decrease in number
of CDI episodes from 2006 - 2007. Orthopaedic and Trauma surgery demonstrated a
peak in 2005 and the remaining specialties have essentially seen a small but steady
increase in the number of episodes over the latter years (Figure 4.1).
Paediatric surgery was considered separately with 19 CDI episodes diagnosed in 14
patients (aged under 18 years old) over the study period, one 14-year old patient had
been admitted through the colorectal surgical service and one 13-year old patient
through the UGI surgical service.
51
Figure 4.1 Trends in the number of CDI episodes per surgical specialty per year from
2000 to 2007.
4.2.2 Clostridium difficile impact on colorectal surgery
The total number of diagnosed toxin positive C. difficile adult in-patients, across all
specialties, medicine and surgery, from 2000 to 2006 increased from 98 patients in
2000 to 1054 patients in 2006, with a total of 3895 patients over the study period. Of
these 7.4% i.e. 288 patients were treated by the colorectal surgical service, with the
number of toxin positive colorectal patients rising from 4 in 2000 to 76 in 2006.
Despite this rising trend in the number of patients identified as C. difficile toxin
positive a similar continued increase was not seen in the number of patients diagnosed
with pseudomembranous colitis with 90 patients diagnosed with PMC over the study
period. These patients were diagnosed by histo-pathology from biopsy and colectomy
specimens and identified from available endoscopic reporting. There was a peak in
2001 in the number of patients identified with PMC with a further peak demonstrated
from 2004 to 2006.
Similarly during 2000 to 2006; the number of patients treated by colorectal surgery
for fulminant CDI did not increase and a total of 23 patients underwent surgical










with surgery for CD
Figure 4.2 Comparison between the numbers of patients diagnosed with CDI, PMC
and those patients who required surgical intervention for CDI, the number of patients
has been plotted on a logarithmic scale due to the large difference in numbers.
Year Total number of C. C. difficile toxin Number ofpatients Number ofpatients
difficile toxin positive colorectal diagnosed with treated with surgical
positive patients patients pseudomembranous intervention for CDI
colitis or fulminant PMC
2000 98 4(4.1%) 7(7.1%) 1
2001 175 26(14.9%) 17 (9.7%) 5
2002 463 35 (7.6%) 10 (2.2%) 0
2003 612 45 (7.4%) 9(1.5%) 2
2004 687 49 (7.2%) 9(1.3%) 5
2005 806 53 (6.6%) 16(2%) 5
2006 1054 76 (7.2%) 22 (2.1%) 5
Table 4.1 Tabulated data of figure 4.2. The proportion of C. difficile positive
colorectal patients compared with the total number is given in brackets, as is the
proportion of patients diagnosed with PMC compared with the total number.
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4.2.3 Surgical Intervention for Clostridium difficile infection
Twenty-three patients underwent surgical intervention for CDI during the evaluated
period, with pathological confirmation of C. difficile in their colectomy specimens.
The median age of patients was 70 years (range 23 to 91 years), with 7 patients aged
less than 65 years and 3 patients less than 45years. There was no particular gender
difference with 11 female and 12 male patients (table 4.2).
Seven patients (30%) were direct emergency admissions to the surgical service from
home. Three patients (13%) were current surgical in-patients who developed CDI
during their admission. The remaining 13 patients (57%) were transferred from
another specialty; UGI surgery (n=2), Vascular Surgery (n=2), Orthopaedics (n=3),
Urology (n=l), Neurosurgery (n=l), Haematology (n=l), Gastrointestinal medicine
(n=l), General Medicine (n=l) and Respiratory Medicine (n=l), following treatment
for cholangitis, urinary tract infections, perinephric collections, pneumonia, leg ulcers
and lymphoma; and following surgical procedures including femoral fixation, total
hip replacements, below knee amputation, subarachnoid haemorrhage drainage and
laparotomy for small bowel obstruction.
Twenty patients (87%) had taken antibiotics within two weeks prior to the
development of CDI and had received broad-spectrum antibiotics which included
second generation penicillins, cephalosporins, fluoroquinolones and clindamycin. In
addition pipericillin and meropenem were also given as supplementary or replacement
antibiotics in four cases. Fourteen of these 20 patients had received at least two of
these antibiotics (Table 4.3).
The presenting abdominal symptoms and signs included abdominal pain in 21 patients
(91.3%) this was localised to the right side in four patients and left side in two
patients with the remainder experiencing generalised abdominal pain. Abdominal
distension was present in 12 patients (52%) and nausea and vomiting in four patients.
Diarrhoea was only present in 14 patients (61%). Localised or generalised peritonism
on abdominal examination was present in 10 patients (43%) (Table 4.4).
Haemodynamic parameters were adopted from Dallal et al. (2002) and Longo et al.
(2004), seven patients (30%) were hypotensive with a systolic blood pressure of
54
<90mmHg, six patients (26%) were markedly tachycardic with a pulse >120 beats per
minute, three patients were on Atenolol (beta-blocker) and remained normocardic pre-
operatively. Pyrexia was not a common feature; with a median of 37.5°C (range
35.4°C to 38.9°C). Nine patients required vasopressor/inotropic support prior to
surgery.
On laboratory blood tests, most patients (83%) demonstrated a leucocytosis with a
neutrophilia, median 29.6 (range 0.4 to 77.1 x 109/1; neutrophils 0.02 to 71). Two
patients were neutropaenic; one patient had received a recent cycle of chemotherapy
for lymphoma, the other due to severe sepsis. Elevated platelets were also noted with
a median of 412 x 109/1 (range 10 to 617 x 109/1). Renal dysfunction was present in
nine patients (39%) determined by a creatinine > 1.5 x baseline for the patient with a
median creatinine of 96 (range 35 to 310 i.u.) (table 4.5). Only 12 patients (52%) had
an arterial blood gas available on review of their notes with seven of these patients
demonstrating a metabolic acidosis with abnormal hydrogen ions- H+ ranging from 49
to 84. Hypoalbuminaemia was common pre-operatively with a median of 25 (range
10 to 35), a more profound hypoalbuminaemia however was noted post-operatively
median 13 (range <10 to 23).
Only 12 (52%) patients had a C. difficile toxin positive faecal sample prior to surgery,
eight patients had had a negative toxin result prior to surgery and three patients had no
result available. On radiological imaging five patients had toxic megacolon
demonstrated on plain radiograph; pneumoperitoneum was identified in one patient
consistent with a viscus perforation. Seven patients underwent CT imaging of the
abdomen and pelvis, in five of the seven patients a pancolitis (diffuse colonic
thickening) was present, in one of the seven scanned patients segmental colitis of the
right colon was present, and in one patient the CT scan was performed for a patient
who had undergone a previous anterior resection with the scan revealing an
anastomotic leak. A water soluble enema was performed in three patients with no
obstructing lesions or leak seen; however some mucosal irregularity of the colon was
noted on these studies. Five patients underwent a rigid or flexible sigmoidoscopy
prior to surgery, and all these patients were found to have pseudomembranes.
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Of the 23 patients only nine patients were thought to have a diagnosis of fulminant
pseudomembranous C. difficile colitis just prior to surgical intervention. Three
patients underwent a Hartmann's procedure. Two patients had undergone a sigmoid
colectomy and anterior resection due to diverticulitis and a rectal cancer respectively
during their admission; these patients went on to develop sepsis due to anastomotic
dehiscence and underwent Hartmann's procedures; both their resection specimens
demonstrated pseudomembranous colitis. A Hartmann's procedure was performed in
another patient due to an intra-operative finding of a distal descending colon
perforation with a thickened sigmoid colon and turbid free fluid; the pathology from
this patient's specimen revealed PMC and B cell lymphoma.
Segmental colectomies were perfomied in a further five patients; four right
hemicolectomies and a sigmoid colectomy. Of the four hemi-colectomies only one
was performed for a query of C. difficile colitis intra-operatively; one was performed
for an obstructing caecal mass with ischaemic appearing small bowel at the time of
surgery, pathology revealed a Duke's C caecal cancer with pseudomembranes
throughout both the colon and resected ileum. Of the other two; caecal wall
thickening with a possible caecal mass were observed intra-operatively, the pathology
specimens demonstrated pseudomembranous colitis only. The sigmoid colectomy was
performed for presumed diverticulitis with a thickened sigmoid colon noted intra-
operatively; the pathology demonstrated pseudomembranous colitis and diverticular
disease.
Sub-total colectomy and end ileostomy formation with sparing of a rectal stump was
perfomied in the majority of patients (n=15; 65%). This procedure was performed in
eight patients thought to have a diagnosis of fulminant CDI prior to the procedure or
at the time of surgery with one patient, who had received chemotherapeutic agents
diagnosed with typhlitis. Of the remaining seven patients the procedure was thought
to be performed for ischaemic colitis (n=3), Crohn's colitis (n=T), megacolon due to a
chronic amotile large bowel with secondary sepsis (n=l) and toxic megacolon due to
an unknown cause (n=2). Perforation was identified in three patients intra-operatively
and large volume ascites in six patients. Thickened oedematous dilated colon was
identified in all patients in this cohort with a pancolitis in 13 of the 15 patients,
oedema of the right colon with cyanotic appearance of the left colon in 1 patient and
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involvement of the small bowel in addition to abnormal ascending and transverse
colon in 1 patient. Pseudomembranous colitis was found in all the pathological
specimens, with associated Crohn's disease in one patient and pseudomembranes with
ulceration and necrosis within the 50cm of additional resected terminal ileum in one
patient.
Post-operative complications of the entire operative cohort included lower respiratory
tract infections and pulmonary insufficiency (n=8), congestive cardiac failure (n=l),
post-operative intra-abdominal bleed (n=l) and rectal stump bleed (n=l), upper GI
bleed due to a bleeding duodenal ulcer (n=l), fractured neck of femur following a fall
(n=l) and large bowel obstruction with repeat laparotomy required in an Hartmann's
procedure patient as the colon had twisted on its mesentery (n=l). Overall the post¬
operative morbidity was 70% (16 of 23 patients).
Six patients (26%) died in the 30-day post-operative period (mean 10 days (range 2 to
21 days). Three out of 15 patients (20%) died in the sub-total colectomy and end
ileostomy cohort, and three out of eight patients (37.5%) died in the segmental
colectomy and Hartmann's procedure cohort. The median ITU admission of the
survivors (17 patients) was 2 days (range 0 to 41 days) and the median HDU
admission 6 days (range 1 to 10 days), with an overall hospitalisation or time to
discharge from the surgical ward of 18 days (range 9 to 74 days) (table 4.6). Four of
the 17 survivors (24%) underwent reversal of their stoma.
There was no statistical significance in post-operative mortality or median
hospitalisation between the two surgical cohorts (sub-total colectomy and end
ileostomy versus segmental colonic resection). Neither was there any statistical
significance in age, pre-operative white cell count and creatinine parameters between
the survival and mortality groups (Tables 4.6 and 4.7).
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Patient Demographics Data
Median age (years) 70 (23-91)
Male: Female ratio 12 : 11
Symptoms developed at home 7 / 23 (30%)
Symptoms developed in hospital 16/23 (70%); 13 transfers to
Colorectal Surgery.
Table 4.2 Data for patient demographics provided as numbers or ranges with
percentages in brackets.
Major risk factors No. of patients
Antibiotic use within 2 weeks of CDI symptoms 20/23 (87%)
Recent intra-abdominal surgery 3/23 (13%)
Recent surgery out with the abdomen 5/23 (22%)
Chemotherapy 1/23 (4%)
Other immunosuppressive agents including steroids 4/23 (17.3%)
Table 4.3 The number of patients compared with the total with specific risk factors
for CDI development with the proportion of patients in brackets.
Presenting symptoms No. of patients
Diarrhoea 14/23 (61%)
Abdominal Pain 21/23 (81%)
Abdominal Distension 12/23 (52%)
Peritonitis/Surgical abdomen 10/23 (43%)
Table 4.4 The number of patients with the main presenting symptoms, the proportion
of patients is given in brackets.
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Laboratory and diagnostic studies Data
Leucocytosis; median white blood cell count 19/23 (83%); median 29.6 (0.4 to 77.1 x 1071)
Renal dysfunction; median creatinine gmol/1 9/23 (39%); 96 (range 35 to 310)
C. difficile toxin positive faecal sample 12/23 (52%)
Sigmoidoscopy 5/23 (22%)
Toxic Megacolon on plain radiographs 5/23 (22%)
Colitis on Computerised Tomography imaging 6/23 (26%)
Table 4.5 Data for laboratory and diagnostic studies performed pre-operatively with





Segmental colectomy (n=8) p value





10/15 (67%) 6/8 (75%)
30-day post-operative
mortality
3/15 (20%) 3/8 (37.5%) 0.66
Median hospitalisation / time
to discharge of survivors
(days)
20 days (12-46) 15 days (9-74) 0.34
Table 4.6 Surgical procedure and post-operative variables for each surgical cohort
with the proportion of patients for each cohort in brackets and the p value provided.
Variable Survivors (n=17) Mortality (n=6) P value
Mean age (years) 77.7 years (23 - 85) 75 years (65 - 91) 0.078
Mean white blood cell count
xl09/l
27.7 (0.4-54.4) 24.7(5.3 -77.1) 0.66
Creatinine pmol/1 113 (35-282) 137 (77-310) 0.56
Pre-operative inotropic support 8/17(47%) 3/6 (50%) -
Table 4.7 Comparison of variables in the post-operative survivors and mortality
groups, with proportion of patients or ranges given in brackets for each variable, and
the p value between the survivors and mortality cohorts also provided.
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4.2 Discussion
Although a relative plateau in incidence was seen in General Surgery from 2002 to
2006, as described in Chapter 3, the figures combined both colorectal and UGI
surgical service figures. On separating the two services, review of the number of
episodes demonstrated peaks and troughs within these two surgical specialties
allowing equilibrium when calculating the incidence for general surgery as a whole.
Often colorectal and UGI surgery are either grouped together or clear delineation
between the two groups is not clarified when general surgery CDI figures are quoted.
With these two surgical specialties separate entities in most academic/teaching
institutions with differing case workloads, patient cohorts and fulminant CDI
generally treated by colorectal surgery, the distinction is important. In this study
episodes ofCDI were more common in the colorectal rather than UGI surgery cohort;
whilst this may seem intuitive few studies have commented on the UGI surgery
population. Yasunaga et al. (2012) reviewed patients undergoing surgical intervention
for cancer, from 2007 to 2010 and found a higher occurrence of CDI in their
colorectal surgery group compared with the gastrectomy and oesophagectomy group.
Zerey et al. (2007) reviewed surgical patients from 1999 to 2003, and determined
colectomy or small bowel resections were associated with the highest risk of CDI
compared with gastrectomy and that patients undergoing a cholecystectomy or
appendicectomy had the lowest risk.
The incidence of potential CDI in Urology, was 1.37/1000 OBD (Chapter 3). This
was much higher than observed by Hossain et al. (2008), who reported an incidence
of 0.66 cases /1000 OBD, they also found no significant increase in C. difficile
incidence between 2000 to 2005 with a range of 3 to 13 cases per year. Conversely
locally, the number of CDI episodes in Urology has overall gradually been increasing
to 2006, with the number of episodes varying from 16 to 43 per year. In part this may
be due to the increase use of fluoroquinolones; in 2006 the European Urology
Association guidelines recommended the use of fluoroquinolones in the treatment of
simple cystitis, pyelonephritis, epididymo-orchitis, prostatitis and uro-sepsis (Patel,
2007).
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The number of episodes in Orthopaedics and Trauma Surgery gradually rose from two
episodes in 2002 to a peak of 45 episodes in 2005 with a subsequent decline and an
overall incidence of 0.62/1000 OBD. Specific data on trends of CDI in this specialty
were not available for comparison. Kurd el al. (2008) reported on 16 cases of CDI
from 2001 to 2006, in patients who had undergone total joint arthroplasty, with an
incidence of 0.16% and no significant increase in CDI over their study period. One of
the tertiary hospitals used in this study has one of the largest Accident and Emergency
departments in Europe, consequently there is a large referral of trauma patients, Al-
Obaydi et al. (2010) found the rate of CDI to be 8-fold higher in trauma than elective
patients. Therefore the rise in numbers may reflect trauma rather than elective
admission related CDI within this specialty, at a time where the overall incidence in
the region was increasing.
Cardiothoracic Surgery has an overall low potential episode rate (0.95/1000 OBD)
accounting for only 6% of all CDI episodes in the surgical specialties. However it has
observed a small but gradual increase in the number of CDI episodes. This may
reflect an increasing age and co-morbidity population undergoing cardiac surgery.
Musa et al. (2011) reviewed cardiothoracic ITU admissions from 2003 to 2008 and
found CDI was rarely acquired in cardiothoracic ITU and was more common in post¬
operative cardiac surgery rather than thoracic surgery patients. Crabtree et al. (2007)
also noted an overall low incidence of 0.79% of CDI in cardiac surgery patients
between 1997 and 2004 with a peak incidence in 2003.
Vascular surgery has previously been quoted as having high CDI rates of 6-9% along
with general surgery (Bradbury & Barrett, 1997). In this study vascular surgery had
one of the lowest number of CDI episodes when compared with the other specialties,
with a peak in 2003. Previous high rates were attributed to the increased use of
clindamycin in this specialty to treat infections associated with peripheral vascular
and venous disease. However as this was an early surgical specialty to describe C.
difficile related disease, this may have resulted in earlier increased awareness.
Ratnayake et al. (2011) reported an outbreak of CDI of ribotype 106 with high-level
of clindamycin resistance in nine patients on a vascular surgery unit within East
Scotland, therefore high-lighting that even in specialties with now low rates of CDI
continued attentiveness to infection control is required.
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Of note the main general surgical specialties, namely colorectal and UGI surgery,
were the only specialties that had faecal samples documented for C. difficile testing by
the enteric laboratory with positive results from 2000 to 2002. Vascular surgery also
had documented samples sent for C. difficile testing but no positively identified CDI
samples. However, all the remaining surgical specialties had no documented samples
requested for C. difficile testing until 2002. This may represent a change in sample
testing and recording by the enteric laboratory from 2000 to 2002, samples may have
been sent without the specialty to which they were attributed known and therefore
categorised in an unknown cohort. General increased awareness of C. difficile
particularly from 2002 onwards may have also resulted in surgical specialties
recognising and testing for CDI. The decline in the number of episodes between 2006
and 2007, in the surgical specialties with the greatest number of CDI episodes,
follows the overall general downwards trend seen locally as described in Chapter 3.
Nineteen episodes of CDI were identified in the paediatric surgical population
accounting for 20.8% of all paediatric associated episodes during the study; increasing
from one episode in 2001 to seven episodes in 2006. Chen et al. (2012) found the
paediatric incidence of CDI doubled from 2002 to 2008, and was identified in
primarily immunosuppressed patients, none of whom required surgical intervention
for treatment. Kim et al. (2012) similarly determined that although severe CDI
accounted for a significant proportion of their paediatric surgical cohort with CDI,
complications including fulminant colitis were uncommon.
Despite the increased number of patients across all specialties found to be toxin
positive from 2000 to 2006, a similar continued increase was not demonstrated in the
number of patients diagnosed with pseudomembranous colitis or the number of
patients that underwent surgery for fulminant CDI. This is in contrast to other studies
which have stated an increase in the number of patients requiring surgical intervention
for CDI (Longo et al., 2004, Koss et al., 2006; Lesperance et al., 2011). Although
patients are at risk of acquiring CDI within the specialty of colorectal surgery itself,
patients are also referred from other specialties for surgical intervention due to severe
fulminant C. difficile colitis and typhlitis. The plateau in surgical intervention patients
may suggest that patients were not being referred for surgical review, patients were
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not suitable for surgery or disease severity did not warrant surgical intervention. Most
studies demonstrating an increased incidence of CDI in General Surgery and the
number of patients requiring surgical intervention were from areas where ribotype
027 was prevalent. This hypervirulent strain was not endemic to the area during the
period of the study and therefore the extent of more extreme forms of CDI may not
have been seen locally.
The proportion of toxin positive colorectal patients compared with the total number of
toxin positive patients per year did not appreciably change (approx 7% - 8% from
2002 - 2006) with the exception of 2001. Therefore the increase in toxin-positive
patients in colorectal surgery is proportionate to the increase demonstrated locally and
again suggests that few patients were likely referred, needed or were suitable for
colorectal surgical management from other specialties. However, as the number of
individual toxin-positive colorectal surgical patients has markedly increased this does
impact on the overall burden of CDI within the specialty with implications for
treatment and infection control.
The numbers of patients with pseudomembranous colitis are likely to be under¬
estimated, as not all patients with pseudomembranous colitis will have undergone a
flexible sigmoidoscopy/colonoscopy or had biopsy specimens sent. Even with this
limitation, the proportion of PMC patients identified from 2002 to 2006 compared to
the total number remained between 1.3% and 2.2% and again may relate to absence of
ribotype 027 locally. Of interest the proportion of PMC patients in 2000 and 2001 was
much higher. This is more likely a reflection of decreased awareness of C. difficile in
many specialties as also seen in some surgical specialties during these years and
therefore a decreased number of toxin positive CDI patients diagnosed in 2000 and
2001. However in 2001, five patients were surgically treated for fulminant CDI
similar to 2004 to 2006 where the number of overall toxin positive patients increased
four to eight fold.
Severe CDI, PMC and fulminant colitis, was present in 2.3% of this study population
and the fulminant form of CDI has been found to develop in 3% to 8% of patients in
other studies (Dallal et al., 2002; Olivas el al., 2010). However not all patients with
fulminant CDI require surgery. Only 0.6% of the total population of toxin positive C.
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difficile patients underwent surgical intervention as a result of CDI during the period
of this study. This is similar to Koss el al. (2006) who found 0.4% of their studied
CDI population underwent colectomy. However both these figures are lower than
other studies that have quoted figures of 1.6% to 3.7% (Dallal et al. 2002; Al-Abed el
al., 2010). Similarly this study found that 25.5% of patients with severe CDI went on
to require surgical management, which is similar to figures quoted by Bhangu el a!.,
(2012) who performed a systematic review of patients requiring surgery for CDI and
found 29.9% of patients with severe CDI required surgery with a range of 2.2% to
86% for individual studies.
The median age of the 23 patients who underwent surgical intervention for CDI
during the study was 70 years (range 23 to 91 years). This median age is similar to
other studies ranging from 64 years to 71 years (Koss et al 2006; Gash et al 2010).
With 7 patients aged less than 65 years and 3 less than 45 years, this is further
evidence that CDI and its complications are not purely related to an elderly
population.
Most studies of surgery for fulminant CDI documented the majority of patients were
transferred from other specialties as with this study. Of interest are the emergency
admissions from home requiring emergency surgery for severe CDI, in this study
accounting for 30% of patients, unlike hospitalised in-patients a good history with
known risk factors for CDI are often not available. Diarrhoea was not present in 39%
of patients at presentation, as a result of severe colonic dysfunction and ileus
associated with fulminant colitis. Similarly 48% of patients did not have a C. difficile
toxin positive faecal sample result available prior to surgery and in this cohort most
were the emergency admissions. Therefore high clinical suspicion is required in these
patients with probable community acquired CDI particularly if a history of prior
antibiotic exposure can be elicited.
Eighty-seven percent of the patients who received surgical intervention had received
antibiotics within two weeks prior to the development of their fulminant CDI
symptoms and had received broad-spectrum antibiotics including second generation
penicillins, cephalosporins, fluoroquinolones and clindamycin and 61% had received
two or more antibiotics. Since this study was performed there has been a change in
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local antibiotic prescribing with greater stewardship. In colorectal surgery the
commonly used combination of ceftriaxone and metronidazole, during this study, for
the treatment of intra-abdominal sepsis and prophylaxis within an hour ofmajor intra¬
abdominal surgery, has changed with cephalosporins being replaced by other
alternatives such as gentamicin (Lothian prescribing guidelines).
Independent risk factors for mortality for patients undergoing surgical intervention for
CDI have been reported and these include a high pre-operative lactate, a high pre¬
operative leucocytosis, a low pre-operative albumin, pre-operative vasopressor
requirements, development of end-organ failure with pre-operative renal failure and a
need for pre-operative intubation and ventilation, advanced age, altered mental status
and immunosuppression (Dallal et al., 2002; Byrn et al., 2008; Lamontagne et al.,
2007; Pepin et al., 2009; Perera et al., 2010). In this study several of the reported
independent risk factors were noted; 83% of patients demonstrated a marked
leucocytosis with a neutrophilia and 8.7% were neutropaenic, renal dysfunction was
present in 39%, hypoalbuminaemia was present in all patients pre-operative ly with a
profound hypoalbuminaemia post-operatively, 21.7% were receiving
immunosuppressive agents, 30% of patients were hypotensive and 47.8% required
pre-operative vasopressor support. No patients required pre-operative intubation out-
with theatre. However on further review between the cohort of patients that survived
and those that died post-operatively there was no significant statistical difference
between the groups for the parameters of age, white cell count, pre-operative renal
dysfunction or creatinine levels. We were unable to statistically analyse the need for
vasopressor support due to an absence of complete data in the clinical notes. Similarly
in a systematic review and meta-analysis performed by Bhangu et al., (2012) of
patients requiring surgery for CDI, a leucocytosis of 20 x 109/1 or more and pre¬
existing renal failure were not significant predictors of death following surgery and
there was insufficient data on albumin and lactate levels to meta-analyse. They did
find that pre-operative intubation, shock requiring vasopressors and multi-organ
failure were identifiable predictors of post-operative death.
A number of severity scoring systems for CDI have been developed to predict
mortality including usage of the Charlson co-morbidity score and the APACHE II
(Acute Physiology and Chronic Health Evaluation II) score. However following
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critical review all severity scoring systems were unable to predict the need for
surgical intervention or predict survivability post-operatively (Pepin et al., 2009;
Carchman el al. 2012; Bhangu et al., 2012)
Pre-operative radiological imaging was performed in 69.5% of patients ranging from
plain radiographs to water soluble enema studies to CT imaging. In this study seven
patients underwent CT imaging of the abdomen and pelvis and a pancolitis was
present in five patients, segmental colitis in one patient and an anastomotic leak in
one patient following previous surgery. Since the period of this study water soluble
enemas are also being superseded by CT for the acute abdomen, and studies have
found a benefit to CT scanning in diagnosing and evaluating complicated CDI with
implications for therapy guidance (Valiquette et al., 2009; Kirkpatrick et al., 2001).
Longo et al., 2004 found CT to be the most sensitive indicator of assessing CDI and
severe colonic inflammation in their CDI operative series. The value of the plain
abdominal radiograph however should not be neglected as toxic megacolon was
demonstrated in 21.7% of patients negating the need for CT and nephrotoxic
intravenous contrast agents. However a CT scan or flexible sigmoidoscopy prior to
surgery is of benefit when diagnosis is in doubt or clear indications for surgery are
absent, particularly in the absence of a C. difficile toxin positive faecal sample result.
Three patients (13%) developed CDI during their in-patient admission following
previous colorectal surgery ofwhich two were elective patients and one an emergency
patient. Two of these patients were found to have anastomotic leaks, likely as a result
of their severe CDI disease, and went on to have Hartmann's procedures performed.
Two further patients were found to have cancers, lymphoma and a Duke's C caecal
cancer in there segmental resection specimens. Lesperance et al. (2011) reviewed a
large cohort of patients who had undergone colonic surgery for causes unrelated to
CDI and found that Caucasian race and a non-elective admission was predictive of
CDI development during hospital stay. (The ethnicity of patients had not been
recorded in our study). Interestingly they also found that diagnosis of a colonic
malignancy and diverticulitis were negative predictors ofCDI.
Small bowel C. difficile enteritis is rare and Kim et al. (2011) identified only 58 cases
in the published literature from 1980 to 2010. Of these pooled cases 82% had had
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previous GI surgery primarily a total colectomy and end ileostomy formation for non-
CDI causes. However in the two cases of small bowel CDI enteritis found in the
surgical cohort in this study neither patient had undergone a previous colonic
resection. One patient was aged 91 and underwent a right hemicolectomy with
increased terminal ileal resection, the other was aged 42 and underwent a total
colectomy with a 50cm resection of the terminal ileum. Pseudomembranes were
found throughout these resected specimens. Similarly Hayetian et al. (2006) reported
a case of CDI involving the colon and distal ileum with perforation of the ileum found
intra-operatively. Therefore in patients with fulminant CDI with CDI enteritis intra-
operatively how much does the enteritis contribute to the extremity of disease and
does the entire small bowel with macroscopic change need to be resected?
Sub-total colectomy and end ileostomy formation with sparing of a rectal stump was
performed in 65% of the surgical intervention cohort and segmental colectomies in
35% comprising four right hemicolectomies, a sigmoid colectomy and three
Hartmann's procedures. Overall the post-operative morbidity was 70% (16 of 23
patients) involving 67% of patients in the sub-total colectomy and end-ileostomy
cohort and 75% of patients in the segmental colectomy cohort. The post-operative
mortality was 26%; three out of 15 patients (20%) in the sub-total colectomy and end
ileostomy cohort died, and three out of eight patients (37.5%) in the segmental
colectomy cohort died.
Mortality associated with CDI generally is approx 6% (Karas et al., 2010), however
mortality associated with fulminant CDI where surgical intervention was performed
has always been high varying from 19% to 64% (Neal et al., 2011; Trudel et al.,
1995). A post-operative mortality rate of 26% was found in this study, and although it
was towards the lower end of reported mortality figures it remains high. Despite
increased CDI awareness and disease recognition mortality rates have not
significantly changed over the past two decades. There has been much debate over the
years about the type of surgery which should be performed for fulminant CDI.
Traditionally subtotal colectomy with end-ileostomy formation has been
recommended rather than a segmental resection, which was thought to be associated
with higher mortality. However there was no significant difference between the two
surgical cohorts in this study with many studies also finding equivocal survivability
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rates in patients who undergo a segmental colectomy for CDI rather than a total
colectomy and end ileostomy. (Dallal et al., 2002; Longo et al., 2004; Pepin et al.,
2009). Hemicolectomies/ segmental resections have been associated with 15.9% re¬
operation rates for CDI (Bhangu et al., 2012), no patients, in particular the survivors,
of the segmental colectomy cohort in this study required a repeat laparotomy due to
CDI. The lowest mortality rate of 19% was reported in a study by Neal et al., (2011),
and they performed a diverting loop ileostomy with colonic lavage as an alternative to
colectomy to treat complicated fulminant CDI, (this procedure is described in the
introduction for this chapter). The biological rationale on which their procedure is
based, is that by creating a loop ileostomy the faecal stream is interrupted thus
depriving the colonic bacteria of nutrition, mechanical lavage through the efferent
limb removes a proportion of the bacteria and surface toxins that induce the local
inflammatory and cytotoxic response on the colonic mucosa and administration of
vancomycin through a catheter left in situ within the efferent limb of the ileostomy
should continue to treat the disease allowing the inflammatory process to settle. Oral
metronidazole is also continued. From their cohort of 42 patients, three required
colectomy for abdominal compartment syndrome. They compared their cohort of
patients to their colectomy and end ileostomy cohort from 2009 and found a
significant reduction in mortality of 19% compared with 50% previously. Their study
certainly merits consideration for surgical therapeutic intervention in the future.
Early surgical referral is hampered by the absence of a validated diagnostic tool that
can help predict at which stage a patient with CDI will benefit from surgical
intervention. However the benefit of early surgical referral from other specialties
should be highlighted. Studies have shown that colectomy for severe fulminant colitis
prior to acute respiratory and acute renal failure in those aged greater than 65 years is
associated with decreased mortality (Seder et al., 2009). A more aggressive approach
with early colectomy for those patients who fail initial treatment with antibiotics prior
to the development of multi-organ failure has also shown decreased mortality rates
(Jabar et al., 2008; Sailhamer et al., 2009). Therefore surgical management of CDI in
patients who do not respond quickly to antibiotics may become a life-saving rather
than a desperate procedure. With 43% of patients in this study presenting with
localised or generalised peritonism on abdominal examination including those
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patients transferred from other specialties it can be postulated that in these cases
surgical referral was occurring much later than desired.
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5. Identification of Clostridium difficile in colorectal
surgical patients.
5.1 Introduction
Awareness of CDI has dramatically increased over the last decade with the first step
to diagnosis being the recognition of clinical disease. Following clinical assessment
and suspicion of symptomatic CDI, the diagnosis of CDI hinges on laboratory testing
of faecal samples. Therefore rapid and accurate diagnosis of CDI is mandatory to
individual patient treatment and infection control procedures.
Only toxigenic C. difficile strains cause disease and subsequently C. difficile toxin
detection was the first diagnostic method employed and in a different guise remains
the mainstay of hospital detection today. The cell cytotoxic neutralisation assay is still
regarded as the gold standard for laboratory confirmation of C. difficile (Whittier et
al., 1993). The method uses detection of cytopathic effects in cell culture that is
neutralised by antibodies to C. difficile or C. sordellii cytotoxins. These cell cultures
are then analysed microscopically at 24 and 48 hours. This method, therefore, is time-
consuming and needs availability of tissue cultures and a skilled workforce. The
identification of toxins progressed further into the development of enzyme
immunoassays (EIA) for toxin A or B or A&B detection kits which can detect toxins
directly from faecal samples. These assays are quick, easy and relatively inexpensive
to perform allowing the high turnover required with increasing numbers of faecal
samples sent for testing. Subsequently commercially produced EIA toxin kits have
been adopted as the diagnostic procedure of choice for CDI by hospital enteric
laboratories. These kits however have been reported to have limited sensitivity and
specificity (Crobach et al., 2009).
Toxigenic culture is a further reference standard. The method relies on the anaerobic
culture of C. difficile from faecal samples grown on media specific plates for at least
48 hours and the identification of typical colonies. This method identifies both
toxigenic and non-toxigenic strains of C. difficile; therefore further assessment of
identified colonies for in vitro toxin production is required. This method, as with cell
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cytotoxin neutralisation assay is laborious, and again the method is used in an
investigatory rather than clinical capacity.
Other newer commonly used hospital diagnostic laboratory tests now include EIA for
the enzyme glutamate dehydrogenase. This enzyme is produced by both toxigenic and
non-toxigenic C. difficile strains and therefore while this test identifies the presence of
C difficile it cannot differentiate between toxin and non-toxin producing strains.
However, it has an extremely high negative predictive value (99%), and is useful for
reporting C. difficile negative patients.
Another development is the application of real-time polymerase chain reaction (RT-
PCR), this is a nucleic acid amplification method that can be used to detect toxin
genes directly from faecal samples. It detects the presence of targeted genes; a
conserved region of tcdB, which encodes toxin B production, or tcdC, the main
negative regulator of toxin A and B production.
During the period of this study only commercially manufactured ELISA toxin kits,
Tox A/B II1M (Techlab), were used as the diagnostic identification modality for CDI
by the Lothian enteric laboratory (EL).
The aim of this study was to determine the proportion of faecal samples and hence
patients not identified as toxin positive by standard enteric laboratory testing, using
the reference standard of toxigenic culture for comparison. Further aims of the study
were to determine asymptomatic carrier rates and to identify C. difficile in colorectal
surgical in-patients and hence determine the specific burden of C. difficile in this
patient cohort and to provide local epidemiological data from C. difficile isolates
within this specialty.
There were two study periods; from June 2007 to November 2007 for recruitment of
out-patient asymptomatic carriers, and from November 2007 to January 2009
inclusive for weekly reclamation of enteric laboratory submitted samples testing, with
materials and methods as described in Chapter 2.
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5.2 Results
5.2.1 Asymptomatic carrier rate in the out-patient surgical
population.
Ninety-eight patients were recruited from patients attending the out-patient colorectal
surgical clinic, attending for day case procedures or elective patients admitted for in¬
patient colorectal surgical procedures. Only those patients who had not been
hospitalised or in a long-term care facility within the last six months and did not have
symptoms of diarrhoea were recruited. Faecal samples were collected at the surgical
out-patient clinic, or within hours (1-4 hours) of admission for day-case or in-patient
procedures, therefore faecal samples were all representative of an out-patient cohort.
Six patients of 98 were culture positive for C. difficile and all were toxin producing C.
difficile strains. Therefore the asymptomatic carrier rate from this cohort is 6.1% for
toxigenic C. difficile.
Four of the six patients' toxigenic C. difficile strains were of ribotype 001, the other
two could not be determined.
Two of these six asymptomatic carriers who were later admitted for surgical operative
procedures went on to develop symptomatic CDI as in-patients.
5.2.2 Identification of Clostridium difficile in colorectal surgical in¬
patients.
Six hundred and thirty-two faecal samples from 483 adult colorectal surgical in¬
patients were reclaimed over the study period from the enteric laboratory for toxigenic
culture.
The enteric laboratory (EL) found 61 (9.7%) of 632 faecal samples to be toxin
positive. Of the remaining 571 faecal samples tested, 505 samples (79.9%) were toxin
negative. Sixty-one faecal samples (9.7%) were not tested for three reasons; patients
from whom they were submitted had already had a C. difficile toxin positive result in
the last 28 days, duplicate sample requesting resulted in repeated samples being sent
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on the same day for the same patient or the faecal samples were non-diarrhoeal
(classified as < 4 on the Bristol stool chart). Four samples were for enteric culture for
other causes not related to CDI, and had inadvertently been sent for toxin testing.
On toxigenic culture of all the 632 faecal samples submitted, a further 72 faecal
samples of the 505 EL-negative samples were culture positive for C. difficile, of these
further identified 72 samples; 68 samples were toxigenic culture positive (i.e. toxin
producing strains) therefore a further 10.8% of all submitted faecal samples were not
identified as toxin positive by EIA testing alone.
Of the 61 EL toxin positive faecal samples; 47 (77%) faecal samples were also
toxigenic culture positive on primary culture, with one EL toxin positive faecal
sample only identified as toxigenic culture positive on a second re-culture. Fourteen
samples found to be EL toxin positive were toxigenic culture negative on triplicate
culture assessment; these faecal samples were also treated with 50% alcohol shock
prior to tertiary re-culture to reduce bacterial overgrowth from other faecal flora.
From the sub-set of 61 not tested EL faecal samples, 14 of the samples not tested were
toxigenic culture positive; including seven non-diarrhoeal samples. Six of these 14
samples were from patients previously toxin positive within a 28 day period and
remained positive (range 1 to 24 days) with toxigenic culture. One of these fourteen
toxigenic culture positive EL not-tested samples was a duplicate sample. Seven of the
EL not-tested faecal samples from patients with previous toxin positive results in the
last 28days were culture negative.
Overall 133 faecal samples from 102 colorectal in-patients were found to be culture
positive and 129 were toxigenic culture positive from 99 colorectal in-patients, with
58 patients not identified as toxin positive by the enteric laboratory at the time the
faecal samples were sent, over the period of the study.
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C. difficile positive samples 61 133
Toxin positive samples 61 129
Negative samples and not tested samples 566 499
Not tested samples 61 0
EL toxin negative - culture positive samples - 72
EL toxin positive - culture negative samples - 14
Table 5.1 Distribution of the number of faecal samples in each category as assessed
in the enteric hospital diagnostic laboratory (EL) by toxin EIA kits or in the research
laboratory with toxigenic culture.
5.2.3 Potential asymptomatic Clostridium difficile colorectal
surgery in-patient carrier rate.
On reviewing all toxigenic culture positive samples 10 (13%) of the 68 toxigenic
culture positive - EL toxin negative samples were grade 4 or less on the Bristol stool
chart, all others were diarrhoeal. Seven of EL not-tested non-diarrhoeal samples were
toxigenic culture positive and 4 of the 47 EL toxin positive and toxigenic culture
positive faecal samples were non-diarrhoeal. These 21 toxigenic culture positive non-
diarrhoeal stool samples were reclaimed from 19 patients (3.9%) of the 483 tested
patients. On review of these patients' available clinical details there was no definitive
evidence of CDI within the one month before and after the faecal sample submission
date; this therefore suggests an in-patient carrier rate of 3.9%.
5.2.4 Characterisation of Clostridium difficile isolates obtained by
toxigenic culture.
Of the 133 culture positive faecal samples, only one C. difficile colony from each
sample was stored and used for analysis. Three toxigenic culture positive samples
could not be cultured from their Robertson's cooked meat broth stores during the
period of MIC antibiotic susceptibility testing and the period when cultures were
being sent to the Health Protection Agency, Colindale for typing and therefore have
not been included in this part of the study.
74
Over the entire study period ribotype 001 was the commonest ribotype found in the
colorectal surgical in-patient faecal isolates, with 61 of the 130 isolates (46.9%)
identified as ribotype 001. Ribotype 012 (6.9%) was the next commonest found in 9
of the 130 isolates, followed by ribotypes 015 (4.6%), 020 (3.8%) and 078 (3%)
(Table 5.2 and figure 5.1). A ribotype was not determined in 21 of the 130 isolates
(16.2%). Further ribotypes 003, 005, 010, 011, 014, 018, 026, 031, 039, 056, 103, 106
and 140 were identified in the remaining isolates.
All ribotype isolates were sensitive to metronidazole. Two isolates showed variable
results to metronidazole with triplicate MIC dilution agar testing however with the E-
test method both isolates were found to be sensitive to metronidazole. An MIC of
4pg/ml was repeatedly demonstrated in 6 isolates (4.6%) to vancomycin, denoting
these isolates with intermediate resistance to vancomycin; the remaining 124 isolates
were all sensitive to vancomycin. Intermediate vancomycin resistance was found in
both the 103 isolates and in one of each of the following ribotype isolates 001, 003,
020 and 106.
The 61 isolates identified as ribotype 001 demonstrated variable resistance to
ceftriaxone and ciprofloxacin. Thirty of the 61 ribotype 001 isolates showed
intermediate resistance to ceftriaxone and 28 of these 30 isolates were resistant to
ciprofloxacin, 22 isolates were resistant to ceftriaxone and again with the exception of
one isolate were resistant to ciprofloxacin, and the remaining nine ribotype 001
isolates were sensitive to ceftriaxone with ciprofloxacin resistance present in only
four of these isolates. Resistance to ciprofloxacin was therefore common in the
ribotype 001 isolates with resistance to ciprofloxacin demonstrated in 93% of these
isolates.
In the isolates with the next most common ribotype 012, all these isolates were
sensitive to metronidazole and vancomycin, with ceftriaxone resistance found in 4
isolates and ciprofloxacin resistance in 3 isolates.
75
Overall ceftriaxone resistance was found in 35 of 130 isolates (26.9%) and
intermediate ceftriaxone resistance in 38 (29.2%) isolates and resistance to
ciprofloxacin was high and present in 71 (53.4%) of all isolates.
The ribotype of the four culture-positive, toxin-negative isolates was not determined
but all these four isolates had the same antibiotic susceptibility profiles with
sensitivity to ceftriaxone, ciprofloxacin, metronidazole and vancomycin.
Figure 5.1 The distribution of ribotypes found in the colorectal surgery in-patient
faecal isolates.
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Table 5.2 (below) Demonstrates the toxigenic culture positive samples, the ribotypes
obtained from each sample (ND indicates not determined) and their antibiotic
susceptibility profdes for the antibiotics ceftriaxone, ciprofloxacin, metronidazole and
vancomycin.
Faecal ET Toxin
Sample Result Culture Toxin Ribotype Ceftriaxone Ciprofloxacin Metronidazole Vancomycin
XE177653Z Positive Positive Y 001 S R S s
XE177742D Negative Positive Y 001 s R s s
XE177743L Negative Positive Y 010 R S s s
XE177755L Negative Positive Y 001 I R s s
XE177811M Negative Positive Y 005 R R s s
XE177849S Positive ReculturePositive Y 001 R R s s
XE177850F Positive Positive Y 001 I R s s
XE178067V Negative Positive Y 001 R R s s
XE178507W Positive Positive Y 001 R R s s
XE178676J Positive Positive Y 056 S S s s
XE179223C Positive Positive Y 001 R R s s
XE179361R Negative Positive Y 001 R R s s
XE179422G Positive Positive Y 001 R R s s
XE 179606V Negative Positive Y 001 R R s s
XE179732Y Positive Positive Y 001 I R s s
XE179876D Negative Positive Y 031 S S s s
XE180136F Negative Positive Y 001 R R s s
XE180748T Positive Positive Y 001 R R s s
XE180825P Positive Positive Y 020 S S s I
XE180846H Negative Positive Y 001 R R s s
XE180847Y Positive Positive Y 012 R S s s
XE180849P Negative Positive Y 001 R R s s
XE181223H Negative Positive Y 002 I S s s
XE181622W Negative Positive Y 001 R S s s
XE181695X Positive Positive Y 003 R R s I
XE182037K Positive Positive Y 001 R R s s
XE182162D Negative Positive Y 103 I R s I
XE182655A Positive Positive Y 001 R R s s
XE182661N NT Positive Y 001 S S s s
XE182742Q Negative Positive Y 103 R R s 1
XE182987K NT Positive Y 001 R R s s
XE183762M Positive Positive Y 001 R R s s
XE184516N Negative Positive Y 001 R R s s
XE184544S Positive Positive Y 001 S S s s
XE 18464 IK Negative Positive Y 001 I S s s
XE184866H Negative Positive Y 001 s S s s
XE 185160V Positive Positive Y 001 s s s s
XE185161B Negative Positive Y 010 s s s s
XE185380C NT Positive Y 002 1 R s s
XE185710G Negative Positive Y ND R R s s
XE185975T Negative Positive Y ND R R s s
XE185976K Positive Positive Y 106 R R s I
XE186192H Positive Positive Y 012 R R s s
XE186772C Positive Positive Y 001 R R s s
XE186788J NT Positive Y 001 I R s s
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XE186789V NT Positive Y
XE186834V NT Positive Y
XE186841F NT Positive Y
XE186861Y Positive Positive Y
XE187798H Negative Positive Y
XE188335Q Positive Positive Y
XE188411J Negative Positive Y
XE188617T Positive Positive Y
XE188856L Negative Positive Y
XE189008H Positive Positive Y
XE189029W Positive Positive Y
XE189103R NT Positive Y
XE189144V Positive Positive Y
XE189187L Positive Positive Y
XE189510Z Negative Positive Y
XE189511N Positive Positive Y
XE189554Q Positive Positive Y
XE189826X NT Positive Y
XE190634E Negative Positive Y
XE190730B Negative Positive Y
XE190799J Positive Positive Y
XE190881Q Positive Positive Y
XE191148M Negative Positive Y
XE191293Q Positive Positive Y
XE191318M Negative Positive Y
XE191936Y Negative Positive Y
XE191938P Negative Positive Y
XE192186A Positive Positive Y
XE192199F Negative Positive Y
XE192238N Negative Positive Y
XE192340A Positive Positive Y
XE192637E Positive Positive Y
XE192966H Negative Positive Y
XE193019R Negative Positive Y
XE193875S Negative Positive Y
XE193883R Negative Positive Y
XE193940B Negative Positive Y
XE194128W NT Positive Y
XE194192F Negative Positive Y
XE194197J Negative Positive Y
XE194448D Positive Positive Y
XE194469B Negative Positive N
XE194712G Negative Positive Y
XE194903V Positive Positive Y
XE195079R Negative Positive Y
XE195471L Negative Positive N
XE195479W Negative Positive Y
XE195591T Negative Positive Y
XE195946P Negative Positive Y
XE196079F Negative Positive Y
XE196086H Positive Positive Y
XE196195D Negative Positive Y
XE 196446N Negative Positive Y
XE198488Q Negative Positive N
I R S s
R R S s
R R s s
R R s s
R R s s
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XE198544N Negative Positive N ND s s s s
XE199902L NT Positive Y 012 s R s s
XE200230V Negative Positive Y ND s R s s
XE200522Y Positive Positive Y 026 s S s s
XE200527C Positive Positive Y 078 s S s s
XE201185G Positive Positive Y 078 s S s s
XE201406Y Negative Positive Y ND s S s s
XE201511V NT Positive Y 078 I R s s
XE201759T NT Positive Y ND I S s s
XE201814H Negative Positive Y 020 s S s s
XE201875S Negative Positive Y 020 s s s s
XE203884V Negative Positive Y ND s s s s
XE204308N Positive Positive Y ND s R s s
XE205076T Negative Positive Y ND s S s s
XE205175Y Negative Positive Y 106 I R s s
XE205293E Negative Positive Y 078 s S s s
XE205321F Positive Positive Y 001 I R s s
XE205452Z Positive Positive Y 001 R R s s
XE205784H Negative Positive Y ND s S s s
XE206131Z Positive Positive Y 015 s S s s
XE206250G Negative Positive Y 002 s s s s
XE206616K Negative Positive Y ND s s s s
XE206800L Negative Positive Y 001 I R s s
XE206887R Negative Positive Y 002 s S s s
XE207256S Negative Positive Y 001 I R s s
XE207368B Negative Positive Y 015 s S s s
XE207368B Negative Positive Y 015 s S s s
XE207421T Positive Positive Y 001 I R s s
XE207996N Negative Positive Y 001 I R s s
XE209383J Negative Positive Y 014 s S s s
XE209853X Negative Positive Y 015 s S s s
Toxinotyping was performed on 21 of the ribotype 001 isolates from the faec
samples towards the beginning of the study i.e. the first 21 isolates of ribotypes 001
listed in table 5.2. Nineteen were of toxinotype 0 with one variant toxinotype IV. A
toxinotype could not be accurately determined from the band patterns obtained from
the isolate of sample XE179223C.
5.2.5 Clostridium difficile re-infection, relapse and recurrence rates
in the colorectal surgery in-patient population.
There was a male preponderance in the entire culture positive patient cohort with 59
male to 43 female adult in-patients. The median age of the entire culture positive
cohort was 78 years (range 26 to 100 years).
79
Six toxigenic, culture-positive patients had two faecal samples sent for testing within
28 days of each other. Both these samples for each patient yielded different toxin
producing ribotype C. difficile strains (table 5.3). The samples were sent to the enteric
laboratory over a range of 1 to 21 days. Ribotypes 001 and 012 were found in three of
the six patients with the others distributed as shown in table 5.3.
Patient Ribotype identified in the Time period between Ribotype identified in the
first sample sent faecal samples
(days)
second sample
I 001 21 012
2 001 1 012
3 010 1 012
4 001 8 012
5 012 21 078
6 106 4 001
Table 5.3 The different ribotypes identified in six patients within a 28 day period.
Five patients demonstrated some evidence of re-infection, relapsing or recurrent
disease during their in-patient admission in colorectal surgery. Over varying time
periods multiple toxigenic C. difficile strains were obtained from these five patients
isolates. Each patient had two to five samples sent over a period of 53 to 149 days
(table 5.4). All these patients had diarrhoea.









7 ND 25 015 20 012 8 015 - -
8 020 21 103 7 103 32 001 - -
9 011 149 078 - - - - - -
10 002 58 002 6 ND - - - -
11 001 1 001 26 001 2 001 29 001
Table 5.4 The ribotypes identified from different isolates sent from each patient over
varying periods of time, with the isolates separated by the time period between each
set of intervening samples. (P = patient, I = Isolate obtained from each faecal sample).
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Patients 9 and 10 were discharged home between their first and second samples and
their second isolates were obtained from their following admission. The presence of
different isolates between their first and second samples suggests re-infection with
new C. difficile strains. Patient 11 due to the persistent identification of ribotype 001
during their single prolonged admission suggests re-lapsing disease. Patient 7 had two
ribotypes identified during their admission with ribotype 015 found in the middle and
end of periods when they had symptomatic disease, it is possible therefore the disease
causing strain was 015 causing relapsing disease and they were carriers of ribotype
012. Again multiple strains were identified in patient 8 and it is likely they were re¬
infected with different strains during their admission.
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5.3 Discussion
The C. difficile asymptomatic carriage rate of out-patients attending colorectal
surgical services was 6.1%. This figure is in accordance with other studies reporting
carriage rates in healthy adults of 3% to 15% (Kato et al., 2001; Kelly & Lamont,
1998). High asymptomatic carriage rates of 14% have also been reported in colonised
individuals at the time of their hospital admissions (Kyne el al. 2000). Within the in¬
patient colorectal population a potential C. difficile carriage rate of 3.9% was
identified on exclusion of patients with symptomatic disease, whilst 16.6% of the
patient cohort in this study (80 of 483 patients) had or developed symptomatic CDI
during their admission without taking into account relapsing or recurrent disease.
Similar figures were reported by Loo et al., (2011) on reviewing 4143 adult patients,
they identified 4.4% as asymptomatic carriers at admission and found 3% had health¬
care associated C. difficile colonisation.
A more recent study by Rea el al. (2012) found carriage rates of C. difficile changed
from 1.6% in the community to 9.5% in the out-patient setting and increased to 21%
in hospital, although they studied carriage rates in an older population aged 67 to 91
years with a mean age of 83 years, the median age of patients in our cohort was 78
years. Kyne et al. (2000) have also reported much higher in-patient acquisition
carriage rates of 40%. Using a colorectal surgical population Lesperance et al. (2011)
reviewed 695,010 hospitalisations during which colonic resections were performed
and found a secondary rate of in-hospital acquired symptomatic CDI of 1.4%.
In this study two of the six patients in the asymptomatic out-patient carrier population
went on to develop symptomatic CDI following elective admission for major
colorectal intra-abdominal surgery. Therefore community-acquired asymptomatic C.
difficile carriage becomes part of the CDI burden once patients are hospitalised. Due
to the inevitable exposure to a host of risk factors hospitalised community acquired
carriers are at risk of in-patient symptomatic CDI. In the cases mentioned pre¬
operative antibiotic prophylaxis and intra-abdominal surgery were the most likely risk
factors. (During the period of this study a single dose of ceftriaxone and
metronidazole were given intravenously in the peri-operative period for major intra¬
abdominal elective surgery). Lanzas et al. (2011) developed a compartmental model
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which showed that transmission of CDI among patients within the ward alone could
not sustain the numbers of new C. difficile colonisations found within in-patients and
therefore new admissions of already colonised patients played an important role in
sustaining transmission on the wards.
Asymptomatic carriage in neonates is well recognised dating back to the original
identification of C. difficile by Hall and O'Toole in 1935; however high carriage in
neonates (Al-Jumaili et al., 1984) and infants is now recognised as a potential
reservoir for toxigenic strains (Rousseau et al., 2012). There is therefore further cross¬
over in C. difficile colonisation between adults and children in the community, with
adults at greater risk of symptomatic CDI development than children once
hospitalised.
The flux, in all the studies mentioned and including the cohort reviewed in this study,
between carrier rates in the community/out-patient to hospital settings shows the
importance of the reservoir and burden of C. difficile and the potential implications
for management and infection control within individual specialties, when colonised
patients are admitted and when colonisation as an in-patient occurs.
Six hundred and thirty-two faecal samples from 483 adult colorectal surgical in¬
patients were reclaimed over the study period from the enteric laboratory for toxigenic
culture. The EL found 9.7% of the faecal samples to be toxin positive by commercial
EIA testing for toxins A and B. On toxigenic culture 20.4% of the faecal samples
were positive i.e. a further 68 faecal samples were identified as toxigenic C. difficile
positive. Four faecal samples were culture positive but non-toxin producing. Of the 61
EL toxin positive faecal samples only 77% of these faecal samples were toxigenic
culture positive on primary culture. EIA toxin detection has been reported to falsely
identify CDI in 1 to 2 samples of every ten positive tested (Wilcox et al. 2009 and
2012).
EIA therefore was 52% less sensitive then toxigenic culture for detection of toxin-
producing C. difficile in this sample population, with a potential false positive
proportion of 23% of all the EL toxin positive samples identified which could have
had implications for individual patients, and a false positive proportion of 2.5% of all
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the 571 faecal samples tested on excluding the sub-set of faecal samples not-tested by
the EL (due to duplicate requesting, non-diarrhoeal samples and repeat requesting
within 28 days of a positive sample). Fifty-eight patients with diarrhoeal samples
were not identified as toxin positive by the enteric laboratory at the time the faecal
samples were sent, over the period of the study.
Similar to this study, low sensitivity for toxigenic C. difficile detection by EIA for
toxins A and B has been reported by other studies. Crobach et al. (2009) provided a
systematic review of studies comparing reference standards (cell culture cytotoxic
assay or toxigenic culture) to EIA for toxins A and / or B, GDH and RT-PCR. It was
found that EIA detecting toxins A and / or B compared with toxigenic culture reported
sensitivities which ranged from 0.32 to 0.79 and the specificities ranged from 0.84 to
1.00. They also found that all the commonly applied hospital diagnostic available
methods of EIA for toxins and GDH and RT-PCR were not suitable as stand-alone
tests to diagnose CDI in endemic populations.
In recognition of the low sensitivities of commonly used tests, a two-step diagnostic
algorithm for CDI was recommended by the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) in 2009. In their algorithm ifEIA is
used to detect toxins A and B and the result is negative, if there is no clinical
suspicion then no CDI can be documented for the patient, if there is a high clinical
suspicion then their samples should proceed to toxigenic culture. In the patients with a
toxin positive result, EIA for GDH, RT-PCR or cytotoxic assays should then be
performed, if these results are also positive then CDI is diagnosed if not no CDI. In
late 2009 the local enteric laboratory adopted a modified version of this which was 9
months after the period of the study reported here. Instead of only EIA to toxins A
and B, EIA for GDH is also performed for toxin positive patients. In toxin negative
patients where high clinical suspicion ofCDI persists then EIA for GDH is performed
+/- culture.
Nucleic acid amplification tests (NAATs) are more sensitive then EIA detection kits
and were developed as more accurate diagnostic tests for CDI and are molecular tests
that detect genes encoding toxin A and B and are now commercially available
however they are also unable to differentiate between symptomatic CDI and
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colonisation and therefore Wilcox (Dec 2012) reported the limitations of a positive C.
difficile NAAT result, after a patient has a primary episode ofCDI if it is to be used as
a single test for CDI.
Repeated samples for individual patients were sent to the local enteric laboratory for
repeated ELA toxin testing during the study period. Of the 58 patients that were EL
EIA toxin negative, 17 patients had had two repeated faecal samples sent within a
period of 1 to 22 days that were all EL toxin negative and toxigenic culture positive.
Repeat sample testing during the same symptomatic episode for individual patients
has been found not to increase the rate of detection in the endemic setting (Crobach et
al., 2009; Bouza, 2012) Garimella et al., 2012) also found decreased clinical utility in
repeat testing for hospitalised patients although recognised a possible benefit in
outbreak settings where the yield of repeat testing was 5%. Clinical recognition and
suspicion of CDI is extremely important in both requesting tests for CDI and for
interpretation of any test results (Dubberke et al., 2011).
Screening of other hospital acquired infections (HAI) is now common such as for
MRSA (Lee et al., 2010) and active surveillance of MRSA and vancomycin resistant
enteroccocus (VRE) has resulted in reduced in-patient rates of these hospital-acquired
infections (Muto et al., 2011). In regards to active surveillance for C. difficile, Bartsch
et al., (2012) evaluated the potential economic value of screening hospital admissions
for C. difficile and screening was found to be cost-effective in a population with a
colonisation rate of > 10.3%. At present however any cost-effective and patient
benefit to screening is limited by toxigenic C. difficile testing as described. In order to
identify and isolate carriers of C. difficile prior to elective admission a sensitive,
specific, rapid cost-effective test needs to be readily available. EIA GDH and NAATs
have been suggested due to a greater ability to detect C. difficile in a low CDI
prevalence population such as the community. Curry et al. (2011) suggested peri¬
rectal swab surveillance with selective broth amplification and RT-PCR as a further
possible method. The definite benefit of screening for C. difficile in the UK has yet to
be fully investigated.
On analysis of the 133 isolates identified as culture positive, 4 were found to be non-
toxin producing isolates and a ribotype for these isolates was not determined but all
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were found to have the same antibiotic profiles with sensitivity to all four of the
antibiotics tested. A further 3 of the 133 isolates could not be grown from their stores.
Of the remaining 126 isolates all were found to be toxigenic C. difficile strains. The
commonest ribotype, within this colorectal surgical population, was 001 found in
46.9% of all samples and this is consistent with other local studies, where ribotype
001 had emerged as the most common ribotype locally over the last decade.
McCoubrey et al. (2003) used a S-layer typing method to type isolates collected from
South-East Scotland from 1999 to 2000 and found 73% of isolates to be S-type 5236
which is equivalent to ribotype 001. An increased incidence in ribotype 001 from
1.5% to 12.2% over a grouped period from 1979 to 2004 was found by Taori et al.
(2010) who also assessed isolates from South-East Scotland, and Mutlu et al. (2007)
examined 149 isolates from different hospitals in the Edinburgh area in 2005 and
reported an incidence of 75.8%. Conversely in Scotland as a whole, over the period
isolates were collected for this study, ribotype 106 was the predominant strain (Health
Protection Scotland 2009). Despite Mutlu et al. (2007) identifying ribotype 106 in
8.1% of their isolates, ribotype 106 was found in only 1.5% of isolates in this study. A
specific cohort of patients was assessed in this study and therefore may not represent
local changes across Lothian.
The incidence of CDI in Scotland is now closely monitored since mandatory data
reporting was introduced in September 2006 for those aged over 65 years and in 2009
mandatory data reporting was increased to include those aged 15 years and over. The
first surveillance report produced by Health Protection Scotland identified ribotypes
106 (64%) and 001 (18.5%) as the two predominant ribotypes between 2006 and 2007
and from 2007 to 2008 the prevalence of ribotype 001 rose to 24.5%. In 2009
ribotypes 106 and 001 remained the most common ribotypes with the emergence of
027 and 078 also noted. Ribotype 078 was found in 3% of our isolates. Towards the
end of 2010 the emergence of 015, 002, 014, 020 and 005 were also noted. All these
ribotypes were found in small incidences within the colorectal population studied.
More recently in 2012, ribotype 078 has become the prevalent ribotype in Scotland.
Ribotype 012 was the next commonest strain identified in this study, after 001, and
was found in 6.9% of isolates. Ribotype 012 was also the third commonest isolate,
comprising 5% of the isolates, in the study by Taori et al. (2010). Ribotype 012 is
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representative of a local epidemiological strain and it is not of significant prevalence
in the rest of Scotland.
Overall 19 ribotypes were identified from the colorectal surgical population and this is
comparable to Mutlu et al., (2007) who reported 15 different ribotypes within their
cohort; however 21 colorectal in-patients isolates ribotypes were not determined by
the end of this study. Twenty-one of the 001 ribotype isolates from earlier on in the
study were also assessed with toxinotyping with 19 of the isolates of toxinotype 0.
This is also similar to Mutlu et al., (2007) who found 96.6% of their isolates to be of
toxinotype 0.
All the toxigenic C. difficile isolates were also assessed for their sensitivity or
resistance to four antibiotics ceftriaxone, ciprofloxacin, metronidazole and
vancomycin. Metronidazole remains the mainstay of antibiotic treatment for CDI
particularly in patients deemed to have mild to moderate disease. Locally, mild to
moderate disease is characterised by an absence of the following severity markers;
leucocytosis >15 x 109 cells/1, creatinine > 1.5 x patient's baseline, pyrexia >38°C,
albumin <25g/l, elevated lactate, suspected or confirmed PMC, ICU admission or
immunosuppression. In the presence of one or more severity markers vancomycin is
advocated and with PMC and or fulminant CDI metronidazole and vancomycin are
given. Only a few C. difficile strains have been reported to have metronidazole
resistance and increases in metronidazole MICs have also been observed (Brazier et
al., 2001, Pelaez et al, 2002, Baines et al., 2008).
All the 130 C. difficile isolates tested in this study were sensitive to metronidazole and
this is comparable to other studies (Aspevall et al. 2006; Taori et al., 2010). An MIC
of 4pg/ml was demonstrated in 6 isolates (4.6%) denoting these isolates with
intermediate resistance to vancomycin and was found in isolates belonging to
ribotypes 103, 001, 020 and 106. The remaining 127 isolates were all sensitive to
vancomycin. Other studies have also demonstrated reduced susceptibility to
vancomycin with MICs of 4ug/ml (Liao et al., 2012) and at a local level Drummond
et al. (2003) identified 2.6% of their isolates had MICs of 4pg/ml to vancomycin and
Mutlu et al., (2007) found 21.6% of their isolates to have intermediate resistance to
vancomycin.
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Overall ceftriaxone resistance was found in 35 of 130 isolates (26.9%) and
intermediate ceftriaxone resistance in 38 (29.2%) isolates. Resistance to ciprofloxacin
was high and present in 71 (53.4%) of all isolates. Studies have reported the
unnecessary use of flouroquinolones particularly for treatment of urinary tract
infections and asymptomatic bacteriuria (Werner 2011), which will also be driving
increased resistance to these antibiotics. Many studies use moxifloxacin as the
fluoroquinolone to test C. difficile antibiotic susceptibility, however in this study
ciprofloxacin was used. This was because ciprofloxacin is widely prescribed within
the UK and moxifloxacin has never been used locally. Therefore this study provides
further information on ciprofloxacin fluoroquinolone resistance in C. difficile, which
is rarely reported on.
Thirty isolates demonstrated resistance to both ceftriaxone and ciprofloxacin, whilst
31 isolates were resistant to ciprofloxacin with intermediate resistance to ceftriaxone.
Studies have reported a higher resistance in dominant ribotypes. In this study ribotype
001 was the dominant strain with 93% of isolates demonstrating resistance to
ciprofloxacin and 95% demonstrating resistance or intermediate resistance to
ceftriaxone. Mutlu et a!., (2007) also found higher resistance to ceftriaxone and
moxifloxacin among their dominant ribotypes 001 and 106, and Taori et al., (2010)
found ribotype 001 displayed the maximum resistance with 50% of isolates resistant
to erythromycin, ceftriaxone and moxifloxacin. The next common ribotype 012,
demonstrated resistance to ceftriaxone in 4 isolates (44.4%) and ciprofloxacin
resistance in 3 isolates (33.3%). Spigaglia et al. (2011) also demonstrated multidrug
resistance in their cohort of ribotype 012 isolates.
Six toxigenic culture positive patients yielded two different ribotypes from two faecal
sample isolates sent for testing within 28 days of each other. Two of a combination of
the ribotypes 001, 012 010, 078 and 106 were found in the 6 patients. Multiple strains
within the same patient at the same time have been previously reported (van den Berg
et al., 2005). As only one isolate was obtained from each faecal sample it is likely that
ifmultiple C. difficile colonies within the faecal samples were evaluated the yield for
multiple strains in individual patients would have been much higher. Although
treatment of disease clinically is the same regardless of the strain, in this locale where
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ribotype 027 is not prevalent, epidemiologically the strain causing disease and why
the other strain remains dormant is of interest. Furthermore does the patient's risk of
recurrence due to re-infection increase in the presence ofmultiple strains?
Recurrence is the term used to cover both re-infection from a different C. difficile
strain and recurrence from the same strain, as clinically it is virtually impossible to
tell the difference without epidemiological typing data. Recurrence rates for CDI can
vary from 18% to 25%, and these patients often develop symptoms within days to
weeks of stopping treatment for their first CDI episode (Bauer et al., 2011; Louie et
ah, 2011). In this study 5% (5 of 99 patients from the toxigenic culture positive
cohort) demonstrated some evidence of re-infection, relapsing or recurrent disease
during their in-patient admission in colorectal surgery. Multiple toxigenic C. difficile
strains were obtained from these five patients and each patient had 2 to 5 samples sent
over a period of 53 to 149 days, and a combination of the following ribotypes were
found 015, 012, 020, 103, 001, 011, 078, 002 and 001, in two of the isolates the
ribotypes were not determined. Two patients were discharged home between their
first and second isolates and differing ribotypes suggested re-infection with a new C.
difficile strain. One patient had persistent identification of ribotype 001 during their
lengthy admission suggesting re-lapsing disease. Two patients were found to have
varying ribotypes within their isolates over a significant period of time. Other studies
have also shown re-infection rates with new strains, some in up to 50% of recurrences
(Poxton 2013; van den Berg et al., 2005). Although no metronidazole or vancomycin
resistance was demonstrated in the isolates from the relapsing/recurrent disease
patient cohort the recognition of these patients is important when considering
treatment options. Fidaxomicin a newer antibiotic for C. difficile treatment has been
shown to be more effective than vancomycin in treating recurrent disease (Poxton
2010) and is now being advocated for use in regimes after vancomycin in patients
with multiple recurrences (Johnson et al., 2013). Another treatment option for
recurrent CDI is faecal microbiota transplant which has also been shown to be of
benefit in recurrent CDI (Gough et al., 2011). Currently tapering doses of vancomycin
are used to treat relapsing CDI however these newer treatment options could be
considered.
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6. Clostridium difficile and the environment in
colorectal surgery.
6.1 Introduction
The environment is an important reservoir for Clostridium difficile including
toxigenic strains; therefore the environment plays an important role in the
transmission of CDI. C. difficile is a spore-forming organism and it is these spores
that exist in the environment and facilitate the transmission of disease.
C. difficile is spread by the faecal-oral route and therefore C. difficile spores and
vegetative cells must be ingested into the gastro-intestinal (GI) tract for disease to
occur. C. difficile spores colonise primarily the colon of the GI tract and under the
correct conditions following exposure to certain risk factors, the spores are able to
germinate into vegetative cells. The vegetative cells produce toxins and other
viadence factors which result in the cytotoxic and inflammatory response of the
colonic mucosa resulting in symptomatic disease, with diarrhoea the primary
presenting symptom in most cases. The vegetative cells also produce more spores and
these shed into the environment whereby the spores can then be ingested by another
patient thus allowing a perpetual cycle of transmission from the host to the
environment and the environment to the host. C. difficile spores and vegetative cells
shed in huge quantities into the environment from infected symptomatic patients
(Mulligan et al., 1980; Wilcox et al., 2003). Asymptomatic carriers also shed spores
and vegetative cells but not to the degree demonstrated in patients with symptomatic
diarrhoea (Kim et al., 1981; Samore et al., 1999). Healthy asymptomatic carriers
treated with antibiotics for non-CDI related pathology also shed large volumes of C.
difficile which is reversed at the completion of the antibiotic course (Chachaty et al.,
1993).
The human reservoir of C. difficile includes both asymptomatic carriers and those
with symptomatic disease. Asymptomatic carriers as a reservoir for C. difficile have
long been established particularly in the neonatal and infant populations (Hall &
O'Toole 1935; Hoist et al., 1981; Matsuki et al., 2005). The asymptomatic carriage
rate in healthy adults of both toxigenic and non-toxigenic strains ranges from 2% to
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14% (Kyne et al., 2006) and of toxigenic strains from 3% to 7% (Ryan et al., 2010).
Epidemic strains are found in asymptomatic carriers and therefore they may
contribute to the spread of nosocomial CDI (Riggs et al., 2007), as previously
discussed in Chapter 5. Asymptomatic carriage has also been documented in hospital
patients with no previous antibiotic exposure history or antibiotic associated diarrhoea
(Varki & Aquino 1982).
The cohorts of patients with the greatest C. difficile reservoir are those who have
symptomatic disease. Direct contact in a shared room with a patient with symptomatic
CDI is a significant risk factor for the transmission of nosocomial disease to patients
who were previously not carriers of C. difficile (Chang et al., 2000). Patients in rooms
neighbouring those containing patients with symptomatic CDI are also at greater risk
of CDI development (Chang et al., 2000). Other factors that also increase the risk of
CDI transmission among ward patients include antibiotic usage (Rotimi et al., 2002;
Fenton et al., 2008) and duration of hospitalisation (Rudensky et al., 1993).
In hospitals the surfaces, food, healthcare workers and visitors the patients come into
contact with are all part of the environmental reservoir for disease transmission. C.
difficile acquisition by health-care workers is uncommon, despite the high level of
contact health-care workers often have with symptomatic CDI patients. Fewer than
fifteen cases of CDI in health-care professionals deemed to be work-related have been
reported (Dom, 2009). Some studies have also found no carriage of C. difficile in
heath-care workers who were in direct contact with CDI patients (Carmeli et al.,
1998). Transfer of C. difficile between symptomatic patients to family contacts and
the transmission of C. difficile between healthy family members has also been
observed (Sutphen et al., 1983; Kato et al., 2001). Therefore patients and their family
members/visitors are at potential risk of acquiring C. difficile from each other.
The potential spread of nosocomial disease via contaminated hospital surfaces has
been demonstrated. Following the isolation of hospital associated organisms from
many surfaces found within the hospital environment it is accepted that the surface
environment within hospitals and long-term care facilities, are a potential source of
hospital-acquired infections (HAI) disease transmission. C. difficile has been cultured
from many surfaces within the hospital setting including floor, mops, bed-linen, sluice
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rooms, computers, telephones, tables, doorknobs, air vents, medication carts and
uniforms (Kim et al., 1981; Fawley & Wilcox 2001; Dumford at al., 2009; Perry et
al., 2001).
Vegetative C. difficile cells are at higher concentrations prior to the start of antibiotic
treatment than during and at the end of treatment (Jump et al 2007). However, unlike
vegetative C. difficile cells which are eliminated by treatment antibiotics,
environmental shedding of C. difficile in particular spores often persists after
symptom resolution and can persist after treatment (McFarland et al., 1998 and Sethi
et al., 2010). C. difficile vegetative cells can survive on moist surfaces for 3 to 6 hours
and occasionally up to 12 hours in aerobic conditions (Weber et al., 2010). C. difficile
spores, however, are hardier entities and are able to survive on surfaces for several
months; C. difficile spores have been isolated from floors for up to five months
following artificial inoculation (Kim et al., 1981). They are also fairly resistant to
external environmental changes such as temperature (Rodriguez-Palacios et al., 2010)
and a patient's internal defence mechanisms such as the acidic low pH of their gastric
contents.
C. difficile spores are resistant to a variety of disinfectant agents especially in the
presence of organic matter whilst vegetative cells are more susceptible to the effect of
sporicides and survive on surfaces for much shorter periods of time than spores (Jump
et al., 2007; Wheeldon et al., 2008). Therefore cleaning agents targeted at C. difficile
must be both bactericidal and sporicidal.
The aims of this study were:
1. To determine the degree of environmental C. difficile surface contamination on the
colorectal surgical wards with residing colorectal surgical in-patients namely wards
22, 23, 24 and 27 at the Western General Hospital, Edinburgh.
2. To assess changes in C. difficile environmental surface contamination on the
colorectal surgical wards over a period of one year.
3. To determine changes in the level of C. difficile environmental surface
contamination and the number of C. difficile positive colorectal in-patients following
implementation of a new cleaning strategy.
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4. To assess the epidemiology of C. difficile strains found in the surface environment
of colorectal surgical wards and in the colorectal surgical in-patients admitted to these
wards during the period of study.
6.2 Materials and Methods
Wards 23, 24 and 27 all had a similar layout with each ward containing four main
bays and five side-rooms. Each main bay contained five patient bed spaces each with
a separate toilet room with a sink and a separate shower room contained within each
main bay. The side-rooms contained one patient bed space with its own en-suite
facilities. Ward 22 contained two main bay areas with four patient bed spaces per bay
and four side-rooms. The main bays and not the side rooms were used for
environmental sampling, as the side rooms were often used for isolation of
symptomatic C. difficile toxin positive patients. Side-room cleaning is generally more
stringent once the side-room is vacated compared with the main patient bay areas and
it is the main bays where CDI transmission between patients is most likely to occur
(Chang et al., 2000). Most patients will have been in a main bay area prior to transfer
to a side-room when symptomatic CDI as an in-patient developed. Therefore in order
to determine accurate background levels of C. difficile contamination particularly in
areas that were generally considered more low risk, sampling of side-rooms
containing a symptomatic C. difficile toxin positive patient would have resulted in
falsely higher results.
Following a pilot study, sites were identified for sampling, due to the poor yield
obtained from fabric during the pilot study with contact plates; it was elected not to
sample bed linen, the segregating bed-space curtains or the window curtains. Within
each main bay; the bed frame, bedside locker and bedside table per patient bed space
was sampled and the main bay toilet room door handle and main bay toilet room sink
were also sampled. The communal main bay sink handles in the corner of each bay
mainly for use by staff but also patients and visitors were also sampled. Other
communal areas and equipment sampled included the floors in the main corridors of
each ward and the communal blood pressure cuffs of all the sphygmomanometers on
each ward. On one occasion a patient did not want their bed frame sampled and
therefore the patient's bed hand control was sampled instead.
93
The original study period for environmental sampling of the colorectal surgical wards
was initially from January 2008 to January 2009 inclusive. This meant that the in¬
patient C. difficile positive colorectal surgical population study (Chapter 5) results
would also include the same time period and could be used for comparison.
Following completion of the original study, it was elected to continue the
environmental sampling portion of the study until the end of March 2009, to
determine if any changes to environmental contamination, within the colorectal
surgical wards, following introduction of a new cleaning strategy could be
maintained. Therefore any comparisons pre and post introduction of the new cleaning
protocol had to include primarily the same duration before and after the new protocol
was introduced. Similarly as colorectal in-patient surgical faecal samples were only
collected to the end of January 2009 comparisons involving the in-patient cohort
could only involve the original study period.
The colorectal surgical in-patient cohort used for comparison in this study was
identified from all the patients found to be C. difficile toxigenic culture positive from
January 2008 to January 2009 inclusive, from the study described in Chapter 5. To
allow direct comparison in this study only those patients that were in-patients on
wards 22, 23, 24 and 27 for a minimum of one night were included. Colorectal
surgical boarders i.e. those patients under the care of the colorectal surgical team
admitted to different specialty wards for a variety of reasons including lack of
available surgical beds, requirements for isolation, transfer to another clinical team
with continued surgical input etc. were not included as these wards' surface
environment were not sampled. Toxigenic culture positive patients that were likely to
have transited through the colorectal surgical wards without overnight admission were
included in the comparative C. difficile strain analysis. Materials and Methods are
otherwise as described in Chapter 2.
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6.3 Results
6.3.1 Clostridium difficile contamination in the colorectal surgical
wards.
Over the study period 72 (4%) of 1800 environmental contact plates were culture
positive for C. difficile and of these 70 environmental contact plates contained
toxigenic strains of C. difficile.
Ward 24 had the greatest proportion of environmental positive contact plates with
40% of all positive plates, followed by ward 23 with 31.4%, ward 27 with 21.4% and
ward 22 with 7.1% (Figure 6.1). Using the same patient cohort from Chapter 5, 99
colorectal in-patients were toxigenic culture positive. On excluding those patients that
were colorectal surgical in-patient boarders and toxigenic culture positive patients out
with the period of the original environmental study, 62 patients were in-patients on
wards 22, 23, 24 and 27 from 1st January 2008 to 31st January 2009. Similar to the
environmental positive samples, ward 24 had the greatest number of C. difficile
toxigenic culture positive patients. However, ward 22 with the next highest number of
toxigenic culture positive patients had the lowest number of positive environmental
samples (Figure 6.1).
C. difficile colonies were obtained from individual patient bed frames, lockers, tables
and a patient bed hand held control; the communal floors; ward bay patient shared
areas including toilet room door handles and the toilet room sink handles; a ward bay
general communal used clean sink and communal sphygmomanometers (Figure 6.2).
Bed frames were the commonest sites of C. difficile contamination with 44.2% of all
culture positive environmental samples obtained from the bed frames. Patients'
bedside lockers, patients' bedside tables and the communal floors were the next
commonest sites with 12.8% of culture positive samples each. A further 7.1% of all
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Figure 6.1 The number of C. difficile culture positive environmental contact plates
obtained from each ward and the number of C. difficile positive in-patients residing in
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Figure 6.2 The number of culture positive environmental contact plates obtained from
each surface over the study period (S = sphygmomanometer cuff, TR = toilet room, H
= handle, MB = main bay, HC = hand control).
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6.3.2. Characterisation of Clostridium difficile isolates obtained
from the colorectal surgical ward surface environment.
Of the 72 culture-positive environmental plates only one C. difficile colony was
identified on each of 70 plates. On two plates two C. difficile colonies were present,
resulting in 74 environmental C. difficile culture positive isolates. Seventy-one
isolates were toxin producing. From the contact plates which had two colonies; on one
plate one of the colonies was a non-toxin producing C. difficile strain and on the other
plate both colonies were toxin producing however one of the colonies could not be
cultured from its Robertson's cooked meat broth store during the period of MIC
antibiotic susceptibility testing and the period when cultures were being sent to the
Health Protection Agency, Colindale for typing. This isolate has therefore not been
included in this part of the study.
Of the three non-toxin producing isolates the ribotype could not be determined and
these three isolates had the same antibiotic susceptibility profiles with sensitivity to
ceftriaxone, ciprofloxacin, metronidazole and vancomycin.
Over the environmental study period of the toxin-producing C. difficile isolates
ribotype 001 was the most common ribotype found from the colorectal ward
environmental isolates with 34 of the 70 isolates (48.6%) identified as ribotype 001.
Ribotypes 020 (7.1%) and 026 (7.1%) were the next commonest found in 5 of the 70
isolates each, followed by ribotype 002 (4.3%) (Table 6.1 and figure 6.3). Further
ribotypes 012, 015, 039, 081, 103, 106 and 176 were identified in the remaining
isolates. A ribotype was not determined in 10 of the 70 isolates (14.3%).
All ribotype isolates were sensitive to both metronidazole and vancomycin.
The 34 isolates identified as ribotype 001 demonstrated variable resistance to
ceftriaxone and ciprofloxacin. Twenty-six of the 34 ribotype 001 isolates showed
intermediate resistance to ceftriaxone and all of these 26 isolates were resistant to
ciprofloxacin. One ribotype 001 isolate was resistant to both ceftriaxone and
ciprofloxacin and the remaining seven ribotype 001 isolates were sensitive to
ceftriaxone with 6 of these resistant to ciprofloxacin and one sensitive to
ciprofloxacin. Resistance to ciprofloxacin was almost ubiquitous in the ribotype 001
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environmental isolates with resistance to ciprofloxacin demonstrated in 97% (33 out
of 34) of these isolates.
In the environmental isolates with the next most common ribotypes 020 and 026, all
the ribotype 020 isolates were sensitive to ceftriaxone and ciprofloxacin, whilst
intermediate resistance to ceftriaxone was found in two of the five ribotype 026
isolates and ciprofloxacin resistance in one of the 026 isolates.
Overall intermediate ceftriaxone resistance was found in 39 of 70 isolates (55.7%)
and ceftriaxone resistance in 2 (2.9%) isolates and resistance to ciprofloxacin was
high and present in 46 (65.7%) of all isolates.
Figure 6.3 The distribution of ribotypes found in the colorectal surgical wards
environment isolates.
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E Number Date ward surface ribotype toxin Ceftriaxone Ciprofloxacin Metronidazole Vancomycin
1 Jan-08 23 TS 12 Y S R S S
2 Jan-08 23 F 1 Y I R S S
4 Jan-08 24 B 1 Y I R S S
5 Jan-08 24 B 1 Y I R S S
6 Jan-08 23 B 12 Y S R S S
8 Jan-08 24 B 26 Y S S S S
9 Jan-08 23 B 1 Y I R S s
10 Jan-08 22 B ND Y I S s s
11 Jan-08 24 B 103 Y I S s s
14 Mar-08 24 bp 1 Y S R s s
15 Mar-08 24 T 1 Y S R s s
16 Mar-08 24 B 1 Y I R s s
17 Mar-08 24 T 1 Y I R s s
18 Mar-08 23 B 1 Y I R s s
20 Mar-08 23 F 1 Y I R s s
21 Mar-08 27 TH 1 Y S R s s
22 Mar-08 27 B 15 Y S R s s
24 Mar-08 27 F 1 Y I R s s
25 Mar-08 22 L 1 Y I R s s
29 May-08 24 F 1 Y I R s s
30 May-08 24 B 1 Y I R s s
31 May-08 24 bp Y I S s s
32 May-08 24 bp Y S S s s
33 May-08 24 bp 103 Y s R s s
34 May-08 23 bp 1 Y s R s s
35 May-08 24 B 1 Y I R s s
36 May-08 24 L 26 Y I S s s
37 May-08 23 L 1 Y I R s s
38 May-08 23 T 20 Y s S s s
41 May-08 23 L 20 Y s S s s
42 May-08 27 TH ND Y s R s s
43 May-08 27 B 20 Y s S s s
44 May-08 27 L ND Y s S s s
45 May-08 27 B 1 Y I R s s
47 May-08 22 F 20 Y s S s s
48 Jul-08 23 B 1 Y I R s s
49 Jul-08 23 B 20 Y s S s s
53 Aug-08 24 F 1 Y s S s s
54 Aug-08 24 T 81 Y I S s s
55 Aug-08 24 T 1 Y I R s s
56 Aug-08 24 B 1 Y I R s s
57 Aug-08 24 L 81 Y s S s s
58 Oct-08 27 B 1 Y I R s s
60 Oct-08 27 B ND Y I S s s
63 Oct-08 27 TS ND Y s S s s
65 Oct-08 27 B 15 Y s S s s
66 Oct-08 27 B 1 Y I R s s
67 Nov-08 24 B 1 Y I R s s
69 Nov-08 24 T 106 Y I R s s
72 Nov-08 23 B 176 Y I R s s
74 Nov-08 23 T 26 Y s S s s
78 Nov-08 23 T 176 Y I R s s


















Jan-09 27 B 39 Y I S S s
Jan-09 27 B 1 Y I R S s
Jan-09 27 F ND Y S S S s
Feb-09 24 B 1 Y S R S s
Feb-09 24 B 2 Y R R S s
Feb-09 24 L 1 Y I R S s
Feb-09 24 B 1 Y I R S s
Feb-09 24 B ND Y S S S s
Feb-09 24 L 39 Y 1 R S s
Mar-09 23 F 26 Y 1 R s s
Mar-09 23 BS ND Y 1 R s s
Mar-09 23 B ND Y S R s s
Mar-09 23 HC 1 Y 1 R s s
Mar-09 23 B 26 Y s S s s
Mar-09 23 L 1 Y 1 R s s
Mar-09 22 T 1 Y R R s s
Mar-09 22 F 1 Y S R s s
Table 5.1 Demonstrates the environmental toxigenic culture positive isolates, the
ward and surface from which they were obtained, the ribotypes obtained from each
isolate (ND indicates not determined) and their antibiotic susceptibility profiles for
the antibiotics ceftriaxone, ciprofloxacin, metronidazole and vancomycin. (B = bed,
bp = sphygmomanometer blood pressure cuff, BS = ward main bay sink, F = floor,
HC = patient bed hand control, L = patient bedside locker, T = patient bedside table,
TS = main bay patients' toilet room sink handle and TH = main bay patients' toilet
room door handle).
6.3.3 The impact of introduction of a chlorine-based cleaning agent
in the distribution of Clostridium difficile in colorectal surgery.
In early June 2008 a new cleaning protocol, as previously described in section 2.7.4 of
the Materials and Methods, was introduced with the major change involving cleaning
of vacated bed spaces with Acti-chlor, a chlorine based cleaning agent, rather than
quaternary ammonium compounds and /or bleach detergents. During the month of
June 2008 there was a transition period as staff, both ward and domestic staff, got
used to using Acti-chlor. Therefore no environmental samples were collected during
June 2008 to accommodate the change and environmental sampling re-commenced in
July once changes were fully implemented and established.
100
Environmental sampling was performed in January, March, May, July, August,
October and November 2008 and January, February and March 2009. The distribution
of environmental toxigenic C. difficile plates over the entire environmental study
period is shown in Figure 6.4. The maximal number of positive plates and hence
isolates were obtained in May 2008. During the period prior to implementation of the
new cleaning protocol 19.4% of the environmental contact plates used were positive
for toxigenic C. difficile and for the same duration following the new cleaning
protocol only 2.3% of the environmental contact plates used were positive. There was
a 48.6% reduction in toxigenic C. difficile environmental contamination following the
new cleaning protocol compared with the same time period prior to the change.
However, only a 25.7% reduction was demonstrated between the extended study
periods in 2009 compared with the similar time period prior to the change in cleaning
protocols.
Over the original environmental study period January 2008 to January 2009 inclusive,
there was a statistically significant reduction in environmental contamination after the
new cleaning procedures were introduced, p = 0.0189, compared with the old cleaning
protocol. Similarly there was a statistically significant reduction in toxigenic culture
positive in-patients on the colorectal wards, p = 0.0026, for the period following the
new cleaning protocol compared with the period prior to its introduction (Figure 6.5).
On reviewing the number of toxigenic C. difficile positive environmental plates and
the number of toxigenic culture positive patients per ward per month, clustering of the
positive plates and patients is demonstrated (Figure 6.6), with an increased number in
both positive plates and patients prior to the introduction of the new cleaning protocol
on each ward.
Over the entire environmental study period, on assessing the number of toxigenic C.
difficile environmental contact positive plates per ward per month (Figure 6.7), it was
noted that prior to the introduction of the new cleaning protocol, that all the wards
with colorectal surgical patients generally had toxigenic C. difficile contamination
each month. Following the new cleaning protocol C. difficile contamination was only
detected on a single ward or a maximum of two wards per month, July 2008 to March
2009 inclusive, rather than on all the wards. Similarly, on reviewing the number of
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toxigenic culture positive in-patients on the colorectal wards, there was a distribution
of positive patients on all of the wards during the period of the old cleaning protocol.
However, once the new cleaning protocol was established, from July 2008 to January
2009 there was an overall decreased distribution of patients across the wards with
patients generally found on the wards where environmental C. difficile contamination
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Figure 6.4 The distribution of toxigenic positive C. difficile environmental plates over
the study period.
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Figure 6.5 The distribution of the number of C. difficile culture positive
environmental contact plates obtained and the number of C. difficile positive in¬
patients per month over the study period.
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Figure 6.6 The number of C. difficile culture positive environmental contact plates
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Figure 6.7 The distribution and number of toxigenic C. difficile positive
environmental contact plates obtained from each ward for each month of the study.
104
6.3.4 Distribution of Clostridium difficile ribotypes pre and post
introduction of the new cleaning protocol.
Eleven different toxigenic C. difficile ribotypes were identified in the colorectal
surgical ward environment over the entire environmental study period. The
distribution of the number of different ribotypes identified in the colorectal surgical
ward environment pre and post the new cleaning protocol did not change with eight
different ribotypes identified prior to the new cleaning protocol and nine different
ribotypes identified after its introduction. However, the proportion of ribotype 001
isolates did decrease by 57.6% over the original study period (January 2008 to
January 2009), pre and post the new cleaning protocol. A recurrent slow rise in the
prevalence of 001 in the environment was noted however from January to March
2009 inclusive (Figure 6.8).
In relation to the environmental isolates, the proportion of in-patients with ribotype
001 also decreased by 65.7% over the original study period, pre and post
establishment of the new cleaning protocol. When taking into account all the
toxigenic culture positive isolates from patients who passed through the colorectal
wards during the study or were treated by the same colorectal clinical teams including
those boarded to other non-colorectal wards and those patients with recurrent disease
seventeen different toxigenic C. difficile ribotypes were identified in the patient
population from January 2008 to January 2009. Again the number of different
ribotypes identified in the patient cohort pre and post the new cleaning protocol did
not change with 14 different ribotypes identified prior to the new cleaning protocol
and 13 different ribotypes identified after its introduction (Figure 6.9).
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Figure 6.8 Distribution of the different environmental toxigenic C. difficile ribotype



















Figure 6.9 Distribution of the different toxigenic culture positive C. difficile patient
isolates identified over the original environmental study period.
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6.4 Discussion
The bed frames were the greatest site of C. difficile contamination with 44.2% of all
positive environmental samples obtained from the bed frames. Two other studies also
found the bed frames to be the most common environmental site from which C.
difficile was recovered (Verity et al., 2000; Guerrero el al., 2012). The patients' bed
side lockers and tables also had reasonable levels of C. difficile contamination with a
combined proportion of 25.6% of the total number of C. difficile positive
environmental samples. These are surfaces upon which the patient's food and
belongings were kept and therefore were a high risk for transmission of CDI as the
spores were more likely to be ingested off these surfaces. All the C. difficile
contamination relating to the patient bed spaces were in main bay areas and not from
isolation rooms in which C. difficile positive patients had been isolated. Therefore the
patients occupying these bed spaces and their visitors were at risk of CDI acquisition
be it asymptomatic acquisition or symptomatic disease. In addition, potential
forgotten reservoirs of C. difficile in the environment, in particular the bed frames
were highlighted.
C. difficile contamination obtained from the wards' main communal floors was
present in 12.8% of all positive environmental samples. The importance of the
presence of C. difficile and other bacteria on floors has been debated and two studies
have shown that the disinfection of floors played a negligible role in the transmission
of disease and had no impact on rates of infection (Fawley & Bond 2001; Danforth et
al., 1987). Similarly Voss et al., 2003 also suggested that routine disinfection of floors
was not necessary unless required in certain situations such as contamination of floors
with organic matter. Arguments in favour of floor disinfection include
implementation of a single cleaning strategy including floors ensures standardisation
and uniformity of cleaning and training procedures for staff (Rutala & Weber, 2001),
and Exner et al., (2004) using an experimental model found that cleaning of floors
with a mop using detergents resulted in the spread of bacteria from contaminated
areas to clean areas and therefore intimated that disinfection including floors should
be part of a complete approach to hospital hygiene. With C. difficile spores able to
exist on floors for up to 5months (Kim et al., 1981) their presence adds to the
contamination burden present within a hospital environment and provides an
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indication of background hygiene levels within a hospital environment. Objects can
be dropped on the floor and picked up further allowing for potential transmission of
spores or spores may be aerosolised from the floor into the air.
Approximately 7% of all the positive environmental samples were obtained from the
communal sphygmomanometer arm cuffs. This equated to five blood pressure cuffs
from two wards identified in March and May of 2008 prior to the new cleaning
protocol. Following the new cleaning protocol C. difficile was not isolated from the
cuffs. Manian et al. (1996) found unexpected contamination of blood pressure cuffs
with C. difficile at a rate of 10% which was similar to that for bedside commodes. In
their study, an observational survey had revealed that healthcare workers not
infrequently forgot to remove their gloves before touching clean surfaces. Despite
their study occurring over a decade ago, it is interesting that similar findings occur.
Two other commonly touched sites by patients, staff and visitors are the main bay
sink handles and the patient bed hand control, C. difficile was only identified from
these on one occasion each, although the hand control had only been assessed once
during the entire study as an alternative to the bed frame. Dumford et al., (2009)
found of the surfaces they sampled; 21% of portable medical equipment such as
medication carts and portable computers were contaminated with C. difficile and that
10% of surfaces in the nursing work area and 31% of surfaces in medical staff work
areas were also contaminated.
C. difficile contamination on the hands of healthcare workers on wards containing
patients with symptomatic CDI has been previously recognised (Fekety et al., 1981;
Samore et al., 1996), and correlation between transmission of CDI between patients
and contamination of the hands of healthcare workers has been described (McFarland
et al., 1989). Taffinder et al. (1997) sampled infants in a neonatal intensive care unit
over a period of 12 months and showed 57% of infants were colonised at first
sampling dropping to 10% latterly as infection control procedures primarily hand
hygiene measures were introduced and therefore cross-infection was most likely to be
occurring by handlers. Corresponding to these, Samore et al. (1996) found that
contamination of the hands of health-care workers directly related to levels of
environmental contamination. Therefore the hands of health-care workers are
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generally considered the primary means of C. difficile spore transmission in health¬
care settings (Bobulsky et al., 2008).
Sethi et al., 2010 determined that skin contamination and environmental shedding of
C. difficile remained common at the time of resolution of diarrhoea, although the
proportions were significantly reduced compared to the proportions before treatment.
They also found more than half their patient cohort tested 1 to 4 weeks after treatment
for CDI had asymptomatic stool carriage and concurrent skin and environmental
contamination. Acquisition of C. difficile from investigators' hands in their study
continued to occur 50% of the time after contact with the patient's chest, abdomen,
arm and hand. In a further study by Guerrero et al., (2012) on assessing a cohort of
patients with symptomatic CDI, they found risk of hand contamination after contact
with commonly examined skin sites and commonly touched environmental surfaces
was identical. The abdomen and groin were the two examined sites which caused the
greatest hand contamination and the bed rail, the environmental site which caused the
greatest hand contamination. Therefore equipment that is not disposable such as
communal sphygmomanometer cuffs, portable ultrasound machines and stethoscopes
etc. are still at risk of contamination even after the patient is asymptomatic and is no
longer in isolation. Alleyne et al., 2009 isolated C. difficile from 4.9% of
stethoscopes.
C. difficile spores were isolated from the main bay patient toilet room door handles
and the toilet room sink handles. These are areas that potentially C. difficile would
expect to be isolated from as C. difficile environmental culture recovery rates have
been shown to be greater from toilet and sluice room floors (Fawley et al., 2001). In
this study, whilst these areas accounted for 5.7% of all positive environmental
samples combined they were only the sixth most common surface identified with C.
difficile contamination. This may be a reflection of good hand hygiene in the patient
population generally. The higher levels of contamination identified on the patient's
bed space surfaces, as described earlier, are therefore not necessarily from the patient
themselves, as colonised asymptomatic carriers, but remain present following
vacation of a symptomatic CDI patient from that bed-space previously or transmission
by hands of staff.
109
Persistence of C. difficile environmental contamination may relate to recent evidence
of aerial dissemination of spores, and therefore improved ward ventilation may also
help to reduce CDI transmission. Fawley el al., (2001) cultured C. difficile from air
vents. Roberts et al., (2008) isolated C. difficile from the air using a portable cyclone
sampler, from a six bedded elderly care bay over a period of two days. They found
that large numbers of particles were found in the air at almost all time points and
therefore C. difficile aerosolisation events occurred throughout the day. Best et al.,
(2010) found C. difficile was more frequently isolated from the air during periods of
activity such as ward rounds and visiting hours. Recently Best et al., (2012) assessed
the affect of aerosolisation following toilet flushing and found C. difficile was
recoverable up to a height of 25cm above the toilet seat whilst surface contamination
occurred 90 minutes after flushing, therefore aerosolisation following flushing
resulted in seeding of the surrounding environment and the simple act of flushing with
the toilet lid closed could reduce environmental and aerosolised C. difficile.
Ward 24 had the greatest proportion of environmental positive contact plates and
therefore not surprisingly had the greatest number of C. difficile toxigenic positive
patients. However, ward 22 with the next highest number of toxigenic culture positive
patients had the lowest number of positive environmental samples. Whilst this does in
part reflect good cleaning procedures, the differences may also be a result of
admission cohort and procedures. Ward 22 often admitted the acute admissions
generally for a maximum 24 hour period and then primarily admitted both colorectal
and urology day case patients. The colorectal surgical admissions to Ward 22 would
then be delegated to Ward 23, 24 or 27 for longer stay or discharged home. Therefore
patients with potential symptomatic CDI admitted as emergencies or day cases will
have had their faecal specimen sent from and recorded as ward 22 but were likely
rapidly transferred to another colorectal ward, therefore decreasing the time period
over which environmental shedding and contamination could occur.
During the period preceding implementation of the new cleaning protocol 19.4% of
the environmental contact plates used were positive for toxigenic C. difficile.
Dumford et al. (2009) similarly found 16% of their samples from rooms of patients
not in isolation for CDI were culture positive (their samples were collected
approximately one year prior to the commencement of this study). For the same
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duration of time following introduction of the new cleaning protocol only 2.3% of the
environmental contact plates were toxigenic C. difficile positive. This figure is
consistent with Faires et al., (2012) who found 2.4% of surfaces they tested were
contaminated with C. difficile in a study performed approximately one year following
the completion of this study. Our figures therefore are likely to be representative of
decreased environmental contamination changes happening in other centres of the
western world over the last few years during endemic rather than outbreak settings, as
awareness increased and improved infection control was introduced.
Over the original environmental study period there was a significant reduction in
environmental contamination (p = 0.0189) and the incidence of toxigenic culture
positive in-patients (p = 0.0026) on the colorectal surgical wards following the
introduction of the new cleaning protocol. The old cleaning protocol had used a
combination of quaternary ammonium compounds and / or bleach (NaOCl) for
disinfection and the new cleaning protocol used Actichlor plus (NaDCC) for
disinfection at lOOOppm of chlorine either with a detergent pre-clean or in
combination with a detergent. NaDCC base agents and bleach are both sporicidal and
bactericidal.
Quaternary ammonium compounds have been found to be significantly less effective
than other agents as a disinfectant (Dharan et al., 1999, Hacek el al., 2010) and may
account for the increased levels of contamination prior to the new cleaning protocol.
Sodium hypochlorite (bleach) has been widely used in hospitals however its
effectiveness as a disinfectant is dependant on the concentration and the duration of
contact it is left in contact with the surface for. Bleach at a concentration of 5000ppm
causes a reduction in C. difficile spores of 6 logio in 10 minutes; however, the use of
bleach at these concentrations requires protective personal equipment, concentrations
of bleach of 3000ppm have to be left for 15 minutes and lOOOppm for up to 25
minutes for a similar reduction in C. difficile spores (Perez et al. 2005). As bleach is
quick-drying, it can be difficult to ensure an even concentration across a surface and
therefore decreased cleaning and disinfection may occur particularly if sprayed onto a
surface using lower concentrations (Omidbakhsh, 2010). During the period of study
using the old cleaning agents it was uncertain at what concentration the agents were
being prepared for use and for how long they were left to act on surfaces. Bleach
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however when used at concentrations of 5000ppm has been found to be effective in
reducing the prevalence density of C. difficile patients (Hacek et cil., 2010).
Sodium dichloroisocyanurate based agents, such as Actichlor, have been found to be
better disinfectants than bleach (Bloomfield & Uso, 1985). Similar to this
environmental study Wilcox et al., (2003) found environmental contamination on a
hospital ward and incidence rates of CDI decreased with the use of a NaDCC based
agent. Wheeldon et al., (2008) found the efficacy of NaDCC was reduced in the
presence of organic matter and contact of 9 minutes at a concentration of lOOOppm, as
used on the wards in this study, was required to eliminate spores to below the
detection limit. Therefore in the presence of organic contamination pre-cleaning with
detergent followed by wiping the surface with the NaDCC based agent improves the
action of the disinfectant. Conversely Vohra et al., (2011) did not find decreased
efficacy ofActichlor, in the presence of organic matter.
There was a 48.6% reduction in toxigenic C. difficile environmental contamination
following the new cleaning protocol compared with the same time period prior to the
change. However, only a 25.7% reduction in environmental contamination was
demonstrated on reviewing January to March 2009 compared with the similar time
period using the old cleaning protocol. This could reflect an increase in admitted CDI
positive patients as the CDI patient population study was not continued beyond
January 2009. Locally, previously symptomatic CDI patients are taken out of isolation
once diarrhoea has stopped for 48 hours, however as previously demonstrated by
Sethi et ah, (2010) continued environmental shedding and skin contamination can
persist at significant levels for 1 to 4 weeks and the changes in environmental
contamination seen at the beginning of 2009 may reflect this. Even with increased
incidence, ideally contamination rates should not increase and may therefore also
reflect decreased awareness in using the new agents following the initial push after
their introduction, such as not leaving the agent on the surface prior to wiping for the
recommended period of time and not targeting potential C. difficile reservoir surface
areas.
Although a slow increase in C. difficile environmental contamination was noted from
January to March 2009, following the initial sustained decrease from July 2008 to
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January 2009, it was noted that, following the new cleaning protocol, C. difficile
contamination was only detected on a single ward or a maximum of two wards per
month. Similarly there was an overall decreased distribution of patients across the
wards, with patients generally found on the wards where environmental C. difficile
contamination had been identified. Prior to the new cleaning protocol all the wards
generally had toxigenic C. difficile contamination and toxigenic culture positive in¬
patients. Therefore environmental contamination and the presence of CDI positive
patients do not generally exist without the other once good cleaning, isolation and
protective measures are established. Kim et al., (1981) found in areas where C.
difficile patients had diarrhoea 9.3% of environmental cultures were positive and in
areas where there were no known CDI carriers, only 2.6% of cultures were positive.
However as previously stated in this study, environmental contamination was not
identified in areas where CDI positive patients were absent once the new cleaning
protocol was introduced.
Over the environmental study period ribotype 001 was the most common C. difficile
strain identified from the colorectal ward environmental isolates with 48.6% of all
isolates identified as ribotype 001. This is identical to the proportion of toxigenic
culture positive faecal isolates from the colorectal surgical in-patients where 46.9% of
isolates were identified as ribotype 001. Therefore the environmental epidemiology
remains consistent with local epidemiology studies where ribotype 001 has been the
prevalent ribotype in Southeast Scotland as described in Chapter 5. Interestingly
ribotypes 020 (7.1%) and 026 (7.1%) were the next commonest ribotypes identified
from environmental isolates as opposed to ribotype 012 which was the next most
common ribotype from the patient faecal isolates.
All environmental isolates were sensitive to both metronidazole and vancomycin,
where as in the patient faecal isolates 4.6% had denoted intermediate resistance to
vancomycin. Of interest 76.5% of ribotype 001 environmental isolates showed
intermediate resistance to ceftriaxone and only one ribotype 001 isolate (2.9%) was
resistant to ceftriaxone, however in the patient faecal isolates 36% of ribotype 001
isolates were resistant to ceftriaxone. Similar to the patient faecal isolates
ciprofloxacin resistance in the ribotype 001 environmental isolates was high and
present in 97%. Overall intermediate ceftriaxone resistance was found in 55.7% and
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ceftriaxone resistance in only 2.9% of environmental isolates (compared with 29.2 %
and 26.9% respectively in the patient faecal isolates) and resistance to ciprofloxacin in
the environmental isolates was high as seen with the patient faecal isolates.
When taking into account the resistance to the tested antibiotics in the environmental
isolates versus the patient faecal isolates as a whole the overall antibiotic resistances
were similar however definite ceftriaxone resistance was higher in the overall patient
faecal isolates in particular the ribotype 001 isolates compared with the environmental
group similarly intermediate vancomycin resistance was only demonstrated in the
patient isolates. Therefore this poses the question - does increased antibiotic resistance
in C. difficile develop in patients once they have been infected by a less resistant C.
difficile strain, due to C. difficile exposure to sub-MIC concentrations of antibiotics or
do C. difficile vegetative cells and spores become less resistant to antibiotics in the
environment? This is of particular importance in dominant ribotypes where studies
have shown increased antibiotic resistance in dominant strains (Mutlu et aI., 2007;
Taori et al., 2010).
Other features of ribotype 001 in addition to its multi-drug resistance, may have
allowed it to emerge locally as the dominant ribotype and persist. Like other epidemic
strains such as 106 and 027 it produces alcohol resistant spores in large quantities and
therefore the previous wide-spread use of alcohol based hand gels in the hospital
environment provided false reassurance of "clean" hands with decreased washing of
hands with soap and water. Higher concentrations of decontaminants and
disinfectants including Actichlor have been required to destroy ribotype 001 C.
difficile vegetative cells (Vohra et al., 2011), again likely pertaining to its resistance
mechanisms. Ribotype 001 also has the ability to cause severe disease (Arvand et al.,
2009 and Sundram et al., 2009) and although the ribotypes causing disease in the
cohort of CDI patients, described in Chapter 3, with pseudomembranous colitis and
requiring surgical intervention for CDI were not known, it is likely ribotype 001 was
responsible for CDI in a proportion of these patients given that it has emerged as the
dominant ribotype locally.
Eleven different toxigenic C. difficile ribotypes were identified in the colorectal
surgical ward environment compared with seventeen different ribotypes in the patient
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faecal isolates. Further adding supporting evidence to Lanzas et al., (2011)
experimental model, that transmission of CDI among patients does not occur within
the ward alone and new patient admissions already colonised with C. difficile play an
important role in sustaining the number of patients with CDI on wards.
The proportion of the dominant ribotype 001 isolates in this study decreased markedly
after introduction of the new cleaning protocol, by 57.6% in the environment and by
65.7% in the colorectal inpatients. The distribution of the number of different
ribotypes identified in the colorectal surgical ward environmental and patient isolates
did not change pre and post the new cleaning protocol and neither did any single
ribotype become more prevalent as ribotype 001 decreased. In this endemic setting,
without notable CDI outbreaks in this population during the study period, improved
infection control results in several different strains being able to subsist and remain
responsible for CDI in the absence of a dominant strain.
Other cleaning agents and methods have also been studied for use in the
environmental disinfection of C. difficile. A hydrogen peroxide dry mist system has
been found to be effective in the de-contamination of C. difficile with reduction rates
of 91% to 94% and has been found to be effective against ribotypes 106, 001 and 027
(Barbut et al., 2007; Shapey et al., 2008; Passaretti et al., 2012). Sexton et al., (2011)
found portable steam vapour systems reduced bacterial levels by greater 90%,
however C difficile could not be evaluated as only one colony was found pre cleaning.
Smith et al., (2011) found re-usable ultra micro-fibre cloths were efficacious at
removing surface organisms associated with HAI including CDI. A UV-C device
demonstrated an 80% spore reduction of contaminated surfaces however cycles took
up to 45 minutes to achieve eradication of spores, and could not be used in rooms
with current in-patients (Nerandzic et al., 2010). A hand-held far-UV radiation device
using a spectrum with a higher photon energy than UV-C, showed a significant
reduction in C. difficile spores when used for only 5 seconds, however it was found to
be less effective in the presence of organic material. The biocidal effect of copper as a
contact surface that can be applied to a clinical setting also continues to be
investigated in laboratory studies (Gant et al., 2007; O'Gorman et al., 2012). The
future of C. difficile decontamination therefore is still to be determined in the interim
this study has shown that good cleaning procedures with a NaDCC based agent can
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Clostridium difficile was identified as an infective agent that originated from outwith
a patient with Clostridium difficile infection and was not simply an overgrowth of part
of the commensal colonic flora in the early 1980s (Poxton, 2013). Prior to this in the
late 1970s Clostridium difficile had been identified as the causative agent of CDI and
pseudomembranous colitis (Larson et al., 1977; Bartlett et al., 1978). Since then the
incidence and recognition of CDI has increased particularly in the western world over
the past four decades and C. difficile has become the principal cause of nosocomial
diarrhoea in adults and an important cause of antibiotic-associated diarrhoea with CDI
associated morbidity and mortality also increasing.
Lothian University Hospitals Division provides for a population of approximately
620 000 people in the Edinburgh area of South-East Scotland, and is a tertiary referral
centre for peripheral district general hospitals and in some specialties for all of
Scotland. Using locally collected data from 2000 to 2007 this was one of the first
studies to assess the C. difficile related burden handled by the diagnostic enteric
hospital microbiology laboratories and provide the first data on potential clinical
workload for an area of Scotland over an eight-year period. The study also provided
epidemiological data on a region not affected by ribotype 027, a hypervirulent C.
difficile strain.
A 27-fold increase in the number of faecal samples analysed by the enteric laboratory
occurred from 2000 to 2006 and the total number of potential CDI cases increased
over the same period, with a decline finally seen in 2007. With one-fifth of all toxin-
positive samples, tested by the enteric laboratory, from age groups under 60 years of
age this was further evidence that CDI was not just a disease of the elderly. Although
Medicine of the Elderly provided the greatest analysis workload for the enteric
laboratory, Renal Medicine / Transplant Surgery, Intensive Care, Infectious Disease
and Gastrointestinal Medicine all had higher incidences of CDI than Medicine of the
Elderly. Similarly the low risk group of Paediatrics was also starting to show a small
but notable increase in potential incidence although these figures were reported with
caution due to the high carriage rates previously reported in children. With extra
associated costs of approximately £4000 per CDI in-patient case the potential excess
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costs for CDI in this region rose from £3.5 million pounds to £29 million pounds over
the study period.
The General Surgical specialties had a greater CDI incidence then General Medicine.
On closer review of the surgical specialties, colorectal surgery had the greatest
number of CDI episodes followed by Upper Gastrointestinal Surgery and Urology.
Despite the total number of C. difficile toxin-positive in-patients across the Lothian
area and the number of colorectal surgical toxin-positive in-patients increasing each
year from 2000 to 2006, a similar continued increase was not demonstrated in the
number of patients diagnosed with more severe forms of CDI, PMC and fulminant
CDI, and similarly an increase was not demonstrated in the number of CDI patients
referred and treated with surgical intervention.
Most patients referred for surgical intervention to treat fulminant CDI were referred
from other specialties and had received broad-spectrum antibiotics associated with
CDI development. Of note, 30% of the surgically treated cohort were emergency
admissions from home with probable community acquired CDI. In these extreme
cases of CDI up to 40% of patients did not present with diarrhoea and up to 50% of
patients did not have a C. difficile toxin-positive faecal sample prior to surgery. This
demonstrated the importance of clinical recognition of the entire spectrum of C.
difficile related disease.
The post-operative mortality rate for fulminant CDI was 26% in this cohort, with
reported mortality figures in other studies varying from 19% to 64% (Neal et al.,
2011; Trudel et al., 1995). High mortality figures for fulminant CDI treated surgically
have not changed significantly over the last two decades. Most of the patients in this
operative CDI cohort were in extremis, as surgical referral for CDI often occurs late,
with earlier surgical referral, surgical management of CDI could become a definitive
life-saving rather than a desperate procedure. New operative procedures such as a
diverting loop ileostomy with colonic lavage and colonic vancomycin treatment may
begin to replace the sub-total colectomy and end ileostomy formation and segmental
colectomy procedures currently performed.
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An asymptomatic carrier rate of 6.1% was identified in the out-patient colorectal
surgical population and an asymptomatic carrier acquisition rate of 3.9% was
identified in the in-patient colorectal surgical population. Asymptomatic carriers in
particular those admitted from the community play an important role in sustaining the
transmission of disease within the hospital environment with 42.8% of C. difficile
strains identified in the in-patients but not in the environment of the colorectal
surgical wards.
CDI diagnosis using enzyme immuno-assay for toxin A+B detection was 52% less
sensitive then toxigenic culture with a false positive rate of 2.5%. Toxigenic culture
identified a further 58 colorectal surgical inpatients with CDI who were not identified
with standard enteric laboratory testing at the time of the study. Since this study was
performed in recognition of the diminished sensitivity of EIA alone in other studies
the local enteric laboratory uses a modified version of recent European Guidelines.
However no one test for CDI testing has been found to be sensitive, rapid,
inexpensive and easy to use to completely replace EIA for symptomatic CDI testing,
and therefore two-step protocols including the detection of glutamate dehydrogenase
and EIA or PCR are currently implemented.
Of all the isolates identified from toxigenic culture-positive CDI in-patients; ribotype
001 was the commonest C. difficile strain isolated, consistent with other local studies
where ribotype 001 has emerged as the dominant strain. Similarly ribotype 001 was
the commonest strain identified in the colorectal surgical ward surface environment.
Although ribotype 012 was the next commonest in-patient strain, 020 and 026 were
found to be the next commonest environmental strains.
A large proportion of the in-patient C. difficile isolates in particular ribotype 001
showed resistance to ceftriaxone and ciprofloxacin. Interestingly the ribotype 001
isolates from the surface environment showed decreased resistance to ceftriaxone
compared with the in-patient strains. Similarly 4.6% of all in-patient isolates showed
intermediate resistance to vancomycin but no vancomycin resistance was
demonstrated in the environmental surface isolates. This may represent increased
development of C. difficile resistance mechanisms once in the host following sub-
MIC exposure to various antibiotics. The study also provided important information
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on ciprofloxacin resistance as fluoroquinolone resistance is usually tested with
moxifloxacin.
Within the colorectal surgical in-patient cohort 5% of patients were identified with
two toxigenic C. difficile ribotypes within a 28 day period. Although clinically the
treatment of disease remains the same regardless of strain particularly in absence of
ribotype 027, epidemiologically multiple toxigenic strains in the same patient poses
interesting questions including does a patient's risk of recurrence increase in the
presence of multiple strains? A further 6% of patients were found to have recurrent
disease over substantial periods of time with multiple C. difficile ribotypes and also
the same ribotype causing disease in each patient with recurrence. With current
treatment of recurrent CDI depending on the use of a tapering vancomycin dose
regimen and intermediate vancomycin resistance being demonstrated, newer
treatment options such as fidaxomicin and faecal microbiota transplant should also be
considered.
The patient bed frames were the commonest contaminated environmental surface with
C. difficile, followed by the patient's bedside lockers and tables. Therefore the risk of
a patient ingesting a C. difficile spore from the surface environment is high. During
the environmental sampling study a statistically significant reduction in
environmental C. difficile surface contamination was demonstrated, following the
introduction of a new cleaning protocol. Similarly a statistically significant reduction
in the number of toxigenic culture positive colorectal in-patients was also
demonstrated following the new cleaning strategy which involved replacing
quaternary ammonium based compound detergents and bleach with a sodium
dichloroisocyanurate based agent, such as Actichlor, with a detergent pre-clean prior
to its use. Following the introduction of the new cleaning protocol there was also a
marked reduction in the proportion of ribotype 001 isolates in both the environmental
surface and colorectal surgical in-patient samples. Therefore ribotype 001 did not
remain the dominant ribotype.
In the first study assessing CDI from 2000 to 2007 retrospectively, approximately
one-tenth of all toxin-positive patients identified, were transferred through a minimum
of two specialties whilst remaining positive for C. difficile toxins. The maximum
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number of inter-specialty transfers (and therefore wards) for an individual CDI patient
was six and this does not take into account the number of individual bed moves within
the same ward itself. Reduction of CDI in in-patients also results in decreased
environmental contamination and vice versa. Therefore acquisition of CDI from the
surface environment in hospitals is not to be under-estimated. With a reasonable
proportion of identified CDI patients transferred through different specialties and the
significant financial burden CDI imposes on healthcare institutions judicious




Aktories K. (1997). "Bacterial toxins that target Rho proteins." J Clin Invest 99(5):
827-829.
Aktories K, Schmidt G, Just I. (2000). "Rho GTPases as targets of bacterial protein
toxins." Biol Chem 381(5-6): 421-426.
al Saif N. and Brazier JS. (1996). "The distribution of Clostridium difficile in the
environment of South Wales." J Med Microbiol 45(2): 133-137.
Al-Abed YA, Gray EA, Rothnie ND. (2010). "Outcomes of emergency colectomy for
fulminant Clostridium difficile colitis." The Surgeon 8(6): 330-333.
Albesa-Jove D, Bertrand T, Carpenter EP, Swain GV, Lim J, Zhang J, Haire
LF, Vasisht N, Braun V, Lange A, von F.ichel-Streiber C, Svergun DI, Fairweather
NF, Brown KA. (2010). "Four distinct structural domains in Clostridium difficile
toxin B visualized using SAXS." J Mol Biol 396(5): 1260-1270.
Ali M., Ananthakrishnan AN, Ahmad S, Kumar N, Kumar G, Saeian K.. (2012).
"Clostridium difficile infection in hospitalized liver transplant patients: a nationwide
analysis." Liver Transpl 18(8): 972-978.
Al-Jumaili IJ., Shibley M, Lishman AH, Record CO.. (1984). "Incidence and origin of
Clostridium difficile in neonates." J Clin Microbiol 19(1): 77-78.
Alleyne SA., Hussain AM, Clokie M, Jenkins DR. (2009). "Stethoscopes: potential
vectors of Clostridium difficile." J Hosp Infect 73(2): 187-189.
Al-Obaydi W., Smith CD, Foguet P. (2010). "Changing prophylactic antibiotic
protocol for reducing Clostridium difficile-associated diarrhoeal infections." J Orthop
Surg (Hong Kong) 18(3): 320-323.
Ananthakrishnan, AN., Guzman-Perez R, Gainer V, Cai T, Churchill S, Kohane
I, Plenge RM, Murphy S. (2012). "Predictors of severe outcomes associated with
Clostridium difficile infection in patients with inflammatory bowel disease." Aliment
Pharmacol Ther 35(7): 789-795.
Ang CW, Heyes G, Morrison P, Carr B. (2008). "The acquisition and outcome of
ICU-acquired Clostridium difficile infection in a single centre in the UK." J Infect
57(6): 435-440.
Arroyo LG, Staempfli H, Weese JS. (2007). "Molecular analysis of Clostridium
difficile isolates recovered from horses with diarrhea." Vet Microbiol 120(1-2): 179-
183.
Arvand M, Hauri AM, Zaiss NH, Witte W, Bettge-Weller G. (2009). "Clostridium
difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in
Hesse, Germany." Euro Surveill 14(45).
viii
Asensio A, Vaque-Rafart J, Calbo-Torrecillas F, Gestal-Otero JJ, Lopez-Fernandez
F, Trilla-Garcia A, Canton R; EPINE Working Group. (2008). "Increasing rates in
Clostridium difficile infection (CDI) among hospitalised patients, Spain 1999-2007."
Euro Surveill 13(31).
Aspevall O, Lundberg A, Burman LG, Akerlund T, Svenungsson B. (2006).
"Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR
ribotypes in a Swedish university hospital." Antimicrob Agents Chemother 50(5):
1890-1892.
Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio
P, Kuijper EJ, Wilcox MH. (2008). "Emergence of reduced susceptibility to
metronidazole in Clostridium difficile." J Antimicrob Chemother 62(5): 1046-1052.
Bakken, JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly
C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C; Fecal
Microbiota Transplantation Workgroup. (2011). "Treating Clostridium difficile
infection with fecal microbiota transplantation." Clin Gastroenterol Hepatol 9(12):
1044-1049.
Bakri, MM, Brown DJ, Butcher JP, Sutherland AD. (2009). "Clostridium difficile in
ready-to-eat salads, Scotland." Emerg Infect Dis 15(5): 817-818.
Barbut, F., et al. (2007). "Prospective study of Clostridium difficile infections in
Europe with phenotypic and genotypic characterisation of the isolates." Clin
Microbiol Infect 13(11): 1048-1057.
Barbut F, Mastrantonio P, Delmee M, Brazier J, Kuijper E, Poxton I; European Study
Group on Clostridium difficile (ESGCD). (2009). "Comparison of the efficacy of a
hydrogen peroxide dry-mist disinfection system and sodium hypochlorite solution for
eradication of Clostridium difficile spores." Infect Control Hosp Epidemiol 30(6):
507-514.
Barroso LA., Moncrief JS, Lyerly DM, Wilkins TD. (1994). "Mutagenesis of the
Clostridium difficile toxin B gene and effect on cytotoxic activity." Microb Pathog
16(4): 297-303.
Barth H, Pfeifer G, Hofmann F, Maier E, Benz R, Aktories K. (2001). "Low pH-
induced formation of ion channels by Clostridium difficile toxin B in target cells." J
Biol Chem 276(14): 10670-10676.
Bartlett, J. G., Onderdonk, A.B., Cisneros, R.L. & Kasper, D.L. (1977).
"Clindamycin-associated colitis due to a toxin-producing species of Clostridium in
hamsters." J infect Dis 136: 701-705.
Bartlett, J. G., Moon, N., Chang, T.W., Taylor, N. & Onderdonk, A.B. (1978). "Role
of Clostridium difficile in antibiotic associated pseudomembranous colitis."
Gastroenterology 75: 778 - 782.
ix
Bartlett, J. G. (2002). "Clinical practice. Antibiotic-associated diarrhea." N Engl J
Med 346(5): 334-339.
Bartlett, J. G. (2008). "Historical perspectives on studies of Clostridium difficile and
C. difficile infection." Clin Infect Dis 46 Suppl 1: S4-11.
Bartlett, J. G., Chang, T.W., Moon, N. & Onderdonk, A.B. ((1978)). "Antibiotic-
induced lethal enterocolitis in hamsters: studies with eleven agents and evidence to
support the pathogenic role of toxin-producing Clostridia." AM J Vet Res 39: 1525-
1530.
Bartlett, J. G. and D. N. Gerding (2008). "Clinical recognition and diagnosis of
Clostridium difficile infection." Clin Infect Dis 46 Suppl 1: S12-18.
Bartsch SM., Curry SR, Harrison LH, Lee BY. (2012). "The potential economic value
of screening hospital admissions for Clostridium difficile." Eur J Clin Microbiol
Infect Dis 31(11): 3163-3171.
Bauer MP, Hensgens MP, Miller MA, Gerding DN, Wilcox MH, Dale AP, Fawley
WN, Kuijper EJ, Gorbach SL. (2012). "Renal failure and leukocytosis are predictors
of a complicated course of Clostridium difficile infection if measured on day of
diagnosis." Clin Infect Dis 55 Suppl 2: S149-153.
Bauer MP, Kuijper EJ, van Dissel JT; European Society of Clinical Microbiology and
Infectious Diseases. (2009). "European Society of Clinical Microbiology and
Infectious Diseases (ESCMID): treatment guidance document for Clostridium
difficile infection (CDI)." Clin Microbiol Infect 15(12): 1067-1079.
Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rupnik M,
Monnet DL, van Dissel JT, Kuijper EJ; ECDIS Study Group.. (2011). "Clostridium
difficile infection in Europe: a hospital-based survey." Lancet 377(9759): 63-73.
Benson L, Song X, Campos J, Singh N. (2007). "Changing epidemiology of
Clostridium difficile-associated disease in children." Infect Control Hosp Epidemiol
28(11): 1233-1235.
Best EL, Fawley WN, Parnell P, Wilcox MH. (2010). "The potential for airborne
dispersal of Clostridium difficile from symptomatic patients." Clin Infect Dis 50(11):
1450-1457.
Best EL, Sandoe JA, Wilcox MH. (2012). "Potential for aerosolization of Clostridium
difficile after flushing toilets: the role of toilet lids in reducing environmental
contamination risk." J Hosp Infect 80(1): 1-5.
Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P; West Midlands Research
Collaborative. (2012). "Systematic review and meta-analysis of outcomes following
emergency surgery for Clostridium difficile colitis." Br J Surg 99(11): 1501-1513.
x
Bloomfield SF, and Uso EE (1985). "The antibacterial properties of sodium
hypochlorite and sodium dichloroisocyanurate as hospital disinfectants." J Hosp
Infect 6(1): 20-30.
Bobulsky GS., Al-Nassir WN, Riggs MM, Sethi AK, Donskey CJ. (2008).
"Clostridium difficile skin contamination in patients with C. difficile-associated
disease." Clin Infect Dis 46(3): 447-450.
Bouttier S, Bare MC, Felix B, Lambert S, Collignon A, Barbut F. (2010).
"Clostridium difficile in ground meat, France." Emerg Infect Dis 16(4): 733-735.
Bouza, E. (2012). "Consequences of Clostridium difficile infection: understanding the
healthcare burden." Clin Microbiol Infect 18 Suppl 6: 5-12.
Bradbury AW. and Barrett S. (1997). "Surgical aspects of Clostridium difficile
colitis." Br J Surg 84(2): 150-159.
Braun V, Hundsberger T, Leukel P, Sauerborn M, von Eichel-Streiber C. (1996).
"Definition of the single integration site of the pathogenicity locus in Clostridium
difficile." Gene 181(1-2): 29-38.
Brazier, J. S. (2001). "Typing of Clostridium difficile." Clin Microbiol Infect 7(8):
428-431.
Brazier, JS, Fawley W, Freeman J, Wilcox MH. (2001). "Reduced susceptibility of
Clostridium difficile to metronidazole." J Antimicrob Chemother 48(5): 741-742.
Bricker E, Garg R, Nelson R, Loza A, Novak T, Hansen J. (2007). "Antibiotic
treatment for Clostridium difficile-associated diarrhea in adults." Cochrane Database
Syst Rev(l): CD004610.
Brown R, Collee, JG. & Poxton IR. (1996). "Mackie and McCartney Practical
Medical Microbiology." Edinburgh: Churchill Livingstone 14th edition: 507-511.
Bryant K. and McDonald LC. (2009). "Clostridium difficile infections in children."
Pediatr Infect Dis J 28(2): 145-146.
Burkart NE, Kwaan MR, Shepela C, Madoff RD, Wang Y, Rothenberger DA, Melton
GB. (2011). "Indications and Relative Utility of Lower Endoscopy in the
Management of Clostridium difficile Infection." Gastroenterol Res Pract 2011:
626582.
Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ, Divino CM. (2008). "Predictors
of mortality after colectomy for fulminant Clostridium difficile colitis." Arch Surg
143(2): 150-154; discussion 155.
Calabi E, Calabi F, Phillips AD, Fairweather NF. (2002). "Binding of Clostridium
difficile surface layer proteins to gastrointestinal tissues." Infect Immun 70(10): 5770-
5778.
xi
Carchman EH, Peitzman AB, Simmons RL, Zuckerbraun BS.. (2012). "The role of
acute care surgery in the treatment of severe, complicated Clostridium difficile-
associated disease." J Trauma Acute Care Surg 73(4): 789-800.
Carmeli Y, Venkataraman L, DeGirolami PC, Lichtenberg DA, Karchmer AW,
Samore MH. (1998). "Stool colonization of healthcare workers with selected resistant
bacteria." Infect Control Hosp Epidemiol 19(1): 38-40.
Cartwright CP, Stock F, Beekmann SE, Williams EC, Gill VJ. (1995). "PCR
amplification of rRNA intergenic spacer regions as a method for epidemiologic typing
ofClostridium difficile." J Clin Microbiol 33(1): 184-187.
Castagliuolo I, Keates AC, Qiu B, Kelly CP, Nikulasson S, Leeman SE, Pothoulakis
C.. (1997). "Increased substance P responses in dorsal root ganglia and intestinal
macrophages during Clostridium difficile toxin A enteritis in rats." Proc Natl Acad
SciUS A 94(9): 4788-4793.
Chachaty E, Bourneix C, Renard S, Bonnay M, Andremont A. (1993). "Shedding of
Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in
51 volunteers treated with oral cefixime." Antimicrob Agents Chemother 37(7): 1432-
1435.
Chang, T. W., Gorbach, S.L., & Bartlett, J.G. (1978). "Neutralization of Clostridium
difficile toxin by Sordellii antitoxins." Infect Immun 22: 418-422.
Chang, V. T. and K. Nelson (2000). "The role of physical proximity in nosocomial
diarrhea." Clin Infect Dis 31(3): 717-722.
Changela U, Cannon JP, Aneziokoro C, Shah PS, Thottapurathu L, Lentino J. (2004).
"Risk factors and mortality associated with Clostridium difficile-associated diarrhoea
at a VA hospital." Int J Antimicrob Agents 24(6): 562-566.
Chen KT, Stephens DJ, Anderson E, Acton R, Saltzman D, Hess DJ. (2012).
"Clostridium difficile infection in the pediatric surgery population." Journal of
Pediatric Surgery 47(7): 1385-1389.
Cohen SH., Tang YJ, Silva J Jr.. (2000). "Analysis of the pathogenicity locus in
Clostridium difficile strains." J infect Dis 181(2): 659-663.
Crabtree T, Aitchison D, Meyers BF, Tymkew H, Smith JR, Guthrie TJ, Munfakh N,
Moon MR, Pasque MK, Lawton J, Moazami N, Damiano RJ Jr. (2007). "Clostridium
Difficile in Cardiac Surgery: Risk Factors and Impact on Postoperative Outcome."
The Annals of Thoracic Surgery 83(4): 1396-1402.
Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. (2009). "European Society of
Clinical Microbiology and Infectious Diseases (ESCMID): data review and
recommendations for diagnosing Clostridium difficile-infection (CDI)." Clin
Microbiol Infect 15(12): 1053-1066.
xii
Curry SR, Schlackman JL, Hamilton TM, Henderson TK, Brown NT, Marsh JW,
Shutt KA, Brooks MM, Pasculle AW, Muto CA, Harrison LH. (2011). "Perirectal
swab surveillance for Clostridium difficile by use of selective broth preamplification
and real-time PCR detection of tcdB." J Clin Microbiol 49(11): 3788-3793.
D'Agata EM, Mount DB, Thayer V, Schaffner W. (2000). "Hospital-acquired
infections among chronic hemodialysis patients." Am J Kidney Dis 35(6): 1083-1088.
Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons
RL. (2002). "Fulminant Clostridium difficile: an underappreciated and increasing
cause of death and complications." Ann Surg 235(3): 363-372.
Danforth D, Nicolle LE, Hume K, Alfieri N, Sims H. (1987). "Nosocomial infections
on nursing units with floors cleaned with a disinfectant compared with detergent." J
Hosp Infect 10(3): 229-235.
Davies A, Pottage T, Bennett A, Walker J. (2011). "Gaseous and air decontamination
technologies for Clostridium difficile in the healthcare environment." J Hosp Infect
77(3): 199-203.
Debast SB, Vaessen N, Choudry A, Wiegers-Ligtvoet EA, van den Berg RJ, Kuijper
EJ. (2009). "Successful combat of an outbreak due to Clostridium difficile PCR
ribotype 027 and recognition of specific risk factors." Clin Microbiol Infect 15(5):
427-434.
Delmee M, Bulliard G, Simon G. (1986). "Application of a technique for
serogrouping Clostridium difficile in an outbreak of antibiotic-associated diarrhoea." J
Infect 13(1): 5-9.
Delmee M, Homel M, Wauters G. (1985). "Serogrouping of Clostridium difficile
strains by slide agglutination." J Clin Microbiol 21(3): 323-327.
Denno DM, Shaikh N, Stapp JR, Qin X, Hutter CM, Hoffman V, Mooney JC, Wood
KM, Stevens HJ, Jones R, Tarr PI, Klein EJ. (2012). "Diarrhea etiology in a pediatric
emergency department: a case control study." Clin Infect Dis 55(7): 897-904.
Deshpande A, Pant C, Jain A, Fraser TG, Rolston DD. (2008). "Do fluoroquinolones
predispose patients to Clostridium difficile associated disease? A review of the
evidence." Curr Med Res Opin 24(2): 329-333.
Dharan S, Mourouga P, Copin P, Bessmer G, Tschanz B, Pittet D. (1999). "Routine
disinfection of patients' environmental surfaces. Myth or reality?" J Hosp Infect 42(2):
113-117.
Dial S, Delaney JA, Schneider V, Suissa S.. (2006). "Proton pump inhibitor use and
risk of community-acquired Clostridium difficile-associated disease defined by
prescription for oral vancomycin therapy." CMAJ 175(7): 745-748.
Dorn, S. D. (2009). "Clostridium difficile colitis in a health care worker: case report
and review of the literature." Dig Dis Sci 54(1): 178-180.
Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL.
(1990). "Molecular characterization of the Clostridium difficile toxin A gene." Infect
Immun 58(2): 480-488.
Drummond LJ, McCoubrey J, Smith DG, Starr JM, Poxton IR. (2003). "Changes in
sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in¬
patients over an 18-month period." J Med Microbiol 52(Pt 3): 259-263.
Dubberke ER, Han Z, Bobo L, Hink T, Lawrence B, Copper S, Hoppe-Bauer J,
Burnham CA, Dunne WM Jr. (2011). "Impact of clinical symptoms on interpretation
of diagnostic assays for Clostridium difficile infections." J Clin Microbiol 49(8):
2887-2893.
Dubberke ER, Reske KA, Noble-Wang J, Thompson A, Killgore G, Mayfield J,
Camins B, Woeltje K, McDonald JR, McDonald LC, Fraser VJ. (2007). "Prevalence
of Clostridium difficile environmental contamination and strain variability in multiple
health care facilities." Am J Infect Control 35(5): 315-318.
Dumford DM 3rd, Nerandzic M, Chang S, Richmond MA, Donskey C. (2009). "What
is on that keyboard? Detecting hidden environmental reservoirs of Clostridium
difficile during an outbreak associated with North American pulsed-field gel
electrophoresis type 1 strains." Am J Infect Control 37(1): 15-19.
Dupuy B, Govind R, Antunes A, Matamouros S. (2008). "Clostridium difficile toxin
synthesis is negatively regulated by TcdC." J Med Microbiol 57(Pt 6): 685-689.
Eckstein BC, Adams DA, Eckstein EC, Rao A, Sethi AK, Yadavalli GK, Donskey CJ.
(2007). "Reduction of Clostridium Difficile and vancomycin-resistant Enterococcus
contamination of environmental surfaces after an intervention to improve cleaning
methods." BMC Infect Dis 7: 61.
Egerer M, Giesemann T, Herrmann C, Aktories K. (2009). "Autocatalytic processing
of Clostridium difficile toxin B. Binding of inositol hexakisphosphate." J Biol Chem
284(6): 3389-3395.
Exner M, Vacata V, Hornei B, Dietlein E, Gebel J. (2004). "Household cleaning and
surface disinfection: new insights and strategies." J Hosp Infect 56 Suppl 2: S70-75.
Faires MC, Pearl DL, Ciccotelli WA, Straus K, Zinken G, Berke O, Reid-Smith RJ,
Weese JS. (2012). "A prospective study to examine the epidemiology of methicillin-
resistant Staphylococcus aureus and Clostridium difficile contamination in the general
environment of three community hospitals in southern Ontario, Canada." BMC Infect
Dis 12: 290.
Falagas ME., Thomaidis PC, Kotsantis IK, Sgouros K, Samonis G, Karageorgopoulos
DE. (2011). "Airborne hydrogen peroxide for disinfection of the hospital environment
and infection control: a systematic review." J Hosp Infect 78(3): 171-177.
xiv
Faris B, Blackmore A, Haboubi N. (2010). "Review of medical and surgical
management of Clostridium difficile infection." Tech Coloproctol 14(2): 97-105.
Fawley, W. N. and M. H. Wilcox (2001). "Molecular epidemiology of endemic
Clostridium difficile infection." Epidemiol Infect 126(3): 343-350.
Fekety R, Kim KH, Brown D, Batts DH, Cudmore M, Silva J Jr. (1981).
"Epidemiology of antibiotic-associated colitis; isolation of Clostridium difficile from
the hospital environment." Am J Med 70(4): 906-908.
Gant VA, Wren MW, Rollins MS, Jeanes A, Hickok SS, Hall TJ (2007). "Three novel
highly charged copper-based biocides: safety and efficacy against healthcare-
associated organisms." J Antimicrob Chemother. 2007 Aug;60(2):294-9.
Garimella PS, Agarwal R, Katz A. (2012). "The utility of repeat enzyme
immunoassay testing for the diagnosis of Clostridium difficile infection: a systematic
review of the literature." J Postgrad Med 58(3): 194-198.
Gash K, Brown E, Pullyblank A. (2010). "Emergency subtotal colectomy for
fulminant Clostridium difficile colitis—is a surgical solution considered for all
patients?" Ann R Coll Surg Engl 92(1): 56-60.
Gellad ZF, Alexander BD, Liu JK, Griffith BC, Meyer AM, Johnson JL, Muir AJ.
(2007). "Severity of Clostridium difficile-associated diarrhea in solid organ transplant
patients." Transpl Infect Dis 9(4): 276-280.
Gerding DN, Muto CA, Owens RC Jr. (2008). "Measures to control and prevent
Clostridium difficile infection." Clin Infect Dis 46 Suppl 1: S43-49.
Geric B, Carman RJ, Rupnik M, Genheimer CW, Sambol SP, Lyerly DM, Gerding
DN, Johnson S.. (2006). "Binary toxin-producing, large clostridial toxin-negative
Clostridium difficile strains are enterotoxic but do not cause disease in hamsters." J
infect Dis 193(8): 1143-1150.
Ghose C, Kalsy A, Sheikh A, Rollenhagen J, John M, Young J, Rollins SM, Qadri F,
Calderwood SB, Kelly CP, Ryan ET. (2007). "Transcutaneous immunization with
Clostridium difficile toxoid A induces systemic and mucosal immune responses and
toxin A-neutralizing antibodies in mice." Infect Immun 75(6): 2826-2832.
Giel JL, Sorg JA, Sonenshein AL, Zhu J. (2010). "Metabolism of bile salts in mice
influences spore germination in Clostridium difficile." PLoS One 5(1): e8740.
Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW,
Bergwerff AA, Dekker FW, Kuijper EJ. (2008). "Emergence of Clostridium difficile
infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078."
Clin Infect Dis 47(9): 1162-1170.
Gough E, Shaikh H, Manges AR. (2011). "Systematic review of intestinal microbiota
transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection."
Clin Infect Dis 53(10): 994-1002.
xv
Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, Hutchinson J, Moore
D, Kelly S, Boyd D, Mulvey M; Canadian Nosocomial Infection Surveillance
Program 1. (2009). "Health care-associated Clostridium difficile infection in adults
admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection
Surveillance Program Study." Clin Infect Dis 48(5): 568-576.
Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. (2012).
"Acquisition of spores on gloved hands after contact with the skin of patients with
Clostridium difficile infection and with environmental surfaces in their rooms." Am J
Infect Control 40(6): 556-558.
Gurtler, V. (1993). "Typing of Clostridium difficile strains by PCR-amplification of
variable length 16S-23S rDNA spacer regions." J Gen Microbiol 139(12): 3089-3097.
Hacek DM, Ogle AM, Fisher A, Robicsek A, Peterson LR. (2010). "Significant
impact of terminal room cleaning with bleach on reducing nosocomial Clostridium
difficile." Am J Infect Control 38(5): 350-353.
Halim HA, Peterson GM, Friesen WT, Ott AK.. (1997). "Case-controlled review of
Clostridium difficile-associated diarrhoea in southern Tasmania." J Clin Pharm Ther
22(5-6): 391-397.
Hall, I. S. O. T., E. (1935). "Intestinal flora in new-born infants with a description of a
new pathogenic anaerobe Bacillus difficilis." Am J Dis Child 49: 390-402.
Hashimoto M, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, Makuuch M.
(2007). "Clostridium difficile-associated diarrhea after living donor liver
transplantation." World J Gastroenterol 13(14): 2072-2076.
Hayetian FD, Read TE, Brozovich M, Garvin RP, Caushaj PF. (2006). "Ileal
perforation secondary to Clostridium difficile enteritis: report of 2 cases." Arch Surg
141(1): 97-99.
Hennequin C, Janoir C, Bare MC, Collignon A, Karjalainen T. (2003). "Identification
and characterization of a fibronectin-binding protein from Clostridium difficile."
Microbiology 149(Pt 10): 2779-2787.
Hensgens MP, Keessen EC, Squire MM, Riley TV, Koene MG, de Boer E, Lipman
LJ, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases
Study Group for Clostridium difficile (ESGCD). (2012). "Clostridium difficile
infection in the community: a zoonotic disease?" Clin Microbiol Infect 18(7): 635-
645.
Hoist E, Helin I, Mardh PA. (1981). "Recovery of Clostridium difficile from
children." Scand J Infect Dis 13(1): 41-45.
Hopkins MJ, Sharp R, Macfarlane GT. (2002). "Variation in human intestinal
microbiota with age." Dig Liver Dis 34 Suppl 2: SI2-18.
xvi
Hossain M, Crook TJ, Keoghane SR. (2008). "Clostridium difficile in urology." Ann
R Coll Surg Engl 90(1): 36-39.
Howerton A, Ramirez N, Abel-Santos E. (2011). "Mapping interactions between
germinants and Clostridium difficile spores." J Bacteriol 193(1): 274-282.
Indra A, Huhulescu S, Schneeweis M, Elasenberger P, Kernbichler S, Fiedler A,
Wewalka G, Allerberger F, Kuijper EJ. (2008). "Characterization of Clostridium
difficile isolates using capillary gel electrophoresis-based PCR ribotyping." J Med
Microbiol 57(Pt 11): 1377-1382.
Jaber, M. R., Olafsson S, Fung WL, Reeves ME. (2008). "Clinical review of the
management of fiilminant Clostridium difficile infection." Am J Gastroenterol
103(12): 3195-3203.
Jangi, S. and J. T. Lamont (2010). "Asymptomatic colonization by Clostridium
difficile in infants: implications for disease in later life." J Pediatr Gastroenterol Nutr
51(1): 2-7.
Jawa, R. S. and D. W. Mercer (2012). "Clostridium difficile-associated infection: a
disease of varying severity." Am J Surg 204(6): 836-842.
Jhung MA, Thompson AD, Killgore GE, Zukowski WE, Songer G, Warny M,
Johnson S, Gerding DN, McDonald LC, Limbago BM. (2008). "Toxinotype V
Clostridium difficile in humans and food animals." Emerg Infect Dis 14(7): 1039-
1045.
Johal SS, Hammond J, Solomon K, James PD, Mahida YR. (2004). "Clostridium
difficile associated diarrhoea in hospitalised patients: onset in the community and
hospital and role of flexible sigmoidoscopy." Gut 53(5): 673-677.
Johal SS, Lambert CP, Hammond J, James PD, Borriello SP, Mahida YR. (2004).
"Colonic IgA producing cells and macrophages are reduced in recurrent and non¬
recurrent Clostridium difficile associated diarrhoea." J Clin Pathol 57(9): 973-979.
Johnson, S. and D. N. Gerding (1998). "Clostridium difficile—associated diarrhea."
Clin Infect Dis 26(5): 1027-1034; quiz 1035-1026.
Johnson, S. and D. N. Gerding (2013). "Fidaxomicin "Chaser" Regimen Following
Vancomycin for Patients With Multiple Clostridium difficile Recurrences." Clin
Infect Dis 56(2): 309-310.
Jones AM, Kuijper EJ, Wilcox MH. (2013). "Clostridium difficile: A European
perspective." J Infect 66(2): 115-128.
Jump RL, Pultz MJ, Donskey CJ. (2007). "Vegetative Clostridium difficile survives in
room air on moist surfaces and in gastric contents with reduced acidity: a potential
mechanism to explain the association between proton pump inhibitors and C. difficile-
associated diarrhea?" Antimicrob Agents Chemother 51(8): 2883-2887.
xvii
Karas JA, Enoch DA, Aliyu SH. (2010). "A review of mortality due to Clostridium
difficile infection." Journal of Infection 61(1): 1-8.
Karjalainen T, Waligora-Dupriet AJ, Cerquetti M, Spigaglia P, Maggioni A, Mauri P,
Mastrantonio P. (2001). "Molecular and genomic analysis of genes encoding surface-
anchored proteins from Clostridium difficile." Infect Immun 69(5): 3442-3446.
Kato H, Kita H, Karasawa T, Maegawa T, Koino Y, Takakuwa H, Saikai T,
Kobayashi K, Yamagishi T, Nakamura S. (2001). "Colonisation and transmission of
Clostridium difficile in healthy individuals examined by PCR ribotyping and pulsed-
field gel electrophoresis." J Med Microbiol 50(8): 720-727.
Kaur S, Vaishnavi C, Prasad KK, Ray P, Kochhar R. (2007). "Comparative role of
antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in
mice." Microbiol Immunol 51(12): 1209-1214.
Kelly, C. P. and L. Kyne (2011). "The host immune response to Clostridium
difficile." J Med Microbiol 60(Pt 8): 1070-1079.
Kelly, C. P. and J. T. LaMont (1998). "Clostridium difficile infection." Annu Rev
Med 49: 375-390.
Keshava A, Collie MH, Anderson DN. (2007). "Nosocomial Clostridium difficile
infection: possible cause of anastomotic leakage after anterior resection of the
rectum." J Gastroenterol Hepatol 22(5): 764.
Khanna, S. and D. S. Pardi (2010). "The growing incidence and severity of
Clostridium difficile infection in inpatient and outpatient settings." Expert Rev
Gastroenterol Hepatol 4(4): 409-416.
Kim J, Shaklee JF, Smathers S, Prasad P, Asti L, Zoltanski J, Dul M, Nerandzic M,
Coffin SE, Toltzis P, Zaoutis T. (2012). "Risk factors and outcomes associated with
severe Clostridium difficile infection in children." Pediatric Infectious Disease
Journal 31(2): 134-138.
Kim, J. H. and R. R. Muder (2011). "Clostridium difficile enteritis: A review and
pooled analysis of the cases." Anaerobe 17(2): 52-55.
Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, Silva J Jr, Waters D. (1981).
"Isolation of Clostridium difficile from the environment and contacts of patients with
antibiotic-associated colitis." J infect Dis 143(1): 42-50.
Kim MJ, Kim BS, Kwon JW, Ahn SE, Lee SS, Park HC, Lee BH.. (2012). "Risk
factors for the development of Clostridium difficile colitis in a surgical ward." J
Korean Surg Soc 83(1): 14-20.
Kirkpatrick, I. D. and H. M. Greenberg (2001). "Evaluating the CT diagnosis of
Clostridium difficile colitis: should CT guide therapy?" AJR Am J Roentgenol
176(3): 635-639.
xviii
Koss K, Clark MA, Sanders DS, Morton D, Keighley MR, Goh J. (2006). "The
outcome of surgery in fulminant Clostridium difficile colitis." Colorectal Dis 8(2):
149-154.
Kuijper EJ, Coignard B, Brazier JS, Suetens C, Drudy D, Wiuff C, Pituch H, Reichert
P, Schneider F, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Barbut F,
Delmee M, Wilcox M, Pearson A, Patel BC, Brown DJ, Frei R, Akerlund T, Poxton
IR, Tiill P.. (2007). "Update of Clostridium difficile-associated disease due to PCR
ribotype 027 in Europe." Euro Surveill 12(6): El-2.
Kuijper EJ, de Weerdt J, Kato H, Kato N, van Dam AP, van der Vorm ER, Weel J,
van Rheenen C, Dankert J.. (2001). "Nosocomial outbreak of Clostridium difficile-
associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain."
Eur J Clin Microbiol Infect Dis 20(8): 528-534.
Kuijper EJ, Oudbier JH, Stuifbergen WN, Jansz A, Zanen HC. (1987). "Application
of whole-cell DNA restriction endonuclease profiles to the epidemiology of
Clostridium difficile-induced diarrhea." J Clin Microbiol 25(4): 751-753.
Kuijper, E. J. and J. T. van Dissel (2008). "Spectrum of Clostridium difficile
infections outside health care facilities." CMAJ 179(8): 747-748.
Kurd MF, Pulido L, Joshi A, Purtill JJ, Parvizi J. (2008). "Clostridium difficile
infection after total joint arthroplasty: who is at risk?" J Arthroplasty 23(6): 839-842.
Kutty PK, Woods CW, Sena AC, Benoit SR, Naggie S, Frederick J, Evans S, Engel J,
McDonald LC. (2010). "Risk factors for and estimated incidence of community-
associated Clostridium difficile infection, North Carolina, USA." Emerg Infect Dis
16(2): 197-204.
Kyne L, Sougioultzis S, McFarland LV, Kelly CP. (2002). "Underlying disease
severity as a major risk factor for nosocomial Clostridium difficile diarrhea." Infect
Control Hosp Epidemiol 23(11): 653-659.
Kyne L, Warny M, Qamar A, Kelly CP. (2000). "Asymptomatic carriage of
Clostridium difficile and seaim levels of IgG antibody against toxin A." N Engl J
Med 342(6): 390-397.
Lacey Benson BA, Song X, Campos J, Singh N. (2007). "Changing Epidemiology of
Clostridium difficile-Associated Disease in Children • " Infection Control and
Hospital Epidemiology 28(11): 1233-1235.
Lamontagne F, Labbe AC, Haeck O, Lesur O, Lalancette M, Patino C, Leblanc M,
Laverdiere M, Pepin J. (2007). "Impact of emergency colectomy on survival of
patients with fulminant Clostridium difficile colitis during an epidemic caused by a
hypervirulent strain." Ann Surg 245(2): 267-272.
Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT. (2011). "Epidemiological
model for Clostridium difficile transmission in healthcare settings." Infect Control
Hosp Epidemiol 32(6): 553-561.
xix
Larson, H. E. P., A.B. (1977). "Pseudomembranous colitis: presence of clostridial
toxin." Lancet 2: 1312-1314.
Larson, H. E. P., A.B., Honour, P & Borriello, S.P. (1978). "Clostridium difficile and
the aetiology of pseudomembranous colitis." Lancet( 1063-1066).
Lawrence SJ, Puzniak LA, Shadel BN, Gillespie KN, KollefMH, Mundy LM. (2007).
"Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization
pressure." Infect Control Hosp Epidemiol 28(2): 123-130.
Lemee L, Bourgeois I, Ruffin E, Collignon A, Lemeland JF, Pons JL. (2005).
"Multilocus sequence analysis and comparative evolution of virulence-associated
genes and housekeeping genes of Clostridium difficile." Microbiology 151 (Pt 10):
3171-3180.
Lesperance K, Causey MW, Spencer M, Steele SR. (2011). "The morbidity of
Clostridium difficile infection after elective colonic resection-results from a national
population database." Am J Surg 201(2): 141-148.
Liao CH, Ko WC, Lu JJ, Hsueh PR. (2012). "Characterizations of clinical isolates of
Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial
agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in
Taiwan." Antimicrob Agents Chemother 56(7): 3943-3949.
Linevsky JK, Pothoulakis C, Keates S, Wamy M, Keates AC, Lamont JT, Kelly CP.
(1997). "IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed
human monocytes." Am J Physiol 273(6 Pt 1): G1333-1340.
Longo WE, Mazuski JE, Virgo KS, Lee P, Bahadursingh AN, Johnson FE. (2004).
"Outcome after colectomy for Clostridium difficile colitis." Dis Colon Rectum
47(10): 1620-1626.
Loo VG, Bourgault AM, Poirier L, Lamothe F, Michaud S, Turgeon N, Toye B,
Beaudoin A, Frost EH, Gilca R, Brassard P, Dendukuri N, Beliveau C, Oughton M,
Brukner I, Dascal A. (2011). "Host and pathogen factors for Clostridium difficile
infection and colonization." N Engl J Med 365(18): 1693-1703.
Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears
P, Shue YK; OPT-80-003 Clinical Study Group. (2011). "Fidaxomicin versus
vancomycin for Clostridium difficile infection." N Engl J Med 364(5): 422-431.
Lumpkins K, Bochicchio GV, Joshi M, Gens R, Bochicchio K, Conway A, Schaub S,
Scalea T. (2008). "Clostridium difficile infection in critically injured trauma patients."
Surg Infect (Larchmt) 9(5): 497-501.
Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R,
Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI. (2009). "Toxin B is
essential for virulence ofClostridium difficile." Nature 458(7242): 1176-1179.
xx
McCoubrey, J. and I. R. Poxton (2001). "Variation in the surface layer proteins of
Clostridium difficile." FEMS Immunol Med Microbiol 31(2): 131-135.
McCoubrey, J., et al. (2003). "Clostridium difficile in a geriatric unit: a prospective
epidemiological study employing a novel S-layer typing method." J Med Microbiol
52(Pt 7): 573-578.
McDonald, L. C. (2005). "Clostridium difficile: responding to a new threat from an
old enemy." Infect Control Hosp Epidemiol 26(8): 672-675.
McFarland, L. V. (1995). "Epidemiology of infectious and iatrogenic nosocomial
diarrhea in a cohort of general medicine patients." Am J Infect Control 23(5): 295-
305.
McFarland LV, Beneda HW, Clarridge JE, Raugi GJ. (2007). "Implications of the
changing face of Clostridium difficile disease for health care practitioners." Am J
Infect Control 35(4): 237-253.
McFarland LV, Surawicz CM, Stamm WE. (1990). "Risk factors for Clostridium
difficile carriage and C. difficile-associated diarrhea in a cohort of hospitalized
patients." J infect Dis 162(3): 678-684.
Mahida YR, Makh S, Hyde S, Gray T, Borriello SP. (1996). "Effect of Clostridium
difficile toxin A on human intestinal epithelial cells: induction of interleukin 8
production and apoptosis after cell detachment." Gut 38(3): 337-347.
Mani, N. and B. Dupuy (2001). "Regulation of toxin synthesis in Clostridium difficile
by an alternative RNA polymerase sigma factor." Proc Natl Acad Sci U S A 98(10):
5844-5849.
Manian FA, Meyer L, Jenne J. (1996). "Clostridium difficile contamination of blood
pressure cuffs: a call for a closer look at gloving practices in the era of universal
precautions." Infect Control Hosp Epidemiol 17(3): 180-182.
Mann SD, Pitt J, Springall RG, Thillainayagam AV (2003). "Clostridium
difficile infection—an unusual cause of refractory pouchitis: report of a case". Dis
Colon Rectum. Feb;46(2):267-70.
Matsuki S, Ozaki E, Shozu M, Inoue M, Shimizu S, Yamaguchi N, Karasawa T,
Yamagishi T, Nakamura S. (2005). "Colonization by Clostridium difficile of neonates
in a hospital, and infants and children in three day-care facilities of Kanazawa,
Japan." Int Microbiol 8(1): 43-48.
Morrison RH, Hall NS, Said M, Rice T, Groff H, Brodine SK, Slymen D, Lederman
ER. (2011). "Risk factors associated with complications and mortality in patients with
Clostridium difficile infection." Clin Infect Dis 53(12): 1173-1178.
Mulligan ME, George WL, Rolfe RD, Finegold SM. (1980). "Epidemiological aspects
of Clostridium difficile-induced diarrhea and colitis." Am J Clin Nutr 33(11 Suppl):
2533-2538.
xxi
Musa SA, Moran C, Thomson SJ, Cowan ML, McAnulty G, Grounds M, Rahman
TM. (2011). "Clostridium difficile-associated disease acquired in the cardiothoracic
intensive care unit." J Cardiothorac Vase Anesth 25(2): 263-267.
Mutlu E, Wroe AJ, Sanchez-Hurtado K, Brazier JS, Poxton IR. (2007). "Molecular
characterization and antimicrobial susceptibility patterns of Clostridium difficile
strains isolated from hospitals in south-east Scotland." J Med Microbiol 56(Pt 7): 921 -
929.
Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, Farr BM;
SHEA. (2003). "SHEA guideline for preventing nosocomial transmission of
multidrug-resistant strains of Staphylococcus aureus and enterococcus." Infect
Control Hosp Epidemiol 24(5): 362-386.
Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, Roberts T,
Croyle K, Krystofiak S, Patel-Brown S, Pasculle AW, Paterson DL, Saul M, Harrison
LH. (2005). "A large outbreak of Clostridium difficile-associated disease with an
unexpected proportion of deaths and colectomies at a teaching hospital following
increased fluoroquinolone use." Infect Control Hosp Epidemiol 26(3): 273-280.
Naggie S, Frederick J, Pien BC, Miller BA, Provenzale DT, Goldberg KC, Woods
CW. (2010). "Community-associated Clostridium difficile infection: experience of a
veteran affairs medical center in southeastern USA." Infection 38(4): 297-300.
Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. (2011). "Diverting
loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the
treatment of severe, complicated Clostridium difficile associated disease." Ann Surg
254(3): 423-427; discussion 427-429.
Nelson, R. (2007). "Antibiotic treatment for Clostridium difficile-associated diarrhea
in adults." Cochrane Database Syst Rev(3): CD004610.
Nelson RL, Glenny AM, Song F. (2009). "Antimicrobial prophylaxis for colorectal
surgery." Cochrane Database Syst Rev(l): CD001181.
Nerandzic, M. M., et al. (2012). "Evaluation of a hand-held far-ultraviolet radiation
device for decontamination of Clostridium difficile and other healthcare-associated
pathogens." BMC Infect Dis 12: 120.
Nguyen GC, K. G., Harris ML, Brant SR. (2008). "A national survey of the
prevalence and impact of Clostridium difficile infection among hospitalized
inflammatory bowel disease patients. ." Am J Gastroenterol 103: 1443-1450.
O'Gorman, J. and H. Humphreys (2012). "Application of copper to prevent and
control infection. Where are we now?" J Hosp Infect 81(4): 217-223.
Olivas AD, Umanskiy K, Zuckerbraun B, Alverdy JC. (2010). "Avoiding colectomy
during surgical management of fulminant Clostridium difficile colitis." Surg Infect
(Larchmt) 11(3): 299-305.
xxii
Omidbakhsh, N. (2010). "Evaluation of sporicidal activities of selected environmental
surface disinfectants: carrier tests with the spores of Clostridium difficile and its
surrogates." Am J Infect Control 38(9): 718-722.
O'Neill, G. L., Ogunsola, F.T., Brazier, J.S. & Duerdan, B.I. (1996). "Modification of
a PCR ribotyping method for application as a routine typing scheme for Clostridium
difficile." Anaerobe 2: 205-209.
O'Neill GL, Beaman MH, Riley TV. (1991). "Relapse versus reinfection with
Clostridium difficile." Epidemiol Infect 107(3): 627-635.
Paltansing S, van den Berg RJ, Guseinova RA, Visser CE, van der Vorm ER, Kuijper
EJ. (2007). "Characteristics and incidence of Clostridium difficile-associated disease
in The Netherlands, 2005." Clinical Microbiology and Infection 13(11): 1058-1064.
Panessa-Warren BJ, Tortora GT, Warren JB. (1997). "Exosporial membrane plasticity
of Clostridium sporogenes and Clostridium difficile." Tissue Cell 29(4): 449-461.
Passaretti CL, Otter JA, Reich NG, Myers J, Shepard J, Ross T, Carroll KC, Lipsett P,
Perl TM. (2013). "An evaluation of environmental decontamination with hydrogen
peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant
organisms." Clin Infect Dis 56(1): 27-35.
Patel, N. S. (2007). "Fluoroquinolone use is the predominant risk factor for the
development of a new strain of Clostridium difficile-associated disease." BJU Int
99(6): 1333-1334.
Pearce, C. D., P. (1960). "A study of pseudomembranous enterocolitis. ." Am J Surg
99: 292-300.
Pechine S, Janoir C, Collignon A. (2005). "Variability of Clostridium difficile surface
proteins and specific serum antibody response in patients with Clostridium difficile-
associated disease." J Clin Microbiol 43(10): 5018-5025.
Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E.
(2002). "Reassessment of Clostridium difficile susceptibility to metronidazole and
vancomycin." Antimicrob Agents Chemother 46(6): 1647-1650.
Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, Godin D, Bourassa C.
(2005). "Increasing risk of relapse after treatment of Clostridium difficile colitis in
Quebec, Canada." Clin Infect Dis 40(11): 1591-1597.
Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M,
Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. (2005)
"Emergence of fluoroquinolones as the predominant risk factor for Clostridium
difficile-associated diarrhea: a cohort study during an epidemic in Quebec." Clin
Infect Dis 41(9): 1254-1260.
xxiii
Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, Pepin K,
Chouinard D. (2004). "Clostridium difficile-associated diarrhea in a region of Quebec
from 1991 to 2003: a changing pattern of disease severity." CMAJ 171(5): 466-472.
Pepin J, Vo TT, Boutros M, Marcotte E, Dial S, Dube S, Vasilevsky CA, McFadden
N, Patino C, Labbe AC. (2009). "Risk factors for mortality following emergency
colectomy for fulminant Clostridium difficile infection." Dis Colon Rectum 52(3):
400-405.
Perera AD, Akbari RP, Cowher MS, Read TE, McCormick JT, Medich DS,
Celebrezze JP Jr, Beck SJ, Fischer PE, Caushaj PF. (2010). "Colectomy for fulminant
Clostridium difficile colitis: predictors ofmortality." Am Surg 76(4): 418-421.
Perez J, Springthorpe VS, Sattar SA. (2005). "Activity of selected oxidizing
microbicides against the spores of Clostridium difficile: relevance to environmental
control." Am J Infect Control 33(6): 320-325.
Perry C, Marshall R, Jones E. (2001). "Bacterial contamination of uniforms." J Hosp
Infect 48(3): 238-241.
Pfeifer G, Schirmer J, Leemhuis J, Busch C, Meyer DK, Aktories K, Barth H. (2003).
"Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal
catalytic domain into the cytosol of eukaryotic cells." J Biol Chem 278(45): 44535-
44541.
Pillai, A. and R. Nelson (2008). "Probiotics for treatment of Clostridium difficile-
associated colitis in adults." Cochrane Database Syst Rev(l): CD004611.
Pituch, H. (2009). "Clostridium difficile is no longer just a nosocomial infection or an
infection of adults." Int J Antimicrob Agents 33 Suppl 1: S42-45.
Pizarro-Cerda, J. and P. Cossart (2006). "Bacterial adhesion and entry into host cells."
Cell 124(4): 715-727.
Polgreen PM, Yang M, Bohnett LC, Cavanaugh JE. (2010). "A time-series analysis of
Clostridium difficile and its seasonal association with influenza." Infect Control Hosp
Epidemiol 31(4): 382-387.
Poxton, I. R. (2010). "Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting
antibiotic for the treatment of Clostridium difficile infections." Future Microbiol 5(4):
539-548.
Poxton, I. R. (2013). "The changing faces of Clostridium difficile: A personal
reflection of the past 34 years." Anaerobe.
Poxton IR, Aronsson B, Mollby R, Nord CE, Collee JG. (1984). "Immunochemical
fingerprinting of Clostridium difficile strains isolated from an outbreak of antibiotic-
associated colitis and diarrhoea." J Med Microbiol 17(3): 317-324.
xxiv
Poxton IR, McCoubrey J, Blair G. (2001). "The pathogenicity of Clostridium
difficile." Clinical Microbiology and Infection 7(8): 421-427.
C. f. d. c. a. (2005). "Severe Clostridium difficile-associated disease in populations
previously at low risk - four States, 2005." MMWR Wkly(54): 1201-1205.
Qa'Dan M, Spyres LM, Ballard JD. (2000). "pH-induced conformational changes in
Clostridium difficile toxin B." Infect Immun 68(5): 2470-2474.
Ratnayake L, McEwen J, Henderson N, Nathwani D, Phillips G, Brown D, C. (2011).
"Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level
clindamycin-resistant Clostridium difficile PCR ribotype 106." J Hosp Infect 79(3):
242-247.
Raveh D, Rabinowitz B, Breuer GS, Rudensky B, Yinnon AM. (2006). "Risk factors
for Clostridium difficile toxin-positive nosocomial diarrhoea." Int J Antimicrob
Agents 28(3): 231-237.
Rea MC, O'Sullivan O, Shanahan F, O'Toole PW, Stanton C, Ross RP, Hill C. (2012).
"Clostridium difficile carriage in elderly subjects and associated changes in the
intestinal microbiota." J Clin Microbiol 50(3): 867-875.
Reddy S, Taori S, Poxton IR. (2010). "Changes in laboratory and clinical workload
for Clostridium difficile infection from 2003 to 2007 in hospitals in Edinburgh." Clin
Microbiol Infect 16(4): 340-346.
Reilly J, Cairns S, Fleming S, Hewitt D, Lawder R, Robertson C, Malcolm W,
Nathwani D, Williams C. (2012). "Results from the second Scottish national
prevalence survey: the changing epidemiology of healthcare-associated infection in
Scotland." J Hosp Infect 82(3): 170-174.
Ricciardi R, Ogilvie JW Jr, Roberts PL, Marcello PW, Concannon TW, Baxter NN.
(2009). "Epidemiology of Clostridium difficile colitis in hospitalized patients with
inflammatory bowel diseases." Dis Colon Rectum 52(1): 40-45.
Rifkin, G. D. F., F.R. & Silva J. (1977). "Antibiotic induced colitis implication of a
toxin neutralised by Clostridium Sordellii antitoxin." Lancet 2(1103-1106).
Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RL, Donskey CJ. (2007).
"Asymptomatic carriers are a potential source for transmission of epidemic and
nonepidemic Clostridium difficile strains among long-term care facility residents."
Clin Infect Dis 45(8): 992-998.
Roberts K, Smith CF, Snelling AM, Kerr KG, Banfield KR, Sleigh PA, Beggs CB.
(2008). "Aerial dissemination of Clostridium difficile spores." BMC Infect Dis 8: 7.
Rodriguez-Palacios A, Stampfli HR, Duffield T, Peregrine AS, Trotz-Williams LA,
Arroyo LG, Brazier JS, Weese JS.. (2006). "Clostridium difficile PCR ribotypes in
calves, Canada." Emerg Infect Dis 12(11): 1730-1736.
xxv
Rotimi VO, Mokaddas EM, Jamal WY, Verghese TL, el-Din K, Junaid TA. (2002).
"Hospital-acquired Clostridium difficile infection amongst ICU and burn patients in
Kuwait." Med Princ Pract 11(1): 23-28.
Rouphael NG, O'Donnell JA, Bhatnagar J, Lewis F, Polgreen PM, Beekmann S,
Guarner J, Killgore GE, Coffman B, Campbell J, Zaki SR, McDonald LC. (2008).
"Clostridium difficile-associated diarrhea: an emerging threat to pregnant women."
Am J Obstet Gynecol 198(6): 635 e631-636.
Rousseau C, Poilane I, De Pontual L, Maherault AC, Le Monnier A, Collignon A.
(2012). "Clostridium difficile carriage in healthy infants in the community: a potential
reservoir for pathogenic strains." Clin Infect Dis 55(9): 1209-1215.
Rudensky B, Rosner S, Sonnenblick M, van Dijk Y, Shapira E, Isaacsohn M. (1993).
"The prevalence and nosocomial acquisition of Clostridium difficile in elderly
hospitalized patients." Postgrad Med J 69(807): 45-47.
Rupnik M, Avesani V, Jane M, von Eichel-Streiber C, Delmee M. (1998). "A novel
toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium
difficile isolates." J Clin Microbiol 36(8): 2240-2247.
Rupnik M, Braun V, Soehn F, Jane M, Hofstetter M, Laufenberg-Feldmann R, von
Eichel-Streiber C. (1997). "Characterization of polymorphisms in the toxin A and B
genes ofClostridium difficile." FEMS Microbiol Lett 148(2): 197-202.
Rutala, W. A. and D. J. Weber (2001). "Surface disinfection: should we do it?" J
Hosp Infect 48 Suppl A: S64-68.
Ryan J, Murphy C, Twomey C, Paul Ross R, Rea MC, MacSharry J, Sheil B,
Shanahan F. (2010). "Asymptomatic carriage of Clostridium difficile in an Irish
continuing care institution for the elderly: prevalence and characteristics." Ir J Med
Sci 179(2): 245-250.
Sailhamer EA, Carson K, Chang Y, Zacharias N, Spaniolas K, Tabbara M, Alam HB,
DeMoya MA, Velmahos GC. (2009). "Fulminant Clostridium difficile colitis: patterns
of care and predictors ofmortality." Arch Surg 144(5): 433-439; discussion 439-440.
Samore, M. H. (1999). "Epidemiology of nosocomial Clostridium difficile diarrhoea."
J Hosp Infect 43 Suppl: SI83-190.
Sauerborn M, Leukel P, von Eichel-Streiber C. (1997). "The C-terminal ligand-
binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific
binding to cells and prevents mouse lethality." FEMS Microbiol Lett 155(1): 45-54.
Savidge TC, Pan WH, Newman P, O'brien M, Anton PM, Pothoulakis C. (2003).
"Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine."
Gastroenterology 125(2): 413-420.
Schirmer, J. and K. Aktories (2004). "Large clostridial cytotoxins: cellular biology of
Rho/Ras-glucosylating toxins." Biochim Biophys Acta 1673(1-2): 66-74.
xxvi
Seder CW, Villalba MR Jr, Robbins J, Ivascu FA, Carpenter CF, Dietrich M, Villalba
MR Sr. (2009). "Early colectomy may be associated with improved survival in
fulminant Clostridium difficile colitis: an 8-year experience." Am J Surg 197(3): 302-
307.
Sethi AK, Al-Nassir WN, Nerandzic MM, Bobulsky GS, Donskey CJ. (2010).
"Persistence of skin contamination and environmental shedding of Clostridium
difficile during and after treatment of C. difficile infection." Infect Control Hosp
Epidemiol 31(1): 21-27.
Sexton JD, Tanner BD, Maxwell SL, Gerba CP. (2011). "Reduction in the microbial
load on high-touch surfaces in hospital rooms by treatment with a portable saturated
steam vapor disinfection system." Am J Infect Control 39(8): 655-662.
Shapey S, Machin K, Levi K, Boswell TC. (2008). "Activity of a dry mist hydrogen
peroxide system against environmental Clostridium difficile contamination in elderly
care wards." J Hosp Infect 70(2): 136-141.
Skoutelis AT, Westenfelder GO, Beckerdite M, Phair JP. (1994). "Hospital carpeting
and epidemiology of Clostridium difficile." Am J Infect Control 22(4): 212-217.
Smith DL, Gillanders S, Holah JT, Gush C. (2011). "Assessing the efficacy of
different microfibre cloths at removing surface micro-organisms associated with
healthcare-associated infections." J Hosp Infect 78(3): 182-186.
Smith, L. D. K. (1962). "Occurence of Clostridium difficile in infections of man." J
Bacteriolo 84: 65-67.
Songer, J. G. (2004). "The emergence of Clostridium difficile as a pathogen of food
animals." Anim Health Res Rev 5(2): 321-326.
Songer, J. G. (2010). "Clostridia as agents of zoonotic disease." Vet Microbiol 140(3-
4): 399-404.
Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM.
(2009). "Clostridium difficile in retail meat products, USA, 2007." Emerg Infect Dis
15(5): 819-821.
Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ,
Lee CK, Wamy M, Monath TP, Kelly CP. (2005). "Clostridium difficile toxoid
vaccine in recurrent C. difficile-associated diarrhea." Gastroenterology 128(3): 764-
770.
Spigaglia P, Barbanti F, Mastrantonio P; European Study Group on Clostridium
difficile (ESGCD). (2011). "Multidrug resistance in European Clostridium difficile
clinical isolates." J Antimicrob Chemother 66(10): 2227-2234.
xxv ii
Spigaglia P, Barbanti F, Mastrantonio P, Brazier JS, Barbut F, Delmee M, Kuijper E,
Poxton IR; European Study Group on Clostridium difficile (ESGCD). (2008).
"Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study
of C. difficile infections in Europe." J Med Microbiol 57(Pt 6): 784-789.
Starr JM, Martin H, McCoubrey J, Gibson G, Poxton IR. (2003). "Risk factors for
Clostridium difficile colonisation and toxin production." Age Ageing 32(6): 657-660.
Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. (1999). "PCR targeted to the 16S-23S
rRNA gene intergenic spacer region of Clostridium difficile and construction of a
library consisting of 116 different PCR ribotypes." J Clin Microbiol 37(2): 461-463.
Sullivan NM, Pellett S, Wilkins TD. (1982). "Purification and characterization of
toxins A and B ofClostridium difficile." Infect Immun 35(3): 1032-1040.
Sundram F, Guyot A, Carboo I, Green S, Lilaonitkul M, Scourfield A. (2009).
"Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors." J
Hosp Infect 72(2): 111-118.
Sunenshine, R. H. and L. C. McDonald (2006). "Clostridium difficile-associated
disease: new challenges from an established pathogen." Cleve Clin J Med 73(2): 187-
197.
Surawicz, C. M. (2007). "Emergency Colectomy in Severe Clostridium Difficile-
Associated Disease: The Sooner the Better for Some." Gastroenterology 133(2): 718-
720.
Sutphen JL, Grand RJ, Flores A, Chang TW, Bartlett JG. (1983). "Chronic diarrhea
associated with Clostridium difficile in children." Am J Dis Child 137(3): 275-278.
Suzuki H, Ogawa H, Shibata C, Haneda S, Watanabe K, Takahashi K, Funayama Y,
Sasaki I. (2012). "The long-term clinical course of pouchitis after total
proctocolectomy and IPAA for ulcerative colitis." Dis Colon Rectum 55(3): 330-336.
Taffinder AJ, B. T., Shepherd JL, Laurenson IF, Brown R, Poxton IR (1997).
"Clostridium difficile in a neonatal intensive care unit." Rev Med Microbiol 8.
Taori SK, Hall V, Poxton IR. (2010). "Changes in antibiotic susceptibility and
ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004." J Med
Microbiol 59(Pt 3): 338-344.
Tasteyre A, Bare MC, Collignon A, Boureau H, Karjalainen T. (2001). "Role of FliC
and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization."
Infect Immun 69(12): 7937-7940.
Tedesco, F. J., Barton, R.W. & Alpers, D.H. (1974). "Clindamycin-associated colitis.
A prospective study." Ann Intern Med 81: 429-433.
xxviii
Trudel JL, Deschenes M, Mayrand S, Barkun AN. (1995). "Toxic megacolon
complicating pseudomembranous enterocolitis." Dis Colon Rectum 38(10): 1033-
1038.
Tsiouris A, Neale JA, Reickert CA, Times M. (2012). "Clostridium difficile of the
ileum following total abdominal colectomy, with or without proctectomy: who is at
risk?" Dis Colon Rectum 55(4): 424-428.
Tucker, K. D. and T. D. Wilkins (1991). "Toxin A of Clostridium difficile binds to the
human carbohydrate antigens I, X, and Y." Infect Immun 59(1): 73-78.
Tullus K, Aronsson B, Marcus S, Mollby R. (1989). "Intestinal colonization with
Clostridium difficile in infants up to 18 months of age." Eur J Clin Microbiol Infect
Dis 8(5): 390-393.
Tung JM, Dolovich LR, Lee CH. (2009). "Prevention of Clostridium difficile
infection with Saccharomyces boulardii: a systematic review." Can J Gastroenterol
23(12): 817-821.
Unger JA, Whimbey E, Gravett MG, Eschenbach DA. (2011). "The emergence of
Clostridium difficile infection among peripartum women: a case-control study of a C.
difficile outbreak on an obstetrical service." Infect Dis Obstet Gynecol 2011: 267249.
Valiquette L, Pepin J, Do XV, Nault V, Beaulieu AA, Bedard J, Schmutz G. (2009).
"Prediction of complicated Clostridium difficile infection by pleural effusion and
increased wall thickness on computed tomography." Clin Infect Dis 49(4): 554-560.
van den Berg RJ, Ameen HA, Furusawa T, Claas EC, van der Vorm ER, Kuijper EJ.
(2005). "Coexistence of multiple PCR-ribotype strains of Clostridium difficile in
faecal samples limits epidemiological studies." J Med Microbiol 54(Pt 2): 173-179.
van den Berg RJ, Schaap I, Templeton KE, Klaassen CH, Kuijper EJ. (2007). "Typing
and subtyping of Clostridium difficile isolates by using multiple-locus variable-
number tandem-repeat analysis." J Clin Microbiol 45(3): 1024-1028.
van Nood E, Speelman P, Kuijper EJ, Keller JJ. (2009). "Struggling with recurrent
Clostridium difficile infections: is donor faeces the solution?" Euro Surveill 14(34).
van Nood E, van Dijk K, Hegeman Z, Speelman P, Visser CE. (2009).
"Asymptomatic carriage of Clostridium difficile among HCWs: Do we disregard the
doctor?" Infect Control Hosp Epidemiol 30(9): 924-925.
Varki, N. M. and T. I. Aquino (1982). "Isolation of Clostridium difficile from
hospitalized patients without antibiotic-associated diarrhea or colitis." J Clin
Microbiol 16(4): 659-662.
Venugopal AA, Gerding DN, Johnson S. (2011). "Clostridium difficile infection rates
and spectrum of disease among peripartum women at one hospital from 2003 to 2007
with molecular typing analysis of recovered Clostridium difficile isolates." Am J
Infect Control 39(3): 206-211.
xxix
Verity P, Wilcox MH, Fawley W, Parnell P. (2001). "Prospective evaluation of
environmental contamination by Clostridium difficile in isolation side rooms." J Hosp
Infect 49(3): 204-209.
Vohra, P. and I. R. Poxton (2011). "Comparison of toxin and spore production in
clinically relevant strains of Clostridium difficile." Microbiology 157(Pt 5): 1343-
1353.
Vohra, P. and I. R. Poxton (2011). "Efficacy of decontaminants and disinfectants
against Clostridium difficile." J Med Microbiol 60(Pt 8): 1218-1224.
von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M.
(1992). "Comparative sequence analysis of the Clostridium difficile toxins A and B."
Mol Gen Genet 233(1-2): 260-268.
von Eichel-Streiber, C. and M. Sauerbom (1990). "Clostridium difficile toxin A
carries a C-terminal repetitive structure homologous to the carbohydrate binding
region of streptococcal glycosyltransferases." Gene 96(1): 107-113.
Vonberg RP, Reichardt C, Behnke M, Schwab F, Zindler S, Gastmeier P. (2008).
"Costs of nosocomial Clostridium difficile-associated diarrhoea." J Hosp Infect 70(1):
15-20.
Voss A, Verweij PE, Kluytmans J. (2003). "Should we routinely disinfect floors?" J
Hosp Infect 53(2): 150.
Voth, D. E. and J. D. Ballard (2005). "Clostridium difficile toxins: mechanism of
action and role in disease." Clin Microbiol Rev 18(2): 247-263.
Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O'Connor L, Griffiths D,
Vaughan A, Finney J, Wilcox MH, Crook DW, Peto TE. (2012). "Characterisation of
Clostridium difficile hospital ward-based transmission using extensive
epidemiological data and molecular typing." PLoS Med 9(2): el001172.
Watt, B. (1973). "The influence of carbon dioxide on the growth of obligate and
facultative anaerobes on solid media." J Med Microbiol 6: 307-314.
Weber DJ, Rutala WA, Miller MB, Huslage K, Sickbert-Bennett E. (2010). "Role of
hospital surfaces in the transmission of emerging health care-associated pathogens:
norovirus, Clostridium difficile, and Acinetobacter species." Am J Infect Control 38(5
Suppl 1): S25-33.
Weese JS, Avery BP, Rousseau J, Reid-Smith RJ. (2009). "Detection and
enumeration of Clostridium difficile spores in retail beef and pork." Appl Environ
Microbiol 75(15): 5009-5011.
Werner NL, Hecker MT, Sethi AK, Donskey CJ. (2011). "Unnecessary use of
fluoroquinolone antibiotics in hospitalized patients." BMC Infect Dis 11: 187.
xxx
Wheeldon LJ, Worthington T, Hilton AC, Elliott TS, Lambert PA. (2008). "Physical
and chemical factors influencing the germination of Clostridium difficile spores." J
Appl Microbiol 105(6): 2223-2230.
Wheeldon LJ, Worthington T, Hilton AC, Lambert PA, Elliott TS. (2008). "Sporicidal
activity of two disinfectants against Clostridium difficile spores." Br J Nurs 17(5):
316-320.
Wheeldon LJ, Worthington T, Lambert PA, Hilton AC, Lowden CJ, Elliott TS.
(2008). "Antimicrobial efficacy of copper surfaces against spores and vegetative cells
ofClostridium difficile: the germination theory." J Antimicrob Chemother 62(3): 522-
525.
Whittier S, Shapiro DS, Kelly WF, Walden TP, Wait KJ, McMillon LT, Gilligan PH.
(1993). "Evaluation of four commercially available enzyme immunoassays for
laboratory diagnosis of Clostridium difficile-associated diseases." J Clin Microbiol
31(11): 2861-2865.
Wilcox CM, Martin T, Phadnis M, Mohnen J, Worthington J, Hirschowitz BI. (2008).
"Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison
syndrome and other acid hypersecretors receiving long-term acid suppression with
lansoprazole." BMC Gastroenterol 8: 18.
Wilcox, M. H. (2012). "Overcoming barriers to effective recognition and diagnosis of
Clostridium difficile infection." Clin Microbiol Infect 18 Suppl 6: 13-20.
Wilcox, M. H. (2012). "Policy development for Clostridium difficile." J Antimicrob
Chemother 67 Suppl 1: i 19-22.
Wilcox MH, Cunniffe JG, Trundle C, Redpath C. (1996). "Financial burden of
hospital-acquired Clostridium difficile infection." J Hosp Infect 34(1): 23-30.
Wilcox MH, Fawley WN, Wigglesworth N, Parnell P, Verity P, Freeman J. (2003).
"Comparison of the effect of detergent versus hypochlorite cleaning on environmental
contamination and incidence of Clostridium difficile infection." J Hosp Infect 54(2):
109-114.
Wilcox, M. H. and T. Planche (2009). "Clostridium difficile infection." BMJ 338:
b2528.
Wiist J, Sullivan NM, Hardegger U, Wilkins TD. (1982). "Investigation of an
outbreak of antibiotic-associated colitis by various typing methods." J Clin Microbiol
16(6): 1096-1101.
Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Fushimi K. (2012). "The burden
of Clostridium difficile-associated disease following digestive tract surgery in Japan."
Journal ofHospital Infection 82(3): 175-180.
xxxi
Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. (2007).
"The burden of Clostridium difficile in surgical patients in the United States." Surg
Infect (Larchmt) 8(6): 557-566.
xxxii
10.111 l/j.1469-0691.2010.03141.x
Changes in laboratory and clinical workload for Clostridium difficile
infection from 2003 to 2007 in hospitals in Edinburgh
S. Reddy1, S. Taori1,2 and I. R. Poxton1
I) Medical Microbiology, Centre for Infectious Diseases, University of Edinburgh College of Medicine and Veterinary Medicine and 2) Clinical Microbiology,
Royal Infirmary Edinburgh, Edinburgh, UK
Clostridium difficile infection (CDI) is a growing concern with regard to increases in incidence and its associated financial burden. A retro¬
spective analysis of patients admitted to Hospitals in Edinburgh from 2003 to 2007 and tested for C. difficile toxins was performed. A
total of 45 412 faecal samples were tested and 6286 (13.8%) were positive. Overall CDI was identified in 1.7 cases/1000 in-patient
occupied bed days (OBD). The incidence of CDI fell from 1.98 cases/1000 OBD in 2006 to 1.48 cases/1000 OBD in 2007. Renal Medi¬
cine, including Transplant Surgery, and Intensive Care had the highest incidence, with >6.2 cases/1000 OBD each, followed by Infectious
Diseases and Gastrointestinal Medicine, with rates of 5.5 and 4.42 cases/1000 OBD, respectively. Medicine of the Elderly had an inci¬
dence of 1.69 cases/1000 OBD. Incidence increased with age, from 0.45 cases/1000 OBD in the 0-20-year-old age group to 2.02 cases/
1000 OBD in the 61-80-year-old age group. Twelve percent of all toxin-positive patients were transferred through a minimum of two
specialties when they remained positive for C. difficile toxins. Estimated costs over the study period for toxin testing were approximately
£126 500 and the minimal potential hospitalization costs for patients with CDI was £20 000 000. The overall incidence of patients iden¬
tified with CDI fell in 2007 compared to 2006. The incidence has increased with age; however, patients in Medicine of the Elderly had a
much lower incidence than in several other specialties and therefore risk assessment of CDI should also be targeted within other spe¬
cialties. Judicious application of infection control measures remains important for preventing CDI.
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known. The present study aimed to use locally collected data
from 2003 to 2007 to assess the laboratory workload associ¬
ated with C. difficile testing and to analyse the maximal
potential rates of CDI across specialties and age groups, in
an area that had not been affected by the hypervirulent 027/
BI/NAP I strain during the period of the study.
Introduction Materials and Methods
Clostridium difficile infection (CDI) has increased over the past Setting
three decades and is the principal cause of nosocomial Lothian University Hospitals Division provides for approxi-
diarrhoea in adults and an important cause of antibiotic-asso- mately 620 000 people in the Edinburgh area of Southeast
dated diarrhoea. CDI covers a spectrum of disease from Scotland. The six major Edinburgh hospitals (three tertiary
asymptomatic carriage, mild self-limiting diarrhoea, through and three secondary care; totalling approximately 2300 beds)
to severe diarrhoea, pseudomembranous colitis and toxic were included in our analysis.
megacolon, with the possibility of perforation and death [I].
Very limited information has been published on the bur- Laboratory diagnosis of CDI
den of CDI to the diagnostic laboratory, and the relative All faecal samples were processed in a single microbiology
incidence of disease in different clinical specialties is not well laboratory, in accordance with local guidelines until September
©2010 The Authors
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2006 and thereafter national guidelines [2]. All diarrhoeal
(semi, unformed or liquid) specimens were tested from 2003
to 2008 inclusive if they were from hospital in-patients aged
over I year old, if a diagnosis of antibiotic-associated diar¬
rhoea or pseudomembranous colitis was present, on clinical
request, or if they had been on recent antibiotic therapy.
Diarrhoeal samples were tested for C. difficile toxins A and B
by enzyme immunoassay (Techlab C. difficile Tox A/B II kit;
TechLab, Blackburg, VA, USA) in accordance with the manu¬
facturer's guidelines.
Inclusion criteria
All in-patients from whom an appropriate faecal sample was
submitted for toxin detection were included. Patients were
identified using the laboratory computer filing system (iLab,
iSOFT, Banbury, UK), which stores details of every sample
tested. The data included patient demographics, ward and
specialty where admitted at the time of sample collection,
date of sample collection, test performed and results.
A new potential CDI episode was defined in line with
Scottish guidelines: 'only persons that have not been diag¬
nosed with Clostridium difficile-associated diarrhoea within the
previous 28 days are counted as new cases' [3]. Therefore,
any repeat samples taken within 28 days after a positive
result for any individual patient were excluded.
Potential CDI rates were calculated as potential episodes
per 1000 in-patient occupied bed days (OBD) using data,
obtained from the Information Analysis Department, Health
Intelligence Unit, NHS Lothian, on annual hospital occupied
bed days per speciality. Data for renal medicine and trans¬
plant surgery had to be combined as a result of the combina¬
tion ward set-up.
For all analyses, other than requisition of faecal samples
and the resultant workload relating to individual age groups,
individuals aged less <18 years were excluded because paedi-
atric age groups have been reported to have disproportion¬
ately high carriage rates [4,5]. This enabled a comparison
with other studies, which have only included adults. With
recognition that every faecal sample positive for C difficile
toxin does not always equate to symptomatic CDI, we have
referred to potential CDI.
Costs data
The most recent published data were used to calculate
potential associated costs [6],
Statistical analysis
Analysis was performed using Microsoft Excel (Microsoft
Corp., Redmond, WA, USA) and Minitab, version 5.1.0.0
(Minitab Inc., State College, PA, USA).
TABLE I. Incidence and number of Clostridium difficile infec¬











"Total number of episodes of CDI per year (as defined by a stool sample posi¬
tive for C difficile toxin). In the case of multiple positive samples from the same
patient within a 28-day period, only one was included in the total.
Changes in the incidence of CDI episodes per 1000 occupied bed days (OBD).
Results
A total of 45 412 samples were tested for toxin and 6286
(13.8%) were positive. After excluding repeat positive sam¬
ples from the same patient in a 28-day period, 4922 new
potential episodes of CDI were identified, increasing from
875 potential cases in 2004-1231 in 2006 (Table I). The
overall rate of potential CDI for in-patients admitted from
2003 to 2007 was 1.70 cases/1000 in-patient OBD with a
peak of 1.98 potential cases/1000 OBD in 2006 (Table I).
The potential number and rate of CDI fell in 2007-928 cases
and 1.48 cases/1000 OBD, respectively.
Laboratory workload
The number of samples tested increased from 6493 in 2003
to 14207 in 2006, falling to 10359 in 2007. The proportion of
these samples identified as positive varied annually from I 1%
to 16% (Fig. la). There was an almost equal proportion of
samples from Medicine of the Elderly, all medical specialties
and all surgical specialties. The former was the specialty that
sent the maximum number overall, and was almost double
the proportion of samples sent by the next three specialties
individually (General Surgery, Gastrointestinal Medicine and
Infectious Diseases). Medicine of the Elderly had the largest
proportion of positive samples (22.9%) followed by Urology
(17.7%), Renal Medicine/Transplant Surgery (16.8%), Respira¬
tory Medicine (15.3%) and General Surgery (14.2%) (Fig. lb).
Stratifying the data according to age, the largest propor¬
tion of samples was sent from the 61-80-year-old age group
and the highest positivity rate was seen in those aged over
80 years. One third of all samples were sent from those
aged 60 years or younger and 18.9% of positive samples
came from this age group (Table 2).
Clinical workload
Renal Medicine/Transplant Surgery with 7.24 cases/1000
OBD and Intensive Care and High Dependency
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FIG. I. Trends in number of laboratory requests for Clostridium diffi¬
cile toxin detection 2003-2007. (a) Total number of laboratory
requests for C difficile toxin detection per year. The figures above
the individual bars represent the percentage of positive samples per
year, (b) Total number of laboratory requests for C. difficile toxin
detection distributed by specialty. Shaded areas: positive results for
C. difficile toxin; nonshaded areas: negative results for C. difficile toxin.
The figures above the individual bars represent the percentage of
samples that were positive per specialty. HAEM-ONC, Haematology
and Oncology; INF-DIS, Infectious Diseases, ITU/HDU, Intensive
Care and High Dependency Units; MED, General Medicine;
MED-CARDIO, Cardiology, MOE, Medicine of the Elderly; MED-GI,
Gastrointestinal Medicine; MED-OTHER, includes all other medical
specialties including dermatology and rheumatology; MED-RESP,
Respiratory Medicine; OBS-GYN, Obstetrics and Gynaecology;
RENAL MED, Renal Medicine and Transplant Surgery; SURG-CT,
Cardiothoracic Surgery; SURG-GEN, General Surgery; SURG-ORTH,
Trauma and Orthopaedic Surgery; SURG-OTHER, includes all other
surgical specialties including vascular; SURG-URO, Urology;
UNKNOWN, Samples that could not be allocated to a particular
specialty.
TABLE 2. Number of samples tested (total and proportion
positive) by the laboratory, distributed according to age
group
Number of samples (%)
Age Percent positivity
range Tested Positive per age group (%)
0-20 1973 (4.3) 94(1.5) 4.8
21—40 4588 (10.1) 293 (4.7) 6.4
41-60 8697 (19.2) 800 (12.7) 9.2
61-80 1821 1 (40.1) 2772 (44.1) 15.2
>80 1 1943 (26.3) 2327 (37.0) 19.5
Total 45412 (100) 6286 (100) 5.9
addition General Surgery and Urology both had higher rates
than Medicine of the Elderly (Fig. 2a).
On review of the trends in potential GUI incidence in the
seven specialties with the highest rates over the 5-year per¬
iod (Fig. 2b), all latterly had a reduction in CDI cases despite
following varying trends. ITU + HDU, Infectious Diseases
and Gastrointestinal Medicine appeared to have the greatest
reduction. For each specialty, the rates peaked at different
times. Renal Medicine/Transplant Surgery had a maximal rate
in 2006, ITU + HDU in 2004, Infectious Diseases and Gas¬
trointestinal Medicine in 2005, Urology in 2006, General Sur¬
gery in 2003 and Medicine of the Elderly in 2006.
The incidence of potential CDI rates also increased with
age from 0.45 cases/1000 OBD in the 0-20-year-old age
group to 2.02 cases/1000 OBD in the 61-80-year-old age
group. Similar to the specialty trends, there was latterly a
reduction in all age groups. Over the period for those aged
above 41 years, each group appeared to follow a similar
trend, with peaks in incidences in 2003 and 2006. However,
in the younger two age groups, the peak occurred later: in
2005 in the 21—40-year-old age group and in 2006 in the
0-20-year-old age group (Fig. 3).
Of all toxin-positive patients, 12% were transferred
through a minimum of two specialties and 17% of these
through a minimum of three to a maximum of six specialties.
These transfers also included movement through acute-
service areas: Accident and Emergency, Combined Assess¬
ment Units and Acute Receiving Units.
Discussion
(ITU + HDU) with 6.23 cases/1000 OBD had the highest
potential CDI incidences followed by Infectious Diseases and
Gastrointestinal Medicine, where rates were 5.50 and 4.42
cases/1000 OBD, respectively. By comparison, Medicine of
the Elderly had an incidence of 1.69 cases/1000 OBD. In
The C. difficile-related burden handled by the laboratory and
the potential clinical workload over a 5-year period within
Edinburgh were assessed. The results represent the first
study from Scotland, and possibly the first ever, demonstrat¬
ing the CDI laboratory workload. The recent CDI trends
©2010 The Authors
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FIG. 2. Distribution of Clostridium difficile infection (CDI) incidence
among the various specialties from 2003 to 2007. (a) Annual
incidence of CDI in the seven specialties with the highest overall
incidence of CDI [episodes per 1000 occupied bed days (OBD)].
(b) The overall incidence of CDI episodes per 1000 OBD per spe¬
cialty. HAEM-ONC, Haematology arid Oncology; INF-DIS, Infectious
Diseases, ITU/HDU, Intensive Care and High Dependency Units;
MED, General Medicine; MED-CARDIO, Cardiology; MOE, Medicine
of the Elderly; MED-GI, Gastrointestinal Medicine; MED-OTHER,
includes all other medical specialties including dermatology and rheu¬
matology; MED-RESP, Respiratory Medicine; OBS-GYN, Obstetrics
and Gynaecology; RENAL MED, Renal Medicine and Transplant
Surgery; SURG-CT, Cardiothoracic Surgery; SURG-GEN, General
Surgery; SURG-ORTH, Trauma and Orthopaedic Surgery; SURG-
OTHER, includes all other surgical specialties including vascular,
SURG-URO, Urology.
and maximal potential specialty-dependent rates are also
reported. Although the study reviews presumptive rates of
specialty-based CDI based on toxin-positive samples rather
than symptomatic disease, it provides valuable information
on the burden of disease prior to mandatory data reporting,
introduced in September 2006, and for age groups below
65 years.
A fall in the rate of CDI occurred between to 2003-2004
and 2006-2007. The initial reduction may be secondary to
increased awareness and improved infection control prac¬
tices with the subsequent rise occurring if infection control
measures relaxed with an associated increase in antibiotic
usage (e.g. of fluoroquinolones). The decline seen latterly
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FIG. 3. Distribution of annual age-related Clostridium difficile infection
(CDI) incidence [episodes per 1000 occupied bed days (OBD)] from
2003 to 2007.
improvements in CDI-related education and judicious antibi¬
otic use.
This is converse to some other reported figures. In Can¬
ada, an increase in incidence from 2.5 cases/1000 admissions
to 4.6 cases/1000 admissions occurred from 2002 to 2007
[7], In Spain, where ribotype 027 is not prevalent, the preva¬
lence rates have increased from 0.39 to 1.22 cases/1000 hos¬
pitalized patients from 1999 to 2007 [8]. The incidence of
1.27 CDI cases/1000 OBD in the whole of Scotland from
October 2006 to September 2007 for those aged 65 years
and over [4] was lower than the 1.99 CDI cases/1000 OBD,
for the same period and cohort of patients, in the present
study. This may be a result of our study representing poten¬
tial CDI in a concentrated urban population.
There was a 54% increase in the number of samples analy¬
sed by the laboratory from 2003 to 2006. Although the num¬
ber decreased from 2006 to 2007, there was a 37% increase
from 2003 to 2007. This will have impacted upon staff as
well as upon an appropriate analysis of samples, timely data
reporting, storage of samples and further testing of repeat
samples from previously positive patients.
This increase will also have had implications for ward-
based staff with regard to rapid and appropriate patient isola¬
tion, cleaning procedures and continued patient management.
One-third of samples were from those aged 60 years and
under, and this population also accounted for approximately
one-fifth of the total positives (Table 2).
This was similar to results from the recent 2009 European
Study (M. Bauer, unpublished data) where 37% of samples
were submitted from those aged 65 years or under. In the
Netherlands in 2005, 42% of samples were submitted from
this age group [9]. In the present study, CDI toxin positivity
was identified in all age groups, including that aged
©2010 The Authors
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0-20 years, and the potential CDI incidence in those aged
21—40 and 41-60 years was not largely dissimilar from that
in those aged over 60 years. It should be noted that the
potential false positive rates will be higher among the younger
age groups because the potential prevalence in these age
groups (aged 60 years and under) is <10%. With mandatory
data reporting in Scotland initially introduced for those aged
65 years and above only, a large and important subset of
patients was excluded from national figures. Subsequent to
May 2009, mandatory data reporting in Scotland will now
include those aged 16 years and above.
The elderly population is deemed to be at high risk for
CDI; however, it is no longer the only at-risk group [10]. An
analysis of our data by specialties revealed that Obstetrics
and Gynaecology patients, a group with minimal CDI, have a
low but noteworthy incidence of disease. Because there are
only a few reports of peripartum CDI in young women [II],
they, along with paediatric patients, comprise a sub-group
where there should be vigilance and a high degree of clinical
suspicion in symptomatic patients.
Advanced age has been found to be an independent pre¬
dictor of mortality in patients with CDI [12]. However, in
the present study. Medicine of the Elderly had a much lower
incidence than several other specialties, although it
accounted for the largest number of samples tested and had
the greatest proportion of positive samples. Renal Medicine/
Transplant Surgery, ITU, Infectious Diseases, Gastrointestinal
Medicine, Urology and General Surgery all had a higher inci¬
dence of CDI.
This is similar to a study from Amsterdam where CDI
occurred more frequently in ITU patients and those admit¬
ted to surgery [13]. Conversely, in Spain, admission to a
general medical ward was associated with higher CDI pre¬
valence as opposed to ITU admission [8],
Renal Medicine/Transplant Surgery had the highest inci¬
dence of CDI over the study period. This may reflect over¬
all antibiotic usage, immunosuppression and repeated
admissions. Chronic haemodialysis patients have a greater
risk of developing nosocomial infections including CDI
[14] and renal insufficiency is associated with increased
risk of CDI after live donor liver transplantation [15]. Liver
disease is also independently associated with severe CDI
outcome [7].
The recognition of patients with severe CDI, subsequent
to outbreaks in Canada [16] and Stoke Mandeville (Bucks,
UK) [17], could have resulted in an increased number of
patients with CDI being referred to ITU and hence the
observed peak in 2004. The marked decline in potential CDI
incidence observed afterwards within ITU and HDU areas
may be a result of increased awareness, stringent infection
control and the overall decrease seen across all specialties.
In the present study, the incidence of CDI among
ITU + HDU patients was 6.23 cases/1000 OBD.
Lawrence et al. [18] reported an incidence of CDI in ITU
to be 3.2 cases/1000 patient days in the absence of an out¬
break. This may be a result of differences in patient popula¬
tions and our figure represents a maximal potential
incidence, which includes patients transferred to ITU with
CDI. In 2008, a study reported that a specific subgroup of
young critically ill trauma patients admitted to ITU developed
CDI even though administration of antibiotics was for surgi¬
cal prophylaxis only [19],
Gastrointestinal Medicine may handle a substantial burden
of CDI as a result of a high prevalence among inflammatory
bowel disease patients. CDI has been reported to be eight¬
fold more prevalent in patients with ulcerative colitis and
five-fold more prevalent in patients with Crohn's disease
compared to the general population [20,21].
General Surgery had a plateau from 2003 to 2006 despite
a rise in the total CDI incidence in 2006. This contrasts to
other studies that noted a rise in CDI among patients admit¬
ted in surgery, particularly for patients requiring surgical
intervention for CDI [22-24], Although patients are at risk
of acquiring CDI within the specialty itself, patients are also
referred for surgical intervention due to severe fulminant
C. difficile colitis and typhlitis. This may suggest that patients
were not being referred for surgical review; disease severity
did not warrant surgery or patients were not suitable for it
Early surgical referral should always be made for severe ful¬
minant colitis as a total colectomy prior to acute respiratory
or renal failure in those aged over 65 years is associated
with decreased mortality [22],
The incidence of CDI in Urology did not vary greatly and
the overall incidence was 1.84 cases/1000 OBD. This was
higher than observed by Hossain et al. [25] who reported an
incidence of 0.66 cases/1000 OBD.
Approximately one-tenth of all toxin-positive patients
were transferred through a minimum of two specialties when
remaining toxin positive. The maximum number of inter-spe-
cialty transfers (and therefore wards) for an individual patient
was six. This does not take into account the number of indi¬
vidual bed moves within the same ward. C. difficile spores
contaminate the hospital environment and are more likely to
be recovered from a room housing a CDI patient [26] and
this can persist for up 40 days after discharge [27,28], Acqui¬
sition of CDI is more rapid, occurring after 3.2 days for
patients sharing a room with a CDI patient compared to
18.9 days for those who do not have close contact [29],
Estimated costs for toxin testing alone were approxi¬
mately £126 500 (€143 000). On the basis of the most
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recent published European costs of CDI by Vonberg et al.
[6], the excess costs per in-patient case was €7147. This
agrees with the only published figures available for Great
Britain from Wilcox eta/. [30] in 1996, where extra costs
were estimated at £4000 (€4500) per case. Without adjust¬
ing for inflation, the potential excess costs for CDI patients
over the study period was £20 000 000 (€22 500 000).
Most local strains of C. difficile associated with CDI belong
to ribotypes 001 and 106 [31]. Ribotype 027, and now 078
[32], is associated with increasing CDI rates and more
severe disease.
The incidence of CDI appears similar to regions where
027 was prevalent Control of CDI should not be focused
solely on 027 and strategies to reduce CDI should consider
the pathogenic potential of local strains. However, the
absence of hypervirulent types may explain the plateau in the
incidence observed in General Surgery.
The present study has confirmed that CDI incidence
increases with age but varies among specialties, indicating
where an assessment of the risk of developing CDI should
be targeted.
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Potential Differences in the Use of Abdominal CT and Imaging Findings between
Differing Clostridium difficile Strains.
Reddy S.N.1'2'3*, Taori S.1, Ewing F.2, Brown D.2, Murchison J.T.3 and Poxton I.R.1
Centre for Infectious Diseases, University of Edinburgh, College of Medicine and
Veterinary Medicine, Edinburgh, Scotland, UK, department of Radiology, Western
General Hospital, Edinburgh, UK. 3Royal Infirmary of Edinburgh, Edinburgh,
Scotland, UK.
Severe Clostridium difficile infection (CDI) is increasingly being assessed by
computed tomography (CT). Our aim is to assess imaging findings in patients affected
by different C. difficile strains.
All C. difficile positive faecal samples from 1 August 2010 to 31 July 2011 were
cultured and PCR ribotyped. A retrospective review of prospectively collected clinical
and radiological data was then performed on all positive, symptomatic, hospitalised
adult patients.
453 CDI patient episodes were identified in 350 symptomatic patients. Overall 72 CT-
scans were performed, 55 scans demonstrated colonic involvement, with pancolitis in
only 31%. Colonic changes were present in 35% of episodes prior to the availability
of a C. difficile positive result (median 2 days).
Ribotype 001 (73 episodes) was the commonest identified C. difficile strain and a CT
was performed in only 11%, compared with ribotype 078, the 6th commonest strain
(19 episodes) where CT was performed in 52%. Patients with 078 had a greater
colonic wall thicknesses (median 16mm) compared with the remaining cohort
(median 11mm). Ascites was present in 64% of the scanned 078 patients compared
with 31% in the remaining cohort.
CDI should be considered in the differential diagnosis of colitides, even prior to a
C.difficile positive result. Increased colonic wall thickness and ascites were more
common in the 078 episode group with a greater proportion of CT scans performed.
078 appears to stimulate a greater inflammatory response within the colon, which has
not been previously described.
CT imaging can provide valuable biological data in assessing potential actions
between different strains of Clostridium difficile. In particular emerging strains in
which pathological mechanisms have not been established.
Although the hypervirulent 027 strain is not endemic to our area; another potentially
emerging aggressive strain-078 has become prevalent.
Presented at the European Congress ofRadiology; Vienna, 2013
Environmental Contamination Of Clostridium Difficile In A Radiology Ultrasound
Department.
Reddy S.N.1'2*, Chambers S.1, and Poxton I.R.2
'Department of Radiology, St. John's Hospital, Livingston, West Lothian, Scotland
UK. 2Medical Microbiology, University of Edinburgh, College of Medicine and
Veterinary Medicine, Edinburgh, Scotland, UK.
Aims: To assess the presence of Clostridium difficile and the potential risk of
transmission to patients and health-care professionals in a high-risk clinical area
within a radiology department.
Methods: Contact plates (cycloserine, cefoxitin, egg-yolk: CCEY) were used to
sample 35 environmental sites for C. difficile. These were designated as high or
moderate risk within two ultrasound (US) rooms with the greatest in-patient
movement. Blood agar contact plates were also used to calculate overall colony
counts in order to assess areas of greatest contamination. Each site was sampled at the
start and end of a standard 8 hour working day. Contact plates were then incubated
and evaluated according to standard or manufacturer protocols. The blood agar
contact plates were divided for both aerobic and anaerobic incubation. This gave a
total of 70 CCEY and 140 blood agar plates.
Results: Two of 70 CCEY contact plates were culture positive for Clostridium
difficile. These were isolated from the curtain rail and under-surface of the patient
couch frame belonging to the same cubicle. Both samples were positive for toxins
A/B, via enzyme immunoassay, and sensitive to both metronidazole and vancomycin
via E-test. The highest overall combined aerobe and anaerobe colony counts were
obtained from the patient couches, computer keyboards, floor, US probe holder, US
control panel and US gel warmer with a median colony count of 198 (range 123 to
954). The areas demonstrating the greatest increase in colony counts over the course
of the day were the US control panel, the US gel warmer and the floor.
Conclusions: Overall minimal C. difficile contamination was identified. The study
however identifies areas which may be overlooked by current cleaning protocols
where C. difficile spores can exist and act as a potential source of hospital acquired
infections. In addition potential areas of increased contamination have been
highlighted, allowing greater awareness of areas to target during standard
decontamination procedures.
Presented at Anaerobe; San Francisco, 2012
Identification of Clostridium difficile in Colorectal Surgery.
Reddy S.N.1'3*, Fewster G.2 Mander B.J.3, Wilson R.G.3 and Poxton I.R.1
'Centre for Infectious Diseases, University of Edinburgh, College of Medicine and
Veterinary Medicine, Edinburgh, Scotland, UK, 2Medical Microbiology, Royal
Infirmary of Edinburgh, Edinburgh, Scotland, UK and Colorectal Surgical Unit,
Western General Hospital, Edinburgh, Scotland, UK.
Objectives: Clostridium difficile Infection (CDI) has become a growing concern
world-wide with an increased reported incidence among patients admitted to surgery.
Our aim was to prospectively review the role of toxigenic culture in the diagnosis of
CDI in colorectal surgical in-patients from December 2007 to January 2009.
Methods: All faecal samples, submitted to Lothian University Hospitals Division,
were processed in a single enteric laboratory following national guidelines - all
hospital diarrhoeal in-patient samples from those aged lyear and above were tested
for C. difficile toxins A and B by enzyme immunoassay. All faecal samples submitted
to the laboratory from colorectal surgical in-patients were reclaimed for toxigenic
culture (culture on selective media and EIA).
Results: 632 samples, from 483 adult patients (median age 71 years, ranging from 18-
100 years) were reclaimed for toxigenic culture. Of these 105 samples (16.6%) were
found by the laboratory to be positive by EIA.
Following toxigenic culture a further 72 samples (11.4%) were identified as positive.
38 patients, who were symptomatic at the time of testing, were not identified with
CDI during their admission.
5 patients whose samples were not tested as they were not diarrhoeal (< 4 on the
Bristol stool chart) were toxigenic culture positive. These patients were symptomatic
ofCDI and subsequent diagnosis was delayed in 3 of these patients and not diagnosed
in 2 patients.
Seven samples found to be toxin positive by the lab were culture negative.
Conclusions: CDI diagnosis or recognition at present may be delayed, as with current
national guidelines CDI detection is based solely upon C. difficile toxins A+B EIA.
Current resources cannot support toxigenic culture for all suspected samples and this
has implications in regards to delayed treatment, further patient management and
infection control procedures. With current testing including diarrhoeal samples only,
a proportion of patients with CDI may go undiagnosed or have diagnosis delayed.
Presented at Anaerobe; Philadelphia, 2010.
Clostridium difficile in the Hospital Environment.
Reddy S.N.1'3*, Fewster J.2 Mander B.J.3, Wilson R.G.3 and Poxton I.R.1
'Centre for Infectious Diseases, University of Edinburgh, College of Medicine and
Veterinary Medicine, Edinburgh, Scotland, UK, 2Medical Microbiology, Royal
Infirmary of Edinburgh, Edinburgh, Scotland, UK and 'Colorectal Surgical Unit,
Western General Hospital, Edinburgh, Scotland, UK.
Objectives: Clostridium difficile Infection (CDI) has become a growing concern
world-wide with an increased reported incidence among patients admitted to surgery.
Our aim was to assess the presence of Clostridium difficile spores within the surgical
wards of a large tertiary referral hospital, to assess the common areas contaminated
and the effects of introducing new cleaning procedures, from December 2007 to
January 2009.
Methods: 4 acute surgical wards were included and 180 CCEY (cefoxitin, ceftriaxone
and egg yolk) contact plates were used every 4-6 weeks to sample the environment.
The same areas were sampled on each occasion in the same manner over a 14 month
period. At the 7 month time point chlorine based cleaning agent was introduced in
addition to the original non-chlorine based detergent. The plates were incubated for 5
days and all Clostridium difficile colonies were tested for toxins A+B.
Results: Over the study period 5% of all contact plates were positive for toxigenic
Clostridium difficile colonies. One ward had 80% fewer positive plates than the other
wards. This is likely to represent the differing patient cohort within the ward
(overnight stay/daycase patients).
Contaminated areas included bed frames, patient tables, bedside lockers, door
handles, sinks, bathroom floors and electronic sphygmomanometers. Bed frames
produced the greatest number of positive contact plates when compared with the other
surfaces tested. Only 11% of the positive contact plates were from rooms which were
occupied by a patient with CDI at the time of sampling.
There was an initial 86% reduction in the number of positive contact plates following
the introduction of chlorine based cleaning agents during months 7-8. Following this
initial reduction, a plateau of between 48-62% reductions was maintained for the
remaining months when compared to the first 6month period.
Conclusions: The environment is an important reservoir for Clostridium difficile
spore contamination and hence potential patient development ofCDI. Attention to the
cleaning of areas which may be overlooked such as electronic sphygmomanometers
should be paid. The use of chlorine based cleaning agents and meticulous cleaning
procedures are vital components of infection control procedures and the control of
CDI dissemination.
Presented at Anaerobe; Philadelphia, 2010.
Clostridium difficile: changing epidemiology trends 2000-2007
Reddy S.N.1'3*, Taori S.1'2Kalima P.2, and Poxton I.R.1
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General Hospital, Edinburgh, Scotland, UK and 3Colorectal Surgical Unit, Western
General Hospital, Edinburgh, Scotland, UK.
Objectives: Clostridium difficile Infection (CDI) has become a growing concern
world-wide with an increased reported incidence and an increase in the associated
financial burden. Our aim therefore was to review trends in CDI occurring from 2000-
2007 inclusive.
Methods: All patients admitted to Lothian University Hospitals Division (LUHD)
tested for C. difficile toxins A+B by EIA were included. Retrospective analysis of
prospectively collected data was performed. The number of occupied bed days was
provided by NHS-Lothian Statistics Department. The most recent published costs
associated with CDI were used to estimate potential costs to Lothian NHS Trust.
Results: 50590 faecal samples were tested for C. difficile toxins from 2000-2007
inclusive; of these 7301 samples were positive. Overall CDI was identified in 15.2
cases/10000 patient days and 5.8 cases/1000 in-patient hospital admissions.
The incidence of identified CDI rose from 3.6cases/10000 patient days in 2000 to
14.8cases/10000 patient days in 2007. Incidence also increased with age from
3.3cases/10000 patient days in the 0-20 years age group to 18.1 cases/10000 patient
days in the 61-80 years age group.
Renal Medicine and Intensive Care had the highest incidences of identified CDI with
greater than 57cases/10000 patient days each followed by Infectious Diseases and
Gastrointestinal Medicine whose rates were 47.5 and 42.6 cases/10000 patient days
respectively . Medicine of the Elderly in comparison had an incidence of
19.5cases/10000 patient days.
Of note 10% of all patients were transferred through a minimum of two specialties
during the period in which they remained positive for C. difficile toxins.
Estimated costs over the study period for toxin testing alone were in the region of
£126,500 and the minimal potential hospitalisation costs of patients with CDI was in
the region of £20,000,000.
Conclusion: The incidence of patients identified with CDI has risen markedly and not
surprisingly the incidence has also been noted to increase with age. Medicine of the
Elderly however had a much lower incidence than several other specialties and
therefore risk assessment of CDI development and containment should now also be
targeted within other specialties.
With 10% of identified CDI patients transferred through different specialties and the
significant financial burden CDI imposes on healthcare institutions judicious
application of infection control measures remains an important factor to prevent CDI
spread.
Presented at the European Congress of Clinical Microbiology and Infectious Diseases;
Helsinki, 2009.
The Incidence of Clostridium difficile in Colorectal Surgery
Reddy, S.1; Driscoll, P. J.1; Kalima, P.2; Anderson, D. N.1; Collie, M. H.1; Mander, B.
J.1; Poxton, I. R.3
1. Colorectal Surgery, Western General Hospital, Edinburgh, United Kingdom.
2. Medical Microbiology, Western General Hospital, Edinburgh, United Kingdom.
3. Centre for Infectious Diseases, University of Edinburgh, Edinburgh, United
Kingdom.
Purpose : There has been increased interest in hospital-acquired infections, in particular
Clostridium difficile (C. difficile) recently. Our aim was to review the incidence of C. difficile
within the adult in-patient population presenting to a University Hospitals Trust and the impact
upon the Colorectal Surgical Service over a 7-year period (2000-2006 inclusive).
Methods : Cross-referencing Medical Microbiology, Pathology and Surgical Audit databases
identified in-patients, from the four main hospitals within the Trust, diagnosed with C.difficile.
Retrospective analysis of prospectively collected outcome data was then performed.
Results : 41,356 faecal samples were tested over the 7-year period. 15% (6325) of faecal samples
tested were toxin positive, via ELISA, for C. difficile. 3895 patients were diagnosed with
Clostridium difficile associated disease (CDAD). 7.6% (296) of patients diagnosed with CDAD
were treated by the Colorectal Surgical Unit only 23 patients underwent surgery. A detailed
analysis is demonstrated below.
Conclusions : Over the 7-year study period, there has been an exponential increase in the number
of faecal samples and consequently the number of patients tested for and diagnosed with CDAD.
Despite the proportion of colorectal patients, compared with the total number of patients, treated
for CDAD each year not appreciably increasing. The number of individual in-patients treated
conservatively for CDAD by the Colorectal Surgical Service has markedly increased impacting on
























2000 532 150 98 4 1
2001 1185 273 175 26 5
2002 3767 653 463 35 0
2003 6833 980 612 45 2
2004 6600 998 687 49 5
2005 7841 1237 806 53 5
2006 14598 2034 1054 84 5
Presented at the American Society of Colon and Rectal Surgeons Triennial Congress;
Boston 2008.
Clostridium difficile in the paediatric population.
S.N.Reddy, P.Kalima, M.H.S.Collie, D.N.Anderson, I.R.Poxton.
Objectives: Clostridium difficile Associated Disease (CDAD) cases are increasing.
There has been a shift in trends with a rising number of cases being reported in low-
risk populations' e.g. children and young peri-partum women. Our aim was to review
the prevalence of C. difficile in the in-patient paediatric population presenting to a
Children's Hospital within a University Hospitals Trust from 2000-2006 inclusive,
and to further assess the data set for 2006.
Methods: Patients were identified via Medical Microbiology databases. Patients
ranging from greater than one-month to less than 14 years were included.
Retrospective analysis of prospectively collected outcome data was then performed.
Results: There has been an increase in the number of diagnosed paediatric CDAD
cases over the last year. A detailed breakdown is shown below.
Age Range 2000 2001 2002 2003 2004 2005 2006
(years)
>1 month - <1 0 0 0 0 0 0 3
1 -4 0 0 0 0 1 2 12
5 - 13 0 1 2 1 1 2 7
Further analysis of data for 2006 revealed 603 faecal samples were tested for C.
difficile of which 33 samples were positive. Taking into account multiple samples
testing, for individual patients, 22 patients were diagnosed with CDAD out of 335. Of
the 22 positive patients there was no significant gender bias (Male:Female=10:12) and
the median age was 3years (range 2months - 13years). For this cohort 117 samples
were analysed ranging from 1-31 samples per patient over a time period of 1-331 days.
Only 54% of patients were found to be toxin positive on their first sample. A median
period of 23days (range 2-102 days) was conceded prior to detection of C. difficile
toxin, from the time of their first negative sample being assessed to the ultimate
positive sample, a median of 3 (range 2-6) samples was sent prior to detection. 23%
of positive patients had CDAD re-diagnosed on subsequent samples following a
negative sample. In these cases the median duration was 22 days (range 15-104days)
following a median of a further 2 samples being analysed (range 2-4).
Conclusions: The diagnosis of C. difficile is increasing in this previously low-risk
paediatric population and therefore is a clinical diagnosis that must be considered
early. Culture in conjunction with toxin testing may have led to an earlier diagnosis in
nearly 50% of patients and there is a possibility that re-infection/re-colonisation may
occur in up to a quarter of Paediatric cases. Mandatory data reporting is only required
for patients over 65years resulting in this important sub-set being excluded.
Presented at the European Congress of Clinical Microbiology and Infectious Diseases;
Barcelona, 2008.
